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Chapter 1 
 
General introduction  
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Abbreviations 
CCR2 C-C chemokine receptor type 2 
CL/P Cleft lip and/ or palate 
CO Carbon monoxide 
CXCL10 C-X-C motif chemokine 10 
ECM Extracellular matrix 
EMT Epithelial to mesenchymal transition 
HO Heme oxygenase 
IL-8 Interleukin-8 
IPC Ischemic preconditioning 
IRI Ischemia-reperfusion injury 
MCP-1 Monocyte chemoattractant protein-1 
MES Midline epithelial seam 
MSC Mesenchymal stem cells 
nrf2 Nuclear-related factor-2 
RIPC Remote ischemic preconditioning 
ROS Reactive oxygen species 
TGF- β Transforming growth factor-beta 
VEGF Vascular endothelial growth factor 
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1.1 Introduction 
 
Cleft lip and/ or palate (CL/P) is the most common developmental craniofacial 
disorder affecting the upper lip, the alveolus and the roof of the mouth (1, 2). The 
prevalence of CL/P is 1:500-1:1000 per newborn with ethnic and geographic variation (3). 
CL/P can be classified in different phenotypes, and be limited to one side (unilateral) or be 
a double-sided (bilateral) cleft of the lip, with or without a cleft of the alveolus and/ or 
palate, and can also occur as an isolated cleft palate only (4, 5). Figure 1.1 shows some 
common types of orofacial clefts and subsequent scar formation following CLP surgery. The 
most severe form is a complete bilateral cleft with a cleft in both the soft and the hard 
tissues of the palate (6). 
Around thirty percent of the CL/Ps are syndromic and have additional phenotypic 
abnormalities, such as Pierre Robin, and Van der Woude syndrome, whereas seventy 
percent are non-syndromic and caused by a combination of genetic and environmental 
factors (7). Diverse genes are associated with the development of CL/P in humans, including 
deletions and mutations in P63, PVRL1, CLPTM1, TBX22, IRF6 (van der Woude syndrome), 
and SOX9 (Pierre Robin syndrome) (8). More details on genetic factors concerning CL/P are 
reviewed in (7, 9). Environmental factors to which pregnant mothers are exposed and are 
associated with an increased risk for CL/P include smoking, alcohol, anti-epileptic drugs, 
diabetes, infections, age >40 years, folate deficiency, zinc deficiency and contact to 
teratogens, such as chemical solvents, pesticides, valproic acid, phenytoin, and retinoic acid 
(10).  
Nutritional guidelines for pregnant women and women who plan to have a baby 
as prevention for getting babies with CL/P include sufficient intake of folic acid and certain 
vitamins, and keeping a healthy lifestyle shortly before and during pregnancy (11, 12). 
Unfortunately, despite these guidelines CL/P development cannot be prevented completely 
as a result of the interplay between genetic predispositions and environmental factors. 
Therefore, more insight into the molecular mechanisms leading to CL/P and scar formation 
is necessary. 
 
1.2 Sequelae of the presence of an orofacial cleft 
 
The presence of an orofacial cleft leads to functional, esthetic, and psychosocial 
problems (Figure 1.1) (1, 13). Well-known functional problems in children with CL/P are 
sucking and feeding problems, hearing impairment, and speech problems. Surgical 
intervention is needed to repair the cleft (14, 15).  
There are many different protocols used in the world to repair CL/P (16). In the 
Radboudumc, Nijmegen, the Netherlands, CL/P patients normally undergo their first 
surgery at an early age of 6-12 months to close the lip and soft palate, and the second 
surgery at three years to close the hard palate. Patients with CL/P require care by a 
multidisciplinary team of specialists, including a plastic and reconstructive surgeon, 
maxillofacial surgeon, orthodontist, otolaryngologist, speech therapist, pediatrician, 
geneticist, and sometimes a psychologist (17, 18).  
Despite the surgical closure of the cleft, scar formation at the lip and the palate 
may further contribute to the morbidity (Figure 1.1) (19, 20). The scarring impairs 
subsequent maxillofacial growth and interferes with the development of the dentition. 
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Inadequate repair of the soft palate can lead to velopharyngeal insufficiency (21, 22). Ten 
to thirty percent of the treated patients remain unable to achieve adequate velopharyngeal 
function and develop complications (23, 24).  
 
 
Figure 1.1: Different types of orofacial clefts before and after operation 
On the top row, extra-oral pictures before surgery at the age of 2-4 weeks. The photos in the middle row represent 
the same persons as above at the age of 5 years, after CL/P surgery showing scar formation of the lip and 
deformation of the nose as a result of the repaired cleft (only first and second picture from the left). The intra-oral 
pictures of the maxilla on the bottom row show scar formation of the palate. (Pictures are courtesy of Maarten 
Suttorp, and are shown with the informed consent of the patients’ representative). 
 
Following tissue injury, for instance, due to surgery, inflammation is initiated to destroy 
invading pathogens and to eliminate injurious agents and damaged cells (25). Although 
inflammation is a protective and necessary process, the inflammatory process needs to be 
tightly controlled to prevent chronic inflammation (26, 27). Extended excessive oxidative 
and inflammatory stress may overwhelm adaptive protective mechanisms and aggravate 
tissue damage (28, 29). Processes that are important during embryological development 
play a similar role during wound repair (30). However, in contrast to adult wound repair, 
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inflammation during early embryological wound repair is attenuated, subsequently 
resulting in reduced scar formation (30-32).  
Resolution of inflammation is important to restore tissue homeostasis, to allow a 
smooth wound repair and to minimize scar formation (29, 33). Controlling the pro-oxidative 
and pro-inflammatory stressors by induction of cytoprotective mechanisms that regulate 
inflammation and tissue repair may thus be necessary to promote tissue regeneration (34). 
For example, excessive levels of the pro-inflammatory and pro-oxidative free heme that get 
released during tissue injury may lead to pathological wound repair (35). Targeting 
protective mechanisms that neutralize free heme molecules by administration of heme-
binding proteins (e.g., hemopexin) or promoting enzymatic degradation by heme oxygenase 
(HO) may provide therapeutic potential (36, 37). Since the surgeries in CL/P patients to close 
the cleft are planned, this offers a therapeutic window for preconditioning strategies 
whereby induction of cytoprotective genes such as nuclear-related factor-2 (nrf2), HO-1, 
hemopexin, and biliverdin reductase before surgery may protect against subsequent 
harmful stressors (38-42). 
This thesis aims to better explore the molecular and cellular mechanisms that 
discriminate between tissue repair and tissue regeneration and proof the hypothesis that 
the induction of cytoprotective pathways leads to improved wound repair. Hereto, we 
focused on novel therapeutic strategies that harness inflammation and promote wound 
regeneration. 
 
 
 
 
 
 
 
 
 
 
The etiology of scar formation following cleft surgery is not entirely understood. However, 
mechanical tension on the healing wound by facial growth and excessive inflammation 
further exacerbates scar formation (43). The scars on the palate may restrict normal 
midfacial growth and impair dento-alveolar development (44). Besides functional problems 
caused by the scars, cosmetic and psychological problems may occur in CL/P patients (45, 
46). It has been shown that in individuals with a cleft that never had cleft surgery, such as 
in less developed countries and isolated habitats, midfacial growth is within normal limits 
(47, 48). However, not performing surgery strongly worsens speech development while 
functional, esthetic, and social problems remain (31, 49). This underscores the need for 
novel strategies to attenuate scar formation after surgery. 
A paradigm within regenerative biology is that molecular and cellular pathways 
controlling tissue generation during embryonic development often also control wound 
repair (30). Therefore, mechanisms regulating developmental processes during 
palatogenesis are likely to provide critical insights into tissue repair and its influence on 
homeostasis following palatal injury. Often mesenchymal-epithelial cross-talk orchestrates 
processes as migration, proliferation, and apoptosis. Better insight into the etiology of CL/P 
What is the difference between tissue repair and tissue regeneration? 
Tissue repair is the restoration of damaged tissue and allows some functionality, but the 
deposition of connective tissue during this process leads to various degrees of scar 
formation. Tissue regeneration is the successful renewal of the tissue to its original state 
without scars and no hampered functionality. While wound repair is also often used to 
define the wound healing process itself, wound regeneration usually refers to the end 
state of wound repair. 
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may eventually thus also lead to novel preventive and therapeutic strategies for scar 
formation. 
 
1.3 Disturbed palatogenesis and the etiology of CL/P compared with wound repair 
 
The palate consists of two distinct regions, the bony and immobile hard palate, and the 
mobile posterior fibro-muscular soft palate (7). The palate of humans and other mammals 
is formed by the fusion of the primary palate, which includes the alveolar arch, and the 
secondary palate that consists of the hard and soft palate (50).  
Development of the palate in humans starts the fourth week after conception, and 
is a sequential process that involves vertical palatal shelf growth (week 7)(Figure 1.2A), shelf 
elevation (week 8) and formation of the midline epithelial seam (MES) by attachment of the 
palatal shelves (weeks 9-12) (Figure 1.2B), and the subsequent disappearance of the MES 
and fusion of the mesenchyme (11, 51). Several mechanisms have been postulated to 
explain the disappearance of the MES: cell migration, apoptosis, and epithelial to 
mesenchymal transition (EMT) (Figure 1.2C) (52, 53). Failure of MES disintegration results 
in cleft palate. However, the etiology of clefting remains still mostly unclear and is complex 
and multifactorial (9).  
 
Figure 1.2: Palatogenesis and the disappearance of the midline epithelial seam (MES)  
A). The bilateral palatal shelves (P) aligned next to the nose (N) grow down vertically along the sides of the tongue 
(T). B). The tongue develops downwards together with the growth of the mandible making space for the elevation 
of the palatal shelves to grow horizontally and form the midline epithelial seam (M) at the place where the palatal 
shelves connect. C). Magnification of the attachment of the palatal shelves leading to the MES formation; the 
asterisk depicts epithelial cells that may either go into apoptosis, differentiate into other cells, or migrate from the 
MES towards the side of the palate as depicted by the arrow. 
 
Palatogenesis has much in common with the wound repair process. During wound repair, 
different cell types are recruited to the site of injury where they proliferate, differentiate, 
and synthesize extracellular matrix (ECM) to restore the lost tissue. Inflammatory and 
damaged cells go into apoptosis, and re-epithelialization occurs by proliferation of epithelial 
cells and keratinocytes and migration of these cells towards each other at the wound edges, 
after which structural re-organization follows (20, 30). These processes can be compared 
with the elongation of the palatal shelves towards each other, the formation of the MES, 
and the migration and apoptosis of cells during the disappearance of the MES, palatal fusion 
and the re-organization of ECM to regenerate the tissue (20). Moreover, from the top 35 
genes associated with CL/P selected by Biggs et al., about 50% share a known role in 
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craniofacial development and wound repair, confirming strong similarities between these 
two processes (20). For example, patients with Van der Woude syndrome have mutations 
in the IRF6 gene, and this leads to more and major wound complications following CL/P 
surgical repair (54). A role for IRF6 in wound healing is further supported by its effects on 
differentiation, proliferation, and migration of epithelial cells (54-57). In this thesis, we will 
mainly focus on genes involved in the inflammatory response and cytoprotective pathways. 
 
1.4 Wound repair and scar formation 
 
The skin’s main function is to maintain homeostasis, to regulate the temperature, 
electrolyte balance and to act as a barrier against external harmful agents, including 
radiation and pathogens (58). The skin of the body consists of several layers; the epidermis, 
dermis, and hypodermis, which further comprise different layers. The lip, in addition, has a 
deeper muscle layer (m. orbicularis oris) and oral mucosa on the inside. It is important to 
connect these different layers correctly during reconstructive CL/P surgery because this 
affects the function of the lip during speech and laugh, and its esthetics. The hard and soft 
palate are involved in different functions that include speech, hearing, sucking and 
swallowing (48, 59). Surgical cleft palate repair aims to close the cleft and to reconstruct the 
velopharyngeal musculature to improve velopharyngeal function. However, this leads to 
the formation of scar tissue that interferes with normal growth and functioning.  
Wound healing is a dynamic and precisely coordinated process of sequential 
cellular, molecular and biochemical events, which are aimed to restore the integrity of the 
injured tissue as quickly as possible (60-63). Following hemostasis, the healing process is 
divided into three distinct, but overlapping phases: inflammation, proliferation, and 
remodeling (Figure 1.3) (61, 64, 65).  
First, blood components leak into the site of injury and platelets aggregate 
together with fibrin (66). The platelets release growth factors and cytokines, initiating the 
inflammatory phase and attract granulocytes, macrophages, and lymphocytes (65). The 
granulocytes will clear the wound from invading pathogens and cellular debris (67). At the 
wound site monocytes differentiate into macrophages and play different roles (68, 69). 
Here, a pro-inflammatory subset of macrophages initially promotes the inflammatory phase 
by attracting additional leukocytes via pro-inflammatory cytokines and chemokines, such as 
IL-8, MCP-1, CCR2, and CXCL10 (70). Later, anti-inflammatory macrophages promote 
resolution of inflammation by clearing apoptotic cells and producing anti-inflammatory 
cytokines, such as IL-10, TGF-β, and VEGF (25, 71). These cytokines stimulate keratinocytes, 
fibroblasts, and endothelial cells to promote tissue regeneration (72).  
The proliferative phase is characterized by the replacement of the provisional 
matrix with newly formed granulation tissue (re-epithelialization) (73). The cellularity of the 
wound increases as fibroblasts, epithelial cells, and vascular endothelial cells migrate to the 
site of injury and start to proliferate, restoring the structure and function of the injured 
tissue (74). A proper vascular structure is of additional importance for supplying oxygen and 
nutrients, and quick tissue repair (75). Moreover, wound sizes are decreased by 
myofibroblasts that through the interactions with surrounding ECM and the expression of 
smooth muscle actin contract the wound (76). Myofibroblasts continue to produce ECM and 
then usually go into apoptosis (77).  
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The remodeling phase begins about a week after injury and may continue for years 
(31, 72). The dense fibers of collagen, which are produced by (myo-) fibroblasts during the 
earlier phases of wound healing, undergo remodeling (76). The aim of this remodeling is to 
create greater tensile strength. Tensile strength is restored to 20% of its original strength 
after three weeks and gradually increases to a maximum of 80% in approximately one year 
(60, 78). Under optimal situations, this leads to the formation of an acellular scar (79).  
However, during pathologic wound healing in the abundance of oxidative, 
inflammatory, and mechanical stressors, these efficient and well-coordinated processes of 
wound repair are disturbed and can result in excessive scarring (Figure 1.3).  
 
 
Figure 1.3: Wound repair may result in scar formation. 
Platelets and fibrin clot together to advance hemostasis, during which pro-inflammatory cytokines and reactive 
oxygen species (ROS) are produced that attract inflammatory cells, including granulocytes and macrophages, or 
normal skin cells, such as fibroblasts and keratinocytes, to form new tissue. Fibroblasts differentiate into 
myofibroblasts and contract the wounds to protect against external pathogens and for a quicker wound repair. 
During the proliferation phase, there is an increase in skin cells and secretion of extracellular matrix (ECM), which 
is mainly caused by the myofibroblasts. During normal wound repair, myofibroblasts go into apoptosis, and wound 
remodeling leads to an acellular scar, however under pathological conditions myofibroblasts fail to die and 
continue contraction and the production of ECM, leading to excessive scar formation.  
 
1.5 Mechanical, oxidative, and inflammatory stress promote excessive scar 
formation 
 
Hampered wound repair can lead to chronic non-healing wounds and severe scar formation, 
e.g., hypertrophic or keloid scars, and may result in loss of function, itching, and cosmetic 
malformations (33, 80-84). Keloids have a genetic linkage and contain thick collagen fibers, 
whereas hypertrophic scars contain thin collagen fibers, which are organized into nodules 
(85, 86). The quality of the wound healing process is determined by the cause and severity 
of the trauma, environmental factors and individual conditions, like age (87), weight (88), 
nutritional status (60, 89), hydration status, comorbidities (88), and medication (62, 72). In 
most chronic wounds, the healing process gets stuck in the inflammatory or proliferative 
phase (90, 91). In acute and chronic wounds, growth factors, cytokines, proteases, and ECM 
molecules play important roles in the different stages of the healing process (61). 
Alterations in one or more of these components could lead to impaired wound repair. The 
vital role of a good working vasculature structure is supported by diabetic and elderly 
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patients, which often suffer from bad healing ulcers due to the lack of good blood supply 
(92). In addition, ischemia and oxidative damage by reactive oxygen species (ROS) may have 
an important role in the non-healing nature of chronic wounds and scar development in 
acute wounds (93). Myofibroblasts speed up wound healing by contraction and by secreting 
ECM molecules. When these cells fail to go into apoptosis, myofibroblasts continue to 
produce ECM (77, 84, 94). These persisting myofibroblasts can lead to mechanical stress on 
the wound and scar formation (Figure 1.3) (76). Also, since babies with a cleft are still 
growing, this leads to extra mechanical stress on the healing wound and may promote 
excessive scar formation (13).  
Under pathologic conditions, such as prolonged inflammation and elevated levels 
of ROS, defective wound repair can develop into chronically inflamed open wounds and/ or 
excessive scarring (33, 81). Patients with increased oxidative stress and inflammation, such 
as diabetic, obese, and elderly people are more prone to develop pathologically healing 
wounds, fibrosis, and scar formation, and their progeny have increased incidence in 
congenital abnormalities, such as CL/P, despite current therapies (95-100). Impaired wound 
healing should be addressed with suitable and effective therapies, for example by the 
inhibition of the inflammatory response in injured tissues (27). Proper wound care stands 
at the basis of wound repair as it determines the outcome of the regenerating tissue. 
Wound repair strategies have evolved for millennia, but the repair process is still not 
completely understood. 
 
1.6 Evolution of wound repair strategies throughout history  
 
Throughout history, humans have been exposed to injuries and challenged to prevent blood 
loss and infection. One of the oldest medical manuscripts describing wound care is a 
Sanskrit clay tablet (Persia) dating back to 2200 BC (101). The tablet describes three healing 
procedures that still exist today: washing the wound (cleansing), making plasters (topical 
therapy), and bandaging the wounds (dressings) (102). Plasters consisted of mixtures of 
substances including mud or clay, molded bread, meat, oil, plants, and herbs, and were 
applied to wounds to achieve hemostasis and provide protection (103).  
Egyptians used honey, Aloe vera, animal fat, and lint as described in the Smith and 
Ebers papyri in circa 1600 BC and 1500 BC, respectively (104, 105). Although the Egyptians 
closed the wounds mainly to prevent evil spirits from invading, it also had functional effects. 
The lint probably aided wound drainage, the fat provided a barrier to environmental 
pathogens, molded bread led to the production of penicillin, and the honey served as a 
natural antibiotic, and thereby together preventing infection (106). The use of honey for 
wound therapy was also used in India more than two millennia ago and is still part of 
modernly advanced wound dressings (107, 108).  
The Greeks stressed the importance of cleanliness and washed the wounds with 
clean (first boiled) water, vinegar (acetic acid), and wine as described by Hippocrates (400 
BC) (103, 109). In addition, they applied cold or a tourniquet to stop bleeding and used a tin 
pipe (syringe) for drainage of pus (110). They also acknowledged the importance of rapid 
wound closure and discriminated between acute (fresh) and chronic (non-healing) wounds 
(103).  
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The Roman Celsus (25BC- 50AD) focused, in addition to controlling hemorrhage, 
also on inflammation, and was the first to describe four fundamental signs of infection: 
rubor, tumor, calor, and dolor (redness, swelling, heat, and pain) (110, 111).  
Two centuries later, the Greek surgeon Galen of Pergamum (200 BC), who served 
Roman gladiators, made large contributions to the fields of anatomy and physiology and 
postulated different treatments to stop hemorrhage (112). He acknowledged the 
importance of maintaining wound-site moisture, applied styptics, used silk to tie off 
bleeding vessels, and believed in blood-letting (113, 114). During the Middle Ages and until 
the Renaissance, Galen’s theories were considered the sole truth. Except for the progress 
in anatomy and the discovery of the circulatory system attributed to Leonardo Da Vinci 
(1452-1519), Andreas Vesalius (1514-1564), and William Harvey (1578-1657), there were 
limited advances in wound therapy besides using hot iron/ oil, egg yolk, and turpentine, 
maggot therapy, or silver nitrate to aid wounds (110).  
Profound advances were made in the 19th century with the development of 
microbiology and the “cell theory” that described the formation, proliferation, and 
regeneration of cells (115, 116). In 1858, Rudolf Virchow added the fifth sign of 
inflammation being ‘function loss’ (functio laesa) (117, 118). 
The interaction of the cells with micro-organisms and the relation with “diseases” 
was made by Louis Pasteur (germ theory of diseases) (119), and antiseptic treatments made 
advances: Ignaz Semmelweis (hand washing) (120), Joseph Lister (sterilization of surgical 
gauze with carbolic acid/ phenol as anti-septic agent) (121), and Robert Wood Johnson (co-
founder of Johnson and Johnson: sterilization of gauze and wound dressings with dry heat, 
steam and pressure) (110).  
The discovery of penicillin by Alexander Fleming (1928), and oral antibiotics (1940) 
revolutionized clinical therapy and helped control infections and decreased mortality (122). 
The last decades more insights into the inflammatory process were gained, and wound 
dressings were further optimized using different materials, and loaded with substances as 
honey, iodide, silver, antibiotics, (stem) cells, and growth factors (123, 124).  
Conventional and novel therapies, such as wound irrigation (125), the use of 
dressings, bandages and bioengineered skin (58, 126), silicone sheets (80), topical 
application of antibiotics and growth factors (87, 127), pressure therapy (126), (hyperbaric) 
oxygen therapy (67, 128), and steroid injections (129), to reduce hypertrophic scarring have 
improved wound repair. 
Unfortunately, these therapies are still of limited success and urge for alternative 
adjuvant wound therapies (82, 130). A better understanding of the injurious and 
cytoprotective factors involved during wound repair is necessary to target the decisive 
factors that determine wound regeneration. 
 
1.7 The levels of injurious and cytoprotective factors determine scar formation 
 
Following injury, as presently following CL/P surgery, pro-oxidative and pro-inflammatory 
stimuli, such as heme, ROS, and pro-inflammatory cytokines are released. This may lead to 
extended survival of myofibroblasts and subsequently promote excessive scar formation.  
Wound repair in early embryos is fast, efficient and scarless, an ability that is lost 
as development proceeds (30, 131, 132). A major difference between embryonic and adult 
wound repair is the strong presence of an inflammatory response at sites of adult wound 
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repair, whereas in embryos the inflammatory response is strongly attenuated (30, 131, 133, 
134).  
A swift resolution of acute inflammation or better protection against these 
injurious stressors seems thus crucial to protect from chronic inflammation, collateral 
damage and excessive scarring. In order to ameliorate wound repair, the balance of 
injurious and protective factors should thus be shifted towards an enhanced cytoprotective 
microenvironment. For this thesis, different strategies to harness inflammation and 
oxidative stress and to improve wound repair and regeneration were therefore probed.  
 Protective mechanisms that can be triggered to improve wound repair are using 
preconditioning strategies, inducing the cytoprotective HO system, and administration of 
stem cells. We will next introduce these subjects in more detail. 
 
1.8 Preconditioning 
 
Preconditioning is the phenomenon that exposure to a substance or little stressor in 
advance to a more harmful stressor reduces tissue damage by inducing cytoprotective 
responses (135). Different preconditioning strategies have been demonstrated to protect 
against oxidative or inflammatory stress in a variety of conditions, such as ischemia-
reperfusion injury (IRI), surgery, and organ transplantation (136-138). Several forms of 
preconditioning exist such as pharmacological and ischemic preconditioning (IPC). 
Pharmacological preconditioning may include medicinal treatments such as administration 
of the anticoagulant heparin to prevent thrombosis and embolisms, or inducers of the 
cytoprotective enzyme HO, which has shown to improve cell survival and to avoid tissue 
damage. IPC is mediated by (repeated) short cycles of ischemia-reperfusion to an organ and 
has shown to protect this organ against subsequent stronger stress. With remote IPC (RIPC) 
not the target organ is subjected to this first stress but a remote organ, e.g., a limb (139, 
140). RIPC has shown promising effects in several settings. 
 
1.9 The heme oxygenase system 
 
One of the most important examples of cytoprotective pathways forms the HO system. HO 
is the rate-limiting enzyme breaking down heme into biliverdin, free iron (Fe2+) and carbon 
monoxide (CO). Biliverdin is rapidly converted into the anti-oxidant bilirubin by biliverdin 
reductase (141, 142). Two distinct isoforms (HO-1 and HO-2) have been identified. HO-2 is 
constitutively expressed, whereas HO-1 is an inducible form and can be induced by a variety 
of pathophysiological stimuli, such as heme, cytokines, endotoxins, hypoxia and oxidative 
stress (143). HO-activity has major effects on the different phases of wound healing, and 
HO-induction leads to an improved and enhanced wound healing, whereas inhibition or lack 
of HO leads to a slower wound repair (144, 145). HO-1 induction is considered to be an 
adaptive cellular response that resolves inflammation enabling inflamed tissues to return 
to homeostasis (146).  
HO-activity improves many aspects that are hampered during tissue repair creating 
a less hostile environment. It suppresses oxidative stress, inflammation, and the formation 
of myofibroblasts from fibroblasts, promotes myofibroblast apoptosis, cell proliferation, 
and angiogenesis, and modulates cytokine expression, probing other protective responses 
(147, 148). HO-activity is important in counteracting various pathological conditions by 
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creating an antioxidant environment that overcomes injurious stressors and hence 
improving the outcome of tissue repair. Choosing the right therapy for specific wounds and 
improving the outcome of wound repair without resulting in function loss and scar 
formation is the next challenge.  
 
1.10 Stem cells  
 
Stem cells can differentiate into different cell types and are crucial during embryogenesis, 
palatogenesis, and repair of injured tissue. Stem cells are stored in niches, and upon 
activation by injury, these cells are mobilized to the site of injury where they can 
differentiate into any cell type necessary for wound repair (149-152). In addition, these 
stem cells produce cytoprotective and anti-inflammatory factors that help to create a micro-
environment permissive for regeneration (96, 149, 153-158). Stem cell therapy is clinically 
used in diverse pathologies, such as leukemia and rheumatoid arthritis, and forms a 
promising novel adjuvant treatment in wound repair to prevent scarring (96, 123, 150, 159-
161). Wound repair can be improved by inducing re-epithelialization and angiogenesis, but 
also by inhibiting oxidative and inflammatory responses (96, 153, 154, 162-170). The 
cytoprotective environment created by the stem cells inhibits the formation of 
myofibroblasts from fibroblasts and prevents fibrosis and hypertrophic scarring (78, 96, 
150, 159, 160, 171). Whether the differentiation potential of the stem cells or their 
paracrine effects plays the major role in wound repair is still point of discussion. Since stem 
cells die quickly after administration to an injury and conditioned media derived from stem 
cells by itself can improve wound repair, it is suggested that the paracrine effects play the 
major role (172-176). In line with this, unilateral administration of stem cells to two-sided 
excisional wounds improved wound repair on both sides, further supporting a role for 
systemic paracrine effects (177). Even when stem cells administered to wounds do not 
differentiate, they can still produce protective paracrine factors, and thus increasing the 
survival of stem cells during therapy may further support their efficacy. 
Many studies are showing that administration of mesenchymal stem cells (MSCs) 
in wound healing is effective and contributes to an enhanced wound repair and proper skin 
restoration during all phases of wound healing in both rodents and humans, (151, 153-155, 
164, 165, 178-182). This has been extensively reviewed by Chen et al. (183), Jackson et al. 
(78, 184), and Maxson et al. (185).  
 
1.11 Objectives and research questions 
 
The purpose of this thesis is to explore several protective strategies to better understand 
the decisive factors determining between tissue repair and damage by studying 
developmental, inflammatory, and wound healing processes. We postulate that decreased 
activity of protective pathways (Part I) will impair wound repair and palatogenesis, whereas 
induction of protective signaling cascades (Part II), will provide a regenerative environment 
that improves wound repair and promotes regeneration (Figure 1.4). 
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Figure 1.4: Summary of the strategies in this thesis to harness inflammatory and oxidative stress  
Reactive oxygen species (ROS), inflammation, mechanical stress, and decreased protective molecules and 
mechanisms promote excessive scar formation (part I). We postulate that inducing protective pathways (part II), 
such as the heme oxygenase (HO) system, administration of stem cells, and applying remote ischemic 
preconditioning (RIPC) will skew the balance towards the formation of a minimal acellular scar. We expect that 
these strategies will neutralize ROS and inflammation, attenuate myofibroblast formation or induce myofibroblast 
apoptosis, stimulate angiogenesis and homeostasis.  
 
Research question 1: How do decreased protective factors contribute to impaired 
palatogenesis and wound repair? 
Genetic components play a large role in the etiology of CL/P. Some of these genes may 
affect protective factors that regulate the levels of oxidative and inflammatory signals. A 
lack of protective signaling pathways most probably will result in hampered wound repair. 
In this thesis, we will investigate the contribution of reduced protective signaling on 
palatogenesis and wound repair using mouse models with mutations that specifically 
knockout protective genes, or apply constant mechanical stress such as also is experienced 
on the wounds of a growing patient after CL/P surgery.  
 
Research question 2: How to harness oxidative and inflammatory stress to facilitate 
wound repair and regeneration? 
Inflammation needs to be controlled to prevent chronic non-healing wounds or excessive 
scar formation. Resolution of acute inflammation is mediated and controlled by 
endogenous antioxidant and anti-inflammatory regulators and pathways. Together these 
protective factors are crucial for preventing excessive tissue damage, chronic inflammation, 
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and allowing normal wound repair. The inflammatory resolution will attenuate the influx of 
activated leukocytes and edema formation into the wounded tissues and thereby form a 
regenerative environment. Therefore, pro-inflammatory chemokines, cytokines, and cell 
adhesion molecules need to be reduced by upregulating cytoprotective pathways. 
 
1.12 Outline of the thesis 
 
In Part I, we investigated the effect of diminished protective pathways:  
• during excisional wound repair; using knockout mice lacking the constitutively 
expressed cytoprotective enzyme HO-2 (Chapter 2),  
• during embryogenesis; using HO-2 deficient mice, in order to better understand 
the process of embryonic development and palatogenesis, and to unravel novel 
therapeutic targets to prevent CL/P formation and improve wound repair (Chapter 
3), 
• as experienced during excisional wound repair under constant mechanical stress, 
such as experienced in growing patients with CL/P after surgery, using a splinted 
excisional wound model; the natural physiological role of HO-1 during this process 
will be evaluated (Chapter 4). 
 
In Part II, the induction of protective mechanisms will be studied as potential 
preconditioning strategy to improve cutaneous wound repair and protection against stem 
cell apoptosis, in specific 
• if the induction of HO-1 can prevent oxidative stress-induced mesenchymal stem 
cell (MSC) death (Chapter 5), 
• whether remote ischemic preconditioning (RIPC) can improve cutaneous wound 
repair via an HO-1 dependent mechanism (Chapter 6), 
• how danger signals and tissue survival factors can discriminate between immune 
activation and tissue protection (Chapter 7). 
 
In Part III, our main findings will be discussed, and future perspectives are proposed 
(Chapter 8). Summaries are given in English (Chapter 9) and Dutch (Chapter 10). 
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Abstract 
Impaired wound healing can lead to scarring, and esthetical and functional problems. The 
cytoprotective heme oxygenase (HO) enzymes degrade heme into iron, biliverdin and 
carbon monoxide. HO-1 deﬁcient mice suffer from chronic inﬂammatory stress and delayed 
cutaneous wound healing, while corneal wound healing in HO-2 deﬁcient mice is impaired 
with exorbitant inﬂammation and absence of HO-1 expression. This study addresses the role 
of HO-2 in cutaneous excisional wound healing using HO-2 knockout (KO) mice. Here, we 
show that HO-2 deﬁciency also delays cutaneous wound closure compared to WT controls. 
In addition, we detected reduced collagen deposition and vessel density in the wounds of 
HO-2 KO mice compared to WT controls. Surprisingly, wound closure in HO-2 KO mice was 
accompanied by an inﬂammatory response comparable to WT mice. HO-1 induction in HO-
2 deﬁcient skin was also similar to WT controls and may explain this protection against 
exaggerated cutaneous inﬂammation but not the delayed wound closure. Proliferation and 
myoﬁbroblast differentiation were similar in both two genotypes. Next, we screened for 
candidate genes to explain the observed delayed wound closure and detected delayed gene 
and protein expression proﬁles of the chemokine (C-X-C) ligand-11 (CXCL-11) in wounds of 
HO-2 KO mice. Abnormal regulation of CXCL-11 has been linked to delayed wound healing 
and disturbed angiogenesis. However, whether aberrant CXCL-11 expression in HO-2 KO 
mice is caused by or is causing delayed wound healing needs to be further investigated. 
 
Keywords: heme oxygenase, wound healing, skin. 
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Abbreviations  
αSMA Alpha-smooth muscle actin 
ColIV Collagen IV 
CXCL-11 Chemokine (C-X-C) ligand 11 
CXCR3   Chemokine (C-X-C) receptor 3 
Gr-1 Granulocyte receptor antigen-1 
HO   Heme oxygenase 
HPF  High power field 
KO Knockout 
MMP Matrix metalloproteinase 
ROS Reactive oxygen species 
WT Wild-type 
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Introduction 
Cutaneous wound repair occurs in temporally coordinated and overlapping phases: 
inﬂammation, granulation tissue formation and remodelling (1). The timely progression of 
the different phases is coordinated by cytokines and growth factors, and each phase is 
characterized by the presence of speciﬁc cell types (2). Both clinical and experimental 
studies have conﬁrmed the importance for a well-regulated inflammatory resolution for 
proper wound healing, since prolonged inﬂammatory and oxidative stress may cause non-
healing, chronic wounds or excessive scarring (3, 4). 
Heme oxygenases (HO) are enzymes that degrade heme into biliverdin, carbon 
monoxide and iron. Biliverdin is then converted into the antioxidant bilirubin by biliverdin 
reductase. HO-1 is highly inducible by a wide range of stresses, including inﬂammatory and 
oxidative stress, whereas HO-2 is mainly constitutively expressed (5, 6). The HO system is 
important in the resolution of inflammation (7, 8). The cytoprotective effects of the stress-
induced HO-1 are evident in various pathological models and settings, whereas the 
constitutive HO-2 is important for physiological maintenance of the heme pool (9).   
HO-1 deficient humans and mice demonstrate chronic inflammatory stress 
accompanied by increased leukocyte recruitment (10, 11). Moreover, genetic or 
pharmacologic ablation of HO-1 expression and activity in mice results in slower cutaneous 
wound closure (12). Also, HO-2 deficient mice show delayed wound healing and an 
exaggerated inflammatory response after corneal epithelial wounding (13, 14) which was 
associated with impaired HO-1 induction and function (13). Notably, HO-2 levels have been 
suggested to regulate HO-1 expression and function in a cell and tissue-specific manner (15), 
and compensatory HO-1 expression in HO-2 deﬁcient tissue has been reported (16, 17). 
Moreover, genetic or pharmacological HO-1 induction as well as administration of HO 
effector molecules biliverdin/bilirubin down-regulate the inflammatory response and 
restore wound healing in HO-1 deficient skin (12, 18) and HO-2 deficient cornea (14, 19). On 
the other hand, HO-1 has pro-angiogenic effects via regulating VEGF synthesis (20, 21). 
Wound healing in HO-1 KO mice occurs with reduced neovascularization in the skin (12) 
whereas exaggerated angiogenesis was found in HO-2 deficient corneas (19). Application of 
biliverdin ameliorated this pathologic angiogenesis occurring after corneal wounding in HO-
2 KO mice (19).   
Because of the described intricate involvement of both HO-1 and HO-2 in wound 
healing and regulation of inﬂammatory responses, this study focused on exploring the 
possible role of HO-2 in cutaneous wound healing using a full-thickness excisional wound 
model and HO-2 KO mice. 
 
Methods and materials 
Animals 
Homozygote HO-2 KO mice generated by targeted disruption of the HO-2 gene (22) and WT 
mice were bred in-house on a mixed 129Sv x C57BL/6 background. Mice were provided with 
food and water ad libitum and maintained on a 12h light/dark cycle and speciﬁc pathogen-
free conditions. All experiments and protocols were approved by the institutional Radboud 
University Nijmegen animal experimentation committee. 
 
Excisional wound model 
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Prior to wounding 6–12 weeks old female mice were shaved using an electrical clipper. The 
following day four full-thickness wounds were made on the back including the m. panniculus 
carnosus using a sterile disposable 4-mm biopsy punch (Kai Medical, Seki City, Japan) and 
the mice were left uncovered to heal (n = 18/genotype). At day 2 after wounding mice were 
killed, and the remaining mice (n = 9/genotype) were followed until day 7 (n = 9/genotype). 
For gene transcript analysis mice were wounded (n = 12/genotype) and killed at day 2 (n = 
6/genotype) and day 5 (n = 6/genotype) after wounding. Punched out tissue at day 0 was 
collected as control. Wounds were collected using a disposable 6-mm biopsy punch (Kai 
Medical) allowing collection of the complete wound together with the surrounding normal 
tissue. 
 
Wound size analysis 
Wounds were digitally documented on different days with a ruler placed next to the wounds 
for size normalization. Wound area was measured at least twice by a blinded investigator 
using ImageJ (NIH) v1.44p software. 
 
Immunohistochemistry 
Tissue samples were ﬁxed for 24h in 4% paraformaldehyde and further processed for 
routine parafﬁn embedding. Sections were deparafﬁnized using Histosafe and rehydrated 
using an alcohol range. Endogenous peroxidase activity was quenched with 3% H2O2 in 
methanol for 20 min., and immunohistochemical stainings were performed and 
photographed as previously described (23). Photographs were taken on a Carl Zeiss Imager 
Z.1 system (Carl Zeiss Microimaging Gmbh, Jena, Germany). For antibodies and antigen 
retrievals used, see Table 2.1. 
 
Table 2.1. Antibodies used for immunohistochemistry 
 
Antibody Specificity Dilution Antigen retrieval Source 
SPA-895 HO-1 1:800 A Stressgen, Victoria, BC, USA 
OSA-200 HO-2 1:800 A Stressgen 
MCA497R F4/80 1:200 A AbD Serotec, Kidlington, UK 
2233PCO Collagen IV 1:200 A Euro-Diagnostica, Malmo, Sweden 
Sc-34785 CXCL-11 1:100 B Santa Cruz Biotechnology, CA, USA 
A2547 αSMA 1:600 A Sigma Aldrich, St. Louis, MO, USA 
A: 10 mM citrate buffer 70°C for 10 min, followed by trypsin digestion for 7 min.  
B: 10 mM citrate buffer RT, 120 min.  
 
Semi-quantitative scoring of immunohistochemical sections 
HO-1 and F4/80 immunoreactivity were evaluated as the number of positive cells (based on 
the percentage of positive staining) and staining intensity of four sections per animal. Extent 
was scored as: 0, ≤5%; 1, 6–25%; 2, 26–50%; 3, >50%. Intensity was scored as: 0, weak; 1, 
moderate; 2, strong. Intensity was designated as weak when only barely detectable. To 
correlate extent and intensity on the staining, a composite score was calculated by 
multiplying the individual scores of extent by intensity. Scoring was done three times by a 
blinded investigator. CXCL-11 immunoreactivity was evaluated by scoring a single section 
per animal by two independent investigators as previously described (24). To assess αSMA 
immunoreactivity four sections per animal were scored twice as earlier described (25). 
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Vascularization was assessed twice on ﬁve high-power ﬁelds (HPF; 400x magnification) on 
four sections per animal as previously described (26). A mean score per animal was used for 
further analysis. 
 
Collagen deposition 
Collagen deposition in AZAN stained wound sections (1–4 sections/ mouse) was determined 
by image analysis using a macro built in Image J (27). The wound area was manually deﬁned 
before running the macro using the edges of the m. panniculus carnosus and epithelium as 
boundaries. Measurements were performed twice, and mean intensity/mm2 per mouse 
was used for further analysis. 
 
Assessment of mRNA expression by quantitative real-time PCR 
Total RNA was extracted from skin and wound samples by using Trizol (Invitrogen, Carlsbad, 
CA, USA) and a RNeasy Mini kit (Qiagen, Hilden, Germany), and cDNA was produced using 
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). To screen for differences in gene 
expression proﬁles of wound associated genes in HO-2 KO and WT mice, pooled cDNAs 
synthesized from individual wounds of HO-2 KO and WT mice isolated at day 5 were tested 
on a Mouse Wound Healing RT2 ProfilerTM PCR Array according to the manufacturer’s 
instructions (SABiosciences, Frederick, MD, USA). Individual cDNAs from all time-points 
were subsequently analyzed for genes up- or down-regulated more than two-fold using 
custom-designed primers (Table 2.2) and iQ SYBR Green Supermix (Invitrogen) in a CFX96 
Real-Time PCR system (Bio-Rad). Relative gene expression values were evaluated using the 
2-ΔΔCt method using GAPDH as housekeeping gene (28). Fold changes were normalized to 
WT mean day 0. 
Table 2.2. Murine primers used for qPCR 
Gene Fw primer (5’→3’) Rv primer (5’→3’) Reference 
HO-1 CAACATTGAGCTGTTTGAGG TGGTCTTTGTGTTCCTCTGTC - 
HO-2 AAGGAAGGGACCAAGGAAG AGTGGTGGCCAGCTTAAATAG - 
TNF CTCTTCTCATTCCTGCTTGTG GAATTGTCCATCTGGCATAAC - 
CXCL-11 CACGCTGCTCAAGGCTTCCTTATG TGTCGCAGCCGTTACTCGGGT - 
Gr-1 TGGACTCTCACAGAAGCAAAG GCAGAGGTCTTCCTTCCAACA - 
F4/80 AATCCTGTGAAGATGTGG GAGTGTTGATGCAAATGAAG - 
ACTA2 CAGGCATGGATGGCATCAATCAC ACTCTAGCTGTGAAGTCAGTGTCG (29) 
GAPDH GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCCTG - 
 
Western blotting 
Protein was extracted from homogenized 4-mm skin biopsies in 100 µl lysis buffer (1 mM 
EDTA, 0.5% Triton X-100, complete protease inhibitor cocktail (Roche, Penzberg, Germany), 
100 µM PMSF), and Western blotting using primary antibodies against HO-1 and HO-2 (SPA-
895 and OSA-200, 1:5000; Stressgen, Victoria, BC, USA) was performed as previously 
described (30).  
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 4.03 software. Normal data 
distribution was assessed using the Kolmogorov–Smirnov test. In case of non-normality, 
data were transformed. Statistical differences in qPCR data, wound closure and collagen 
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deposition were determined using Student’s t-test with Bonferroni-correction in case of 
multiple testing. Semi-quantitative scores were analyzed with non-parametric Mann–
Whitney U test or Kruskall–Wallis test with Dunn’s post hoc test. Collagen deposition, 
wound closure and qPCR data are presented as mean ± SD. Semi-quantitative scores are 
presented as box-and-whisker plots of median with 10–90 percentiles. p<0.05 was 
considered statistically signiﬁcant. 
 
Results 
Delayed cutaneous wound closure in HO-2 deﬁcient mice 
Prior to experimental start, we veriﬁed that HO-2 KO mice indeed were devoid of HO-2 
mRNA and protein expression (Figure S2.1). To investigate the role of HO-2 in cutaneous 
wound closure, full-thickness wounds were made on the backs of HO-2 KO and WT mice 
and monitored in time (Figure 2.1). Wound area assessment demonstrated signiﬁcantly 
larger wounds in HO-2 KO mice compared to WT controls at day 2 [6.9 ± 1.8 mm2 versus 5.1 
± 1.1 mm2 (n = 18/ genotype); p<0.01], day 5 [4.9 ± 1.6 mm2 versus 2.3 ± 0.4 mm2 (n = 
9/genotype); p<0.001] and day 7 [2.1 ± 0.6 mm2 versus 1.1 ± 0.3 mm2 (n = 9/genotype); 
p<0.001] after wounding. 
 
Normal inﬂammatory response in HO-2 KO mice after cutaneous wounding 
To determine whether delayed cutaneous wound healing in HO-2 KO mice is because of an 
exaggerated inﬂammatory response as observed after corneal injury, we compared gene 
expression proﬁles of different inﬂammatory factors and cell markers in skin of HO-2 KO 
and WT mice at day 2 and 5 (Figure 2.2). The pro-inﬂammatory cytokine TNF and the stress-
induced enzyme COX-2 demonstrated an injury-induced increase in transcript levels 
compared to unwounded skin in both WT and HO-2 KO mice, however, we did not detect 
any differences between the two genotypes at any of the investigated time points (Figure 
2.2A and B). Furthermore, granulocyte marker receptor antigen-1, Gr-1 and macrophage 
marker F4/80 both demonstrated an injury-induced increase in transcript levels compared 
to unwounded skin, however, no differences between HO-2 KO and WT mice were evident 
(Figure 2.2C and D). This was also reﬂected at the protein level, as semi-quantitative 
assessment of F4/80 immunoreactivity in wound sections demonstrated no signiﬁcant 
differences between HO-2 KO and WT mice at day 2 and day 7 after wounding (Figure 2.2E 
and F). 
 
A).      B). 
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Supplemental Figure S2.1. Cutaneous HO-2 expression in WT and HO-2 KO mice. 
(A) HO-2 gene transcript levels in WT (white bars) and HO-2 KO (grey bars) mice in time presented as mean ± SD. 
Controls represent samples collected at day 0, and data was normalized to WT mean day 0. (B) Western blot (insert) 
of cutaneous HO-2 protein expression in unwounded skin of WT (white bar) and HO-2 KO (grey bar) mice. Band 
intensity was normalized to housekeeping protein β-actin. Data is presented as mean ± SD. (C) 
Immunohistochemical staining of HO-2 in skin sections of WT and HO-2 KO mice at day 2 and day 7 after wounding. 
Anatomical indications by E, epidermis; D, dermis; H, hypodermis; Pc, panniculus carnosus. Bars, 500 µm (upper 
panel), 100 µm (lower panel).  
 
A). 
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Figure 2.1 Slower cutaneous wound closure in HO-2 KO after excisional wounding. (A) Wound closure in WT (upper 
panel) and HO-2 KO (lower panel) mice in time; bar, 5 mm. (B) Wound area (mm2) reduction in WT (white bars) 
and HO-2 KO (grey bars) mice in time presented as mean ± SD. **p<0.01, ***p<0.001. 
 
A).      B). 
   
C).     D). 
     
F). 
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E).       
      
Figure 2.2 HO-2 KO mice demonstrate a normal inﬂammatory response after wounding. Gene transcript levels of 
pro-inﬂammatory proteins (A) TNF and (B) COX-2 and inﬂammatory cell markers (C) Gr-1, and (D) F4/80 in WT 
(white bars) and HO-2 KO (grey bars) mice in time presented as mean ± SD. Controls are tissue biopsies collected 
at day 0, and data were normalized to WT mean day 0. (E) Box-and-whisker plot with 10–90 percentiles of semi-
quantitative assessment of F4/80 immunoreactivity in (F). (F) F4/80 immunoreactivity in representative wound 
sections of WT and HO-2 KO mice at day 2 and 7 after wounding. Anatomical indications by E, epidermis; D, dermis; 
H, hypodermis; Pc, panniculus carnosus; bars, 500 µm (upper panel), 100 µm (lower panel). 
 
Injury-induced HO-1 expression in both HO-2 KO and WT mice 
In contrast to HO-2 deﬁcient cornea (13) we detected both HO-1 mRNA transcript and 
protein in the skin of HO-2 KO mice (Figure 2.3). Similar levels of HO-1 protein were detected 
in unwounded skin of HO-2 KO and WT mice (6.9 ± 3.2 and 9.3 ± 6.7, respectively; Figure 
2.3A). Also, a comparable injury-induced increase in HO-1 transcript levels was evident in 
both HO-2 KO and WT mice (Figure 2.3B). Furthermore, injury-induced HO-1 protein 
expression was detected in both WT and HO-2 KO skin (Figure 2.3C). HO-1 positive cells 
were present at high numbers both in the wound area and in the surrounding tissue at day 
2, while at day 7 HO-1 positive cells were predominantly found in the wound area (Figure 
2.3C). Semi-quantitative assessment of HO-1 immunoreactivity demonstrated a signiﬁcant 
reduction in HO-1 expression at day 7 compared to day 2 in both WT and HO-2 KO wounds 
(P<0.05 for both genotypes), however, no signiﬁcant differences between the genotypes 
were detected (Figure 2.3D). 
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Figure 2.3 HO-2 KO mice induce cutaneous HO-1 expression after wounding. (A) Western blot (insert) of cutaneous 
HO-1 expression in unwounded skin in WT (white bar) and HO-2 KO (grey bar) mice. Band intensity was normalized 
to housekeeping protein β-actin. Data are presented as mean ± SD. (B) HO-1 gene transcript levels in WT (white 
bars) and HO-2 KO (grey bars) mice in time as represented as mean ± SD. Controls represent biopsies collected at 
day 0, and data were normalized to WT mean day 0. (C) HO-1 immunoreactivity in representative wound sections 
of WT and HO-2 KO mice at day 2 and day 7 after wounding. Anatomical indications by E, epidermis; D, dermis; H, 
hypodermis; Pc, panniculus carnosus; bars, 500 µm (upper panel), 100 µm (wound, periphery). (D) Semi-
quantitative scores of HO-1 immunoreactivity in (C) presented as box-and-whisker plot with 10–90 percentiles. 
*p<0.05. 
 
Reduced collagen deposition and lower vessel density in HO-2 KO wounds 
HO-2 KO mice demonstrated no abnormalities compared to WT mice with respect to the 
inﬂammatory phase. We therefore questioned whether the delayed wound healing was a 
result of a dysregulated granulation phase. Assessment of collagen deposition in wound 
sections of HO-2 KO and WT mice using an Image J macro demonstrated a signiﬁcant lower 
percentage collagen deposition per area in HO-2 KO wounds compared to WT controls at 
day 7 after wounding (8.8 ± 4.2%/mm2 versus 29.8 ± 10.8%/mm2, p<0.001; Figure 2.4A and 
B). Also, we investigated the degree of vascularization in the wound areas of HO-2 KO and 
WT mice by semi-quantitative scoring of wound sections stained for collagen IV, a basement 
membrane protein found in the walls of blood vessels (31). We detected a signiﬁcant lower 
density of vessels per HPF in wound sections of HO-2 KO mice compared to WT mice at day 
7 after wounding (p<0.05; Figure 2.4C and D). We wondered if the delayed wound healing 
could be related to a lower cell proliferation capacity in HO-2 deﬁcient cells, and we 
therefore assessed the mRNA levels of Ki67, a marker of actively cycling cells (32). We 
detected a time-dependent increase in Ki67 mRNA levels consistent with an increased inﬂux 
and proliferation of wound repair associated cells; however, no differences between HO-2 
KO and WT mice were evident at any of the investigated time-points (Figure 2.5A). 
During the granulation phase keratinocytes dominate epithelization and 
(myo)ﬁbroblasts produce ECM such as collagen and close the wound (33). We therefore 
investigated whether the presence of less (myo)ﬁbroblasts could be an explanation for the 
reduced collagen deposition. We detected similar mRNA levels of ACTA2, the murine 
counterpart of myoﬁbroblast marker αSMA, at all examined time-points (Figure 2.5B). 
Moreover, we did not detect any difference in αSMA protein immunoreactivity level at day 
7 after wounding as evaluated by semi-quantitative scoring (Figure 2.5C and D). 
 
A).  
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Figure 2.4 Reduced collagen deposition and vessel density in HO-2 KO mice. (A) Representative images of AZAN 
stained wound sections of WT and HO-2 KO mice at day 7 after wounding; bar, 200 µm. (B) Collagen deposition in 
WT (open circles) and HO-2 KO (closed circles) mice at day 7 after wounding. (C) Representative images of collagen 
IV immunoreactivity, a common blood vessel marker, in WT and HO-2 KO mice at day 7 after wounding; bar, 200 
µm. (D) Semi-quantitative scoring of high-power ﬁelds of (C). Data are represented as box-and-whisker plot with 
10–90 percentiles. *p<0.05, ***p<0.001. 
 
A).      B).  
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Figure 2.5 Myoﬁbroblast differentiation occurs in HO-2 KO mice. Ki67 (A) and ACTA2 (B) gene transcript levels in 
WT (white bars) and HO-2 KO (grey bars) mice in time as represented as mean ± SD. Controls represent biopsies 
collected at day 0, and data were normalized to WT mean day 0. (C) Representative images of αSMA 
immunoreactivity in wounds of WT and HO-2 KO mice at day 7 after wounding; bar, 200 µm. (D) Semi-quantitative 
scoring of αSMA in (C) presented as box-and-whisker plot with 10–90 percentiles. 
 
Different expression levels of CXCL-11 in WT and HO-2 KO mice after wounding 
HO-1 deﬁciency is linked to delayed wound healing and impaired angiogenesis after injury. 
However, HO-2 deﬁcient skin demonstrates injury-induced HO-1 expression, and we 
therefore wondered which genes could be explanatory for the reduced collagen deposition 
and lower vessel density observed in HO-2 KO mice. First, we compared gene expression 
proﬁles of pooled cDNAs isolated from day 5 wound tissue of HO-2 KO and WT mice using 
a PCR wound healing array, followed by validation by custom-designed primers and 
individual cDNAs. Unexpectedly, after individual validation we only detected signiﬁcant 
differences between HO-2 KO and WT mice in the expression proﬁle of a single gene out of 
84 screened genes, namely CXCL-11 (Figure 2.6A, data not shown). Injury-induced CXCL-11 
gene transcription observed in WT mice was absent in HO-2 KO mice at day 2 (49.4 ± 25.3 
versus 11.5 ± 5.1; p<0.05). However, at day 5 after wounding we detected similar CXCL-11 
gene transcription levels in WT and HO-2 KO mice, which was mainly because of a down-
regulation of gene transcription in WT mice (Figure 2.6A). In contrast, immunohistochemical 
staining and semi-quantitative scoring of wound tissue isolated from HO-2 KO and WT mice 
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7 days after wounding showed a markedly higher level of CXCL-11 positive cells in the 
wounds of HO-2 KO mice compared to WT controls (p= 0.0503; Figure 2.6B and C). 
 
A). 
  
B). 
 
C). 
 
Figure 2.6 Different CXCL-11 expression in HO-2 KO and WT mice after injury. (A) CXCL-11 gene transcript levels in 
WT (white bars) and HO-2 KO (grey bars) mice in time presented as mean ± SD. Controls represent biopsies 
collected at day 0, and data were normalized to WT mean day 0. (B) Semi-quantitative scoring of CXCL-11 
immunoreactivity in (C) of WT (white) and HO-2 KO (grey) wounds presented as box-and-whisker plot with 10–90 
percentiles. *p<0.05. (C) Representative images of CXCL-11 immunoreactivity in wound tissue of WT and HO-2 KO 
mice at day 7 after wounding; bar, 200 µm. Insert represent magniﬁed boxed area; bar, 70 µm. 
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Discussion 
In this study, we investigated the role of HO-2 in cutaneous wound closure using HO-2 KO 
mice and a full-thickness excisional wound model. High levels of HO-2 in the skin have been 
suggested to be a ﬁrst line of defense against acute injury (34). Following excisional 
wounding we observed signiﬁcantly slower cutaneous wound closure accompanied by 
reduced collagen deposition and lower vessel density in HO-2 KO mice compared to WT 
controls at day 7. The most pronounced difference in wound healing rates between HO-2 
KO and WT seems to be during the ﬁrst days of wound healing.  
Cutaneous wounding is followed by hemolysis and free heme release leading to 
local oxidative stress and inﬂammation. HO-1 is rapidly induced after wounding (35, 36) and 
promotes inﬂammatory resolution by down-regulating inﬂammatory mediators and 
attenuating inﬁltration of inﬂammatory cells (37, 38). Moreover, pharmacologic induction 
or overexpression of HO-1 accelerates both corneal and cutaneous wound healing (12, 39). 
On the contrary, HO-1 deﬁciency in man and mice leads to a chronic inﬂammatory state (10, 
11). Also, pharmacologic or genetic inhibition of HO-1 slows down cutaneous wound closure 
via suppressed re-epithelialization and neovascularization in murine models (12). In HO-2 
KO mice impaired corneal wound healing is associated with exaggerated inflammation (13, 
40). We therefore have been suggested that also the delayed cutaneous wound closure 
observed in HO-2 KO mice results from an exaggerated inﬂammatory response. 
Unexpectedly, we did not detect signiﬁcant differences in the mRNA or protein 
expression level of the pro-inﬂammatory proteins, such as TNF and COX-2 and markers for 
granulocytes and macrophages. This rules out that exaggerated inﬂammation is the 
underlying cause of delayed cutaneous wound closure in HO-2 KO mice. The exaggerated 
corneal inﬂammatory response was associated with impaired HO-1 induction and function 
(13). The importance of HO-activity was further supported by amelioration of corneal 
inﬂammatory resolution after application of biliverdin in HO-2 KO mice (14, 19).    
HO-2 can regulate HO-1 induction and function in a tissue- and cell-speciﬁc manner 
(15, 17). Increased HO-1 expression has been suggested to be a compensatory mechanism 
in HO-2 deﬁcient lung and myocardium (16, 41). We detected similar levels of both HO-1 
mRNA and protein expression in unwounded skin and injury-induced HO-1 up-regulation 
after wounding of HO-2 KO and WT mice, explaining the normal inﬂammatory resolution in 
both genotypes. Cell-type-speciﬁc compensatory HO-1 expression likely dampens the 
inﬂammatory response after cutaneous wounding, as we observed a normal inﬂammatory 
phenotype in HO-1 expressing skin compared to the exaggerated inﬂammatory response in 
HO-1 deﬁcient corneal tissue in HO-2 KO mice (13, 40, 42). Notably, delayed cutaneous 
wound closure in HO-1 KO mice is also not accompanied by an uncontrolled inﬂammatory 
response following excisional wounding (12).  
We next turned our focus to the granulation phase of cutaneous wound healing 
that is dominated by migration, proliferation and differentiation of ﬁbroblasts, 
keratinocytes and endothelial cells in the wound area. Differential expression of HO-1 and 
HO-2 in keratinocytes and ﬁbroblasts has been demonstrated (43). This difference is critical 
for different sensitivities towards UV-induced oxidative stress (15, 44). This could also have 
consequences in a more complex setting, such as during wound repair. However, we did 
not observe any differences between HO-2 KO and WT mice with respect to the 
proliferation marker Ki67 or expression of the myoﬁbroblast marker αSMA during the time 
course of wound healing.  
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Angiogenesis is a crucial process for proper wound healing, and disturbed blood 
vessel formation leads to delayed wound healing. Pro-angiogenic properties of HO-1 have 
been demonstrated (20, 21). Both diabetic db/db mice having weaker injury-induced HO-1 
expression and HO-1 deﬁcient mice demonstrate impaired vascularization and delayed 
wound closure which could be restored with HO-1 gene transfer (12). Here, we also 
observed lower vessel density in the wounds of HO-2 KO mice despite normal HO-1 
expression. This may restrict the blood supply to the healing tissue and set back wound 
healing.  
To probe the molecular mechanism responsible for the delayed cutaneous wound 
closure in HO-2 KO mice, we used a PCR array containing 84 wound healing associated 
genes. Surprisingly, we only detected signiﬁcant differences between HO-2 KO and WT mice 
in the expression proﬁle of a single gene, namely CXCL-11. CXCL-11 is a versatile cytokine 
that via interaction with its receptor CXCR3 is thought to modulate several cell types 
important during several phases of cutaneous wound repair (45). Decreased CXCL-11 or 
CXCR3 expression leads to delayed re-epithelialization, impaired epidermis maturation and 
is associated with altered angiogenesis (46-49). CXCL-11 is also an antagonist for C-C 
chemokine receptor type 5 (CCR5) (50). CCR5 KO mice have delayed wound closure, 
impaired neovascularization and reduced collagen production following excisional 
wounding (51). In contrast to WT controls, we did not detect any injury-induced up-
regulation of CXCL-11 mRNA in HO-2 KO mice at day 2 after wounding. But, surprisingly, 
more CXCL-11 positive cells were present in the wounds of HO-2 KO mice compared to WT 
controls at day 7 after wounding. These observations imply that there is a slight delay in the 
expression of CXCL-11 gene and protein in HO-2 KO mice compared to WT controls. 
However, whether this is a consequence or a causing factor of the delayed cutaneous 
wound closure in HO-2 KO mice warrants further investigation. Summarizing, we 
demonstrated delayed dermal wound closure, decreased vascularization and reduced 
collagen deposition in HO-2 KO mice independent from inﬂammation and HO-1 expression. 
These data indicate a tissue-speciﬁc role for HO-2, as HO-2 seems to play a pivotal role in 
corneal, but not cutaneous, wound healing. This is directly linked to the regulation of injury-
induced HO-1 expression. Furthermore, we report differences in the expression of the 
cytokine CXCL-11 between HO-2 KO and WT mice during wound repair. Whether this 
difference is causative or caused by the observed delay in cutaneous wound closure needs 
to be further investigated. 
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Chapter 3   
 
Chemokine signaling during midline epithelial seam 
disintegration facilitates palatal fusion.  
 
Suttorp CM, Cremers NA, van Rheden R, Regan RF, Helmich P, van Kempen S, 
Kuijpers-Jagtman AM, Wagener FADTG.  
 
Front Cell Dev Biol, 2017 Oct 30;5:94. 
 
  
62 
Abstract 
Disintegration of the midline epithelial seam (MES) is crucial for palatal fusion, and failure 
results in cleft palate. Palatal fusion and wound repair share many common signaling 
pathways related to epithelial-mesenchymal cross-talk. We postulate that chemokine 
CXCL11, its receptor CXCR3, and the cytoprotective enzyme heme oxygenase (HO), which 
are crucial during wound repair, also play a decisive role in MES disintegration. Fetal growth 
restriction and craniofacial abnormalities were present in HO-2 knockout (KO) mice without 
effects on palatal fusion. CXCL11 and CXCR3 were highly expressed in the disintegrating MES 
in both wild-type and HO-2 KO animals. Multiple apoptotic DNA fragments were present 
within the disintegrating MES and phagocytized by recruited CXCR3-positive wt and HO-2 
KO macrophages. Macrophages located near the MES were HO-1-positive, and more HO-1-
positive cells were present in HO-2 KO mice compared to wild-type. This study of embryonic 
and palatal development provided evidence that supports the hypothesis that the MES itself 
plays a prominent role in palatal fusion by orchestrating epithelial apoptosis and 
macrophage recruitment via CXCL11-CXCR3 signaling. 
 
Keywords: Embryology, cleft palate, chemokine, chemokine receptor, CXCL11, CXCR3, 
macrophage, heme oxygenase, cytoprotective enzymes, cell migration, apoptosis. 
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Abbreviations 
ABC avidin-biotin peroxidase complex 
AP Alkaline phosphatase 
BCIP 5-bromo-4-chloro-3'-indolyphosphate 
CLP Cleft palate with cleft lip 
CPO Cleft palate without cleft lip 
CO Carbon monoxide 
CXCL11 Chemokine (C-X-C) ligand 11  
CXCR3 Chemokine (C-X-C) receptor 3 
DAB diaminobenzidine-peroxidase 
E0 Embryonic day 0 
EMT Epithelial-to-mesenchymal transformation 
FragEL Fragment End Labeling 
HE Haematoxylin and eosin 
HO Heme oxygenase 
KO Knockout 
KS-test Kolmogorov-Smirnov test 
MEE Midline epithelial edge 
MES Midline epithelial seam 
NBT Nitro-blue tetrazolium 
PBSG Phosphate-buffered saline with glycine 
ROS Reactive oxygen species 
TdT Terminal deoxynucleotidyl Transferase 
WT Wild-type 
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Introduction 
Formation of the secondary palate requires adhesion by the midline epithelial edge (MEE) 
of both palatal shelves, formation of the transient midline epithelial seam (MES), 
disintegration of the MES, and fusion of the palatal shelves (1). Only after disintegration of 
the MES the mesenchyme of the palatal shelves can fuse to form the secondary palate. 
Failure of epithelial adhesion between both palatal shelves (2) or a lack of MES 
disintegration (3, 4) will result in cleft palate with (CLP) or without cleft lip (CPO). Multiple 
mechanisms have been proposed to explain the disappearance of the MES. The main 
hypotheses underlying MES disintegration involve epithelial cell migration to the oral or 
nasal epithelium (5), epithelial-to-mesenchymal transformation (EMT) (6), epithelial cell 
apoptosis (7-10), or a combination of these events (3).  
CLP is the most common congenital facial malformation in humans and occurs in 
approximately 1/700 live births (11). However, CPO is the rarest form of oral clefting, with 
an incidence ranging from 1.3 to 25.3/10,000 live births (12). Although the exact biological 
mechanisms underlying orofacial clefting are not completely understood (13), a 
combination of genetic and environmental factors is thought to play a role. Approximately 
50% of children born with CPO have a genetic syndrome (14), compared to 30% with CLP 
(15). Notably, maternal smoking, diabetes, and infections have been shown to strongly 
increase the risk for babies with orofacial clefts (13, 16), suggesting that control of oxidative 
and inflammatory stress is important.  
Accumulating data suggest that the heme-degrading antioxidative enzyme heme 
oxygenase (HO) is a key regulator during embryological development (17-19). HO facilitates 
placentation, fetal growth, and -development by restricting excessive free heme levels. 
Heme promotes oxidative and inflammatory stress (20, 21) and may lead to intrauterine 
fetal growth restriction and fetal loss (17). HO protects against this inflammatory stress by 
degrading heme and generating free iron/ferritin, carbon monoxide (CO), and 
biliverdin/bilirubin (22). These HO effector molecules regulate vasodilation and anti-
apoptotic signaling, inhibit platelet aggregation, reduce leukocyte adhesion, and reduce 
pro-inflammatory cytokines (22, 23). Two functional isoforms of HO have been described, 
HO-1 and HO-2. HO-1 has low basal levels but is strongly inducible, whereas HO-2 is largely 
constitutively expressed. HO-2 is highly expressed in the brain, testes, and blood vessels 
(24). Interestingly, the cytoprotective HO-1 and HO-2 enzymes are both strongly expressed 
in the placenta during embryonic development and in neural crest cells that form the 
craniofacial tissues in mice and humans (18, 25). Elevated inflammatory, oxidative, and 
angiogenic factors have been demonstrated in the endothelial cells of HO-2 knockout (KO) 
mice (26). During pregnancy, down-regulation of both HO-1 (27) and HO-2 (18) in the 
placenta is associated with pregnancy failure. Spontaneous abortion, pre-eclampsia, or fetal 
growth retardation are associated with lower HO-2 protein levels compared to healthy 
pregnant controls (18).  
Palatal fusion and wound repair are regenerative processes that share common 
signaling pathways and gene regulatory networks (28). Epithelial-mesenchymal cross-talk is 
essential in both processes. Decreased signaling between the versatile CXCL11 and its 
receptor CXCR3 on epithelial cells leads to delayed re-epithelialization and impaired 
epidermis maturation during wound repair (29). Moreover, CXCR3 KO mice present 
excessive scar formation following injury (30). Macrophages are important in regenerative 
and embryonic developmental processes (31-34), and blocking the CXCL11-CXCR3 axis 
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suppresses macrophage infiltration (35, 36). Recently, slower wound closure and delayed 
CXCL11 expression in wounds was observed in HO-2 KO mice (37). Interestingly, HO-2 
deficiency was shown to result in impaired macrophage function (38). Although CXCL11-
CXCR3 signaling regulates diverse cellular functions, including influx of immune cells during 
inflammation (39, 40) and wound repair (29, 41), little is known about its role during palatal 
fusion.  
We postulate that palatal fusion is hampered in HO-2 KO mice by disruption of 
epithelial cell and macrophage cross-talk in the MES due to hampered CXCL11-CXCR3 
signaling. In the present study, MES disintegration is investigated in relation to chemokine 
signaling and the effects of HO-2 deficiency on embryonic development and palatal fusion.  
 
Materials and Methods 
 
Animals used for the study 
To obtain fetuses for this study, 8-week-old female wild-type (wt) (n=7) and HO-2 KO (n=8) 
mice were mated with respectively wt and HO-2 KO male mice. Homozygote HO-2 KO mice 
generated by targeted disruption of the HO-2 gene (26, 42), and wt mice, both of a mixed 
129Sv x C57BL/6 background, were bred and maintained in our animal facility. The animals 
were housed under normal laboratory conditions with 12 h light/dark cycle and ad libitum 
access to water and powdered rodent chow (Sniff, Soest, The Netherlands) and were 
allowed to acclimatize for at least 1 week before the start of the experiment. Ethical 
permission for the study was obtained according to the guidelines of the Board for Animal 
Experiments of the Radboud University Nijmegen (RU-DEC 2012-166). 
 
Hormone administration before mating 
Preliminary experiments (RU-DEC 2009-160) demonstrated that young animals (8-10 weeks 
old), that were mated for the first time, often did not carry fetuses. This was demonstrated 
for both wt mice and HO-2 KO mice. The chance of pregnancy was therefore enhanced using 
the hormones Folligonan (Genadotropin serum, Intervet Nederland B.V., Boxmeer, The 
Netherlands) and Pregnyl (Human chorionic gonadotropin, N.V. Organon, Oss, The 
Netherlands). Because there is a lag time period of approximately 13 days between 
hormone application and palatal formation, we expected minor influence on the 
experimental outcome. At day -3 at 4.00 p.m. Folligonan (6E in 30 μl) and at day -1 at 4.00 
p.m. Pregnyl (6E in 30 μl) was administered by intraperitoneal injection. 
 
Plugging day and obtaining wt and HO-2 KO fetuses 
The presence of a vaginal copulation plug, indicating that mating has occurred, was taken 
as day 0 of pregnancy (embryonic day 0; E0) (43). 1 wt mouse and 2 HO-2 KO mice 
demonstrated no plugged status. These animals were mated again 4 weeks later, and all 
demonstrated then a plugged status.  
Since the palatal shelves fuse between embryonic day E14.5 and E15.5 in wt mice 
(44) we presumed that fetuses of E15 were suitable for our study. At embryonic day E15, 7 
wt and 7 HO-2 KO animals were killed by CO2/O2 inhalation for 10 minutes. Only 3 out of 7 
plugged wt mice, and 4 out of 7 plugged HO-2 KO mice carried fetuses. In total, 16 wt fetuses 
of E15 and 11 HO-2 KO fetuses of E15 were obtained.  
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In order to monitor the growth restriction found in HO-2 KO fetuses in more detail, 
we also analyzed the body size of E16 HO-2 KO fetuses. Therefore, 1 pregnant HO-2 KO 
mouse was killed at embryonic day 16, resulting in 12 HO-2 KO fetuses of E16.  
 
Implantation rate  
The uterus and fetuses were photographed (Figure 3.1). For the fetus carrying mice the 
mean implantation rate was analyzed by calculating the percentage of fetuses to the total 
number of embryonic implantations (fetuses+non-viable or hemorrhagic embryonic 
implantations).  
 
Figure 3.1: A: Isolation of the fetuses and measurement of body length, body surface, head surface. Plugged 
mouse (e.g., HO-2 KO at E15) was sacrificed by CO2 inhalation for 10 minutes, the uterus and organs were removed. 
Fetuses were isolated from the uterus. Location of the 6 fetuses in the uterus before they were removed (green 
arrows). Location of the 5 non-viable/hemorrhagic embryonic implantations (red arrows). B: A square scale bar 
was drawn at the ruler in each photograph of 10 x 10 mm (1 cm2) and the total number of pixels within the square 
was determined (e.g., 13225 pixels). C: A line in the length of the body of the fetus was drawn and the number of 
pixels was recorded (e.g., 158 pixels). The length was calculated (e.g., 158/√13225 = 13,7 mm). D: The outline of 
the total body surface of the fetus was drawn and the number of pixels was recorded (e.g., 11733 pixels). The total 
body surface was calculated (e.g., 11733/13225 = 0,89 cm2). E: The outline of the head surface was drawn and the 
number of pixels was recorded (e.g., 4761 pixels). The head surface was calculated ( e.g., 4761/13225 = 0,36 cm2). 
 
The wt and HO-2 KO fetuses compared for weight, length and body surface  
The weight and size of wt fetuses (E15) and HO-2 KO fetuses (E15/E16) was measured. 
Severely malformed fetuses (n=2) were excluded for weight and size analysis. The body 
length, body surface and head surface of the fetuses were measured from photographs 
using ImageJ (1.48v) software (National institutes of health, Bethesda, MD, USA) and used 
for statistical analysis, for details see Figure 3.1.  
 
67 
Assessment of mRNA expression of HO-2, CXCL11, CXCR3 and HO-1 in fetus head samples 
by quantitative real-time PCR 
To screen for differences in gene expression between HO-2 KO and wt fetuses, cDNAs were 
synthesized from samples from heads of wt (E15; n=5) and HO-2 KO (E15; n=4) fetuses. 
Fetuses were decapitated and total RNA was extracted using Trizol (Invitrogen, Carlsbad, 
CA, USA) and a RNeasy Mini kit (Qiagen, Hilden,Germany), and cDNA was produced using 
the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). cDNAs were analyzed for gene 
expression of HO-1, HO-2, CXCL11 and CXCR3, using custom-designed primers (Table 3.1) 
and iQ SYBR Green Supermix (Invitrogen, Carlsbad, CA, USA) in a CFX96 real-time PCR 
system (Bio-Rad, Hercules, CA, USA). Relative gene expression values were evaluated with 
the 2^(−ΔΔCt) method using GAPDH as housekeeping gene (45).  
 
Table 3.1: Custom-designed mouse primers used for assessment of mRNA expression of GAPDH, HO-1, HO-2, 
CXCL11 and CXCR3 in fetus head samples by quantitative real-time PCR. 
 
 
Haematoxylin-Eosin staining of transversal sections through the secondary palate 
Mouse tissue samples were fixed for 24h in 4% paraformaldehyde and further processed 
for routine paraffin embedding. Paraffin sections were deparaffinized using Xylol, 
rehydrated using an alcohol range (100%-70%), and used for immunohistochemistry and 
FragEL™ analysis. Serial transversal sections through the secondary palate region of 5 µm 
thickness mounted on Superfrost Plus slides (Menzel-Gläser, Braunschweig, Germany) were 
routinely stained with Haematoxylin and Eosin (HE) for general tissue survey. The exact 
location of the fusing palatal shelves was determined per individual fetus. The HE stainings 
were subdivided into the four stages of palatogenesis based on the anatomy of the palatal 
shelves: elevation, horizontal, midline adhesion and fusion, according to Dudas et al. (44) 
and screened for anatomical abnormalities. These series were used as reference to obtain 
transversal sections containing palatal shelves in midline adhesion and fusion for 
immunohistochemical staining (Figure 3.2).  
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Figure 3.2: Palatal fusion observed in both wt and HO-2 KO fetuses at E15. HE stainings demonstrated horizontal 
orientation of the palatal shelves, midline adhesion and fusion within the same fetus. A: wt fetus at E15 
(magnification: x100). Palatal shelves in a later stage of the palatal fusion increased in size. The MES changed from 
a multi-cell-layer into a continuous one-single-cell-layer, to a disintegrating MES, during which islands of 
epithelium in the midline were observed. B: HO-2 KO fetus at E15 (magnification: x100). Palatal shelves in a later 
stage of the palatal fusion increased to some extend in size. Several islands of epithelium in the midline were 
observed. 
 
Immunohistochemistry 
Selected paraffin embedded sections were deparaffinized using Xylol and rehydrated using 
an alcohol range (100%-70%). Endogenous peroxidase activity was quenched with 3% H2O2 
in methanol for 20 min, and immunohistochemical stainings for HO-1, CXCL11, CXCR3 and 
macrophage marker F4/80 were performed as previously described (46). In brief, tissue 
sections were incubated for 60 min with a biotin-labeled secondary antibody (Table 3.2). 
Next, the sections washed with PBSG (phosphate-buffered saline with glycine) and treated 
with avidin-biotin peroxidase complex (ABC) for 45 min in the dark. After extensive washing 
with PBSG, diaminobenzidine-peroxidase (DAB) staining was performed for 10 min for the 
HO-1, CXCL11 and CXCR3 stainings.  
 
Analysis of apoptosis and recruited F4/80 positive macrophages in the palate 
For studying apoptosis in the MES, transversal sections containing palatal shelves in midline 
contact and fusion stage of wt and HO-2 KO fetuses were selected. During apoptosis, cellular 
endonucleases cleave nuclear DNA between nucleosomes, producing specific DNA 
fragments with free 3’-OH groups at the end. These 3’ OH group can be labeled using 
Fragment End Labeling (FragEL™, Calbiochem, San Diego, CA, USA) allowing detection of 
apoptotic DNA fragments at the individual cell level as previously described (47). The 
procedure was performed according to the protocol of the manufacturer (Calbiochem, San 
Diego, CA, USA). In brief, rehydrated paraffin sections were subjected to proteinase K 
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digestion (0,5 µg/ml) for 10 min. Endogenous peroxidase activity was quenched with 3% 
H2O2 in methanol for 20 min. TdT (Terminal deoxynucleotidyl Transferase) added biotin 
labeled deoxynucleotides to the end of these DNA fragments. After addition of ABC, DAB 
was added and incubated at room temperature for 10 min. For the F4/80 staining + AP 
(alkaline phosphatase) + NBT (nitro-blue tetrazolium) + BCIP (5-bromo-4-chloro-3'-
indolyphosphate) was used. For used antibodies and antigen retrievals, see table 3.2 and 
3.3. Photographs were taken using a Carl Zeiss Imager Z.1 system (Carl Zeiss Microimaging 
Gmbh, Jena, Germany) with AxioVision (4.8v) software (Zeiss, Göttingen, Germany). 
 
Table 3.2: Antibodies and antigen retrievals used for immunohistochemical stainings for HO-1, CXCL11, 
CXCR3,F4/80 and apoptotic DNA fragments.  
 
 
Table 3.3: Secondary antibodies used for HO-1, CXCL11, CXCR3, apoptotic DNA fragments immunohistochemical 
staining, and F4/80 with apoptotic DNA fragments/CXCR3/HO-1 double stainings. Antigen retrieval used for double 
stainings: Combi = Citrate buffer 70°C for 10 min + Trypsin digestion in PBS 0,075% 37°C for 5 min. 
 
 
Quantification of CXCL11, CXCR3 and HO-1 immunoreactivity within the epithelium of the 
palatal shelves 
Transversal sections through the secondary palate of wt and HO-2 KO fetuses were 
screened. For quantification sections were selected following the inclusion criteria: 
transversal sections containing palatal shelves in midline adhesion and fusion with at least 
the presence of a part of the MES.  
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The immunostained sections were first categorized into two categories based on 
their palatal morphology (palatal morphology classification): fusing palatal shelves, and 
fusing palatal shelves with adhesion to the nasal septum, see Figure 3.3.  
Within each section the epithelium of the palatal shelves was then subdivided into 
three separate regions (Figure 3.3) according to morphological characteristics (Epithelium 
region classification): epithelium of the palatal shelves from the edge, including the MES, to 
the half of the width of the shelves (in RED), epithelium of the lateral half of the palatal 
shelves (in BLUE), epithelium of the lateral wall of the nasal cavity, this region is positioned 
outside the palatal shelves and served as a control region (in YELLOW), see Figure 3.3. 
CXCL11, CXCR3 and HO-1 immunoreactivity was evaluated by two observers, by 
blindly scoring, independently of each other. The epithelial regions per single section were 
semi-quantitatively scored according to the immunoreactivity scoring scale in three 
categories (HIGH, MODERATE and LOW). For each individual fetus the modus of the scoring 
per epithelial region was used for further statistical analysis. For details see Figure 3.3. To 
determine the inter-examiner reliability, 10 sections were measured by the two observers 
and acceptable coefficient of determination (R2) scores > 0.80 were obtained for 
immunoreactivity scoring.  
 
 
Figure 3.3: Palatal morphology classification: The CXCL11, CXCR3 and HO-1 immunostained sections were 
categorized in two stages according to their morphological characteristics: fusing palatal shelves, and fusing palatal 
shelves with adhesion to the nasal septum. Epithelium region classification: For each section epithelial layers were 
subdivided in 3 regions of interest according to morphological characteristics: epithelium of the palatal shelves 
from the edge, including the MES, to half of the width of the shelves (in RED), epithelium of the lateral half of the 
palatal shelves (in BLUE), epithelium of the lateral wall of the nasal cavity, this region is positioned outside the 
palatal shelves and served as a control region (in YELLOW). Immunoreactivity scoring scale: Semi-quantitative 
scoring of CXCL11, CXCR3 and HO-1 immunoreactivity in epithelium of the palatal shelves. Each epithelial region 
was semi-quantitatively scored according to the following scale: HIGH) Immunoreactivity present in the entire 
epithelial region, MODERATE) Immunoreactivity present only partially in the epithelial region, LOW) Almost no 
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immunoreactivity present in the epithelial region. Right lower panel: Immunoreactivity scored for the 3 epithelial 
locations in a CXCL11 immunostained section (e.g., wt fetus, E15, section with adhesion of the palatal shelves and 
adhesion to the nasal septum). RED region was scored as HIGH, BLUE region was scored as MODERATE, YELLOW 
region was scored as LOW for CXCL11 immunoreactivity. 
 
Quantification of CXCL11, CXCR3 and HO-1 positive cells in the mesenchyme of the palatal 
shelves 
The immunostained sections, wt and HO-2 KO, were first categorized based on their 
morphology (Palatal morphology classification, Figure 3.3). Since a significant variance in 
the size of the palatal shelves was present, expression was adjusted to surface area. The 
individual surface of each pair of shelves was measured using ImageJ (1.48v) software (Zeiss, 
Göttingen, Germany). Then, the number of CXCL11, CXCR3 and HO-1 positive cells within 
the outline of the mesenchyme of the palatal shelves was counted. For details see Figure 
3.4. For each section the number of positive mesenchymal cells/mm2 was calculated. Cell 
counting was performed twice, by two blinded observers independently of each other, and 
the mean value of positive cells/mm2 per fetus was calculated and used for statistical 
analysis. To determine the inter-examiner reliability, 10 sections were measured by the two 
observers and acceptable coefficient of determination (R2) scores > 0.80 were obtained for 
cell counting.  
 
 
Figure 3.4: Palatal shelf surface measurement for determining the number of CXCL11, CXCR3 and HO-1 positive 
immunostained cells cells/mm2 within the mesenchyme of the palatal shelves. A square scale bar was drawn in 
the microscopic picture (magnification: x100) of the section of 1000μm x 1000μm (1 mm2) and the total number 
of pixels within the square was determined (e.g., 1 mm2 = 3442880 pixels). The contour of the mesenchyme of the 
shelves was drawn (yellow line). The number of pixels for this area was determined by the ImageJ (1.48v) software 
(323768 pixels). The number of positive immunostained cells within this mesenchymal area of the palatal shelves 
were counted by direct observation using the Zeiss microscope (e.g., 52 CXCL11 positive cells). The number of 
cells/mm2 was calculated (3442880/323768) x 52 = 553 cells/mm2). 
 
Apoptotic DNA fragments in macrophages   
Transversal sections containing palatal shelves in midline adhesion and fusion of wt and HO-
2 KO fetuses were selected for the F4/80-immuno staining - FragEL™ DNA fragmentation kit 
combination. The F4/80 surface receptor is considered as one of the best markers for 
mature macrophages (48). The proximity of macrophages to apoptotic DNA fragments 
within the MES and the presence of apoptotic DNA fragments within the F4/80 positive 
macrophages were studied. For used antibodies and antigen retrievals, see tables 3.2 and 
3.3. 
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CXCR3 and HO-1 expression in macrophages studied by immunofluorescence microscopy 
Double staining for F4/80 with CXCR3/HO-1 were performed on paraffin sections of wt and  
HO-2 KO fetuses. Tissue samples were fixed for 24h in 4% paraformaldehyde and further 
processed for routine paraffin embedding. Sections were deparaffinized using Histosafe and 
rehydrated using an alcohol range (100%-70%). Fluorescent immunohistochemical double 
stainings for F4/80 with CXCR3, and F4/80 with HO-1 were performed. Nuclear staining was 
performed with DAPI. For antibodies used, see tables 3.2 and 3.3. 
 
Statistical analysis 
The data for the implantation rate, fetus weight, fetus length, fetus surface, fetus head 
surface and the PCR data for the mRNA expression of HO-1, HO-2, CXCL11, and CXCR3 
showed a normal distribution as evaluated by the Kolmogorov-Smirnov test (KS-test).  
To compare differences in implantation rate between the wt group and HO-2 KO 
group the Independent-Samples T-test was performed.  
To analyze the fetus weight, fetus length, fetus surface, fetus head surface for the 
wt E15 group, the HO-2 KO E15 group and the HO-2 KO E16 group the ANOVA and Tukey’s 
multiple comparison post hoc test were used. 
The HO-1, CXCL11 and CXCR3 immunoreactivity in the epithelium regions was 
semi-quantitatively scored and analyzed using the non-parametric Kruskal-Wallis ANOVA 
on ranks test and Dunn’s Multiple Comparison post hoc test to compare differences 
between the wt group and HO-2 KO group.  
The data from quantification of the number of HO-1 positive cells in the 
mesenchyme showed a non-normal distribution as measured by the KS-test and the non-
parametric Mann-Whitney U test was used to compare differences between the wt group 
and HO-2 KO group. 
Quantification data of the number of CXCL11 and CXCR3 positive cells in the 
mesenchyme showed a normal distribution as measured by the KS-test. Independent-
Samples T-test was performed to compare differences between the wt group and HO-2 KO 
group. 
To determine the inter- examiner reliability, the coefficient of determination (R2) 
was calculated by the square of the Pearson correlation coefficient for the quantitative data, 
and calculated by the square of the Spearman correlation coefficient for the semi-
quantitative data. 
Differences were considered to be significant if p<0.05. All statistical analyses were 
performed using Graphpad Prism 5.03 software (GraphPad Software, San Diego, CA, USA). 
 
Results 
Fetal growth restriction and malformations occur in the absence of HO-2 expression 
Quantitative real-time PCR confirmed the genotypes of mice by showing that HO-2 mRNA 
was only present in samples from wild-type (wt) fetuses, and not in HO-2 KO fetuses 
(p<0.001, Figure 3.5A). Hemorrhagic embryonic implantations were found in both wt and 
HO-2 KO animals (Figure 3.1A). No significance difference in the mean implantation rate 
was found between pregnant wt and HO-2 KO mice (46% versus 52%, p=0.79). At E15, HO-
2 KO fetuses weighed significantly less (p<0.05, Figure 3.5B) with a significantly smaller body 
surface than wt fetuses (p<0.01, Figure 3.5C). The differences fetus length (p=0.25, Figure 
3.5D) and in head/body surface ratio (p=0.97, Figure 3.5E) for both genotypes were not 
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significantly different at E15. To monitor the restriction of fetal growth in HO-2 KO fetuses 
in more detail, we also analyzed the body size of E16 HO-2 fetuses. No significant difference 
was found between the E15 wt fetuses and E16 HO-2 KO fetuses in regards to weight (Figure 
3.5B) and body surface (Figure 3.5C). No malformations or craniofacial anomalies were 
found in the wt fetuses (Figure 3.5F). Among the 15 HO-2 KO fetuses (E15 and E16), 1 E16 
fetus had severe malformations (Figure 3.5I), 1 E16 fetus exhibited a craniofacial anomaly 
(Figure 3.5J), and 1 E15 fetus appeared to be the smallest fetus without anomalies (Figure 
3.5K).  
 
Figure 3.5: Fetal growth restriction and malformations occur in the absence of HO-2 expression. A: HO-2 mRNA 
was not found in HO-2 KO fetuses. HO-2 mRNA was observed in wt fetuses E15 (n=5), but not in HO-2 KO fetuses 
E15 (n=4). wt fetuses (E15; n=15), HO-2 KO fetuses (E15; n=4) and HO-2 KO fetuses (E16; n=11) were compared for 
B: weight, C: body surface and D: length (p=0.25), E: head/body surface ratio (p=0.97). Data present mean ± SD. 
(*=p<0.05; **=p<0.01), (***=p<0.001). F: wt fetus at E15 (0,28g; 12,9mm). G: HO-2 KO fetus at E15 (0,13g; 
12,5mm). H: HO-2 KO fetus at E16 (0,31g; 12,4mm). I: HO-2 KO fetus at E16 demonstrating severe malformations 
(0,065g; 10mm). J: HO-2 KO fetus at E16 demonstrating a craniofacial anomaly (0,20g, 12,2mm). K:  HO-2 KO fetus 
at E15 appeared to be the smallest fetus without anomalies (0,10g, 10,3mm). 
 
Palatal fusion observed in both wt and HO-2 KO fetuses at E15 
Though the HO-2 KO fetuses were smaller in size, no difference in the adhesion and fusion 
of the palatal shelves was observed between the sections from wt and HO-2 KO fetuses at 
E15. In 2 wt fetuses and 2 HO-2 KO fetuses at E15, the palatal shelves were not yet elevated. 
In both genotypes, different phases of palatogenesis were observed in histological sections 
from the same fetus. The MES changes from a multi-cell layer into a continuous single-cell 
layer, to a disintegrating MES, during which islands of epithelium are observed. For more 
details, see Figure 3.2. 
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CXCL11 expression in the MES and mesenchyme 
Because CXCL11 plays an important role in wound repair, we investigated the mRNA 
expression of chemokine CXCL11 in fetal head samples. CXCL11 mRNA was observed in 
samples from both wt and HO-2 KO fetuses without reaching a significant difference 
between the two genotypes (p=0.88, Figure 3.6). 
Next, we investigated the cellular expression of CXCL11 during palatal fusion. 
CXCL11 protein was significantly higher expressed in the epithelium of the MES compared 
to the other epithelial layers of the fusing palatal shelves and the epithelium of the nasal 
cavity in both wt (p<0.001) and HO-2 KO fetuses (p<0.001)(Figure 3.6B, C, F-H). No 
significant difference was found between the genotypes. High CXCL11 protein expression 
was also found within the epithelium of the tips of the palatal shelves lacking midline 
adhesion, in sections of both genotypes (data not shown). CXCL11-positive cells were also 
observed in the mesenchyme of the palatal shelves, but no significant difference in the 
number of CXCL11-positive cells/mm2 was found between the wt and HO-2 KO groups 
(p=0.97, Figure 3.6D) or in the samples with fusing palatal shelves with adhesion to the nasal 
septum (p=0.47, Figure 3.6E).  
 
Figure 3.6: CXCL11 expression in the MES and mesenchyme in both wt and HO-2 KO fetuses. A: CXCL11 mRNA 
expression was both present in wt (n=5) and in HO-2 KO E15 fetuses (n=4)(p=0.88). Data present mean ± SD. 
CXCL11 overexpression in the MES in wt and HO-2 KO fetuses. Scoring was performed according to figure 3.3. B: 
Significant higher CXCL11 expression was observed in the MES (in RED)(***=p<0.001) compared to the other 
epithelial regions in the fusing palatal shelves (in BLUE) and the nasal cavity (in YELLOW) in the wt group and HO-
2 KO group. C: Significant higher CXCL11 expression was observed in the MES (in RED)(***=p<0.001) compared to 
the BLUE region and YELLOW region in the HO-2 KO sections with fusing palatal shelves with adhesion to the nasal 
septum. D: No significant difference in the number of CXCL11 positive cells/mm2 in the mesenchyme of the fusing 
palatal shelves was found between the wt and HO-2 KO fetuses)(p=0.97). Data present mean ± SD. E: No significant 
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difference in the number of CXCL11 positive cells/mm2 was found in the mesenchyme between the wt and HO-2 
KO group in the sections with fusing palatal shelves with adhesion to the nasal septum(p=0,97). Data present mean 
± SD. F: Representative CXCL11 immunostaining in fusing palatal shelves without adhesion to the nasal septum of 
a wt fetus (E15) (magnification: x100). The MES (in RED) was highly CXCL11 positive compared to the other 
epithelial regions; epithelium of the lateral half of the palatal shelves (in BLUE) and epithelium of the lateral wall 
of the nasal cavity (in YELLOW). G: Several CXCL11 positive cells in the mesenchyme were observed (e.g., black 
arrow indicates a CXCL11 positive cell in the mesenchyme) (magnification: x400). This was found in both wt and 
HO-2 KO fetuses. H: Moderate CXCL11 expression in the epithelium of the lateral half of the palatal shelve (in 
BLUE), and in the epithelium of the lateral wall of the nasal cavity (in YELLOW) (magnification: x400). 
 
CXCR3 expression in the MES and mesenchyme 
Next, we investigated the expression of CXCL11 receptor CXCR3 at the mRNA level. In 
samples from heads of wt and HO-2 KO fetuses, CXCR3 mRNA expression was observed but 
with no significant difference between the groups (p=0.16, Figure 3.7). 
CXCR3 protein expression was significantly higher in the epithelium of the MES 
than the other epithelial layers of the palatal shelves and the epithelium of the nasal cavity 
in the fusing palatal shelves of the wt fetuses (p<0.05, Figure 3.7B, F-H). Higher CXCR3 
protein expression in the epithelium of the MES was also observed in the fusing palatal 
shelves with adhesion to the nasal septum from the HO-2 KO fetuses (p<0.001, Figure 3.7C).  
Interestingly, CXCR3-positive cells were also observed in the mesenchyme of the 
palatal shelves. No significant difference in the number of CXCR3-positive cells/mm2 was 
found between the wt and HO-2 KO groups in the fusing palatal shelves (p=0.96, Figure 
3.7D) or the fusing palatal shelves with adhesion to the nasal septum (p=0.20, Figure 3.7E).  
 
CXCR3-positive macrophages were located near the MES and phagocytized apoptotic cell 
fragments of the MES 
CXCR3-positive cells are suspected of being macrophages based on morphology and 
because macrophages have been shown to be positive for CXCR3 (35, 36). Therefore, we 
investigated whether CXCR3-positive macrophages are present within the fusing palate 
using immunofluorescence microscopy. F4/80-CXCR3 double-positive macrophages were 
observed in the fusing palatal shelves, with some located near the disintegrating MES, in 
both wt and HO-2 KO fetuses (Figure 3.8).  
In both wt and HO-2 KO fetuses, multiple apoptotic DNA fragments were present 
in the epithelial cells of the disintegrating MES. No apoptotic cell fragments were observed 
in the other epithelial regions. To assess whether the recruited macrophages phagocytose 
these apoptotic cell fragments, we stained for both apoptotic fragments and macrophages 
(FragEL™ DNA fragmentation assay in combination with F4/80). Macrophages located near 
the MES did phagocytose apoptotic DNA fragments (Figure 3.9A, B, C). Other macrophages 
were observed in the mesenchyme closely localized near the apoptotic DNA fragments 
within the disintegrating MES (Figure 3.9B).  
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Figure 3.7: CXCR3 expression in the MES and mesenchyme in both wt and HO-2 KO fetuses. A: CXCR3 mRNA 
expression was found in wt fetuses E15 (n=5) and in HO-2 KO fetuses E15 (n=4)(p=0.16). Data present mean ± SD. 
B: Statistically significant higher CXCR3 expression was observed in the wt group in the MES (in RED)(*=p<0.05) 
compared to the YELLOW region. C: Significant higher CXCR3 expression was observed in the MES (in RED) 
(***=p<0.001) compared to the BLUE region  and YELLOW region in the HO-2 KO sections with adhesion of the 
palatal shelves and adhesion to the nasal septum. D: No significant difference in the number of CXCR3 positive 
cells/mm2 in the mesenchyme of the fusing palatal shelves was found between the wt and HO-2 KO 
fetuses)(p=0.96). Data present mean ± SD. E: No significant difference in the number of CXCR3 positive cells/mm2 
in the mesenchyme was found between the wt and HO-2 KO group of the sections with adhesion of the palatal 
shelves and adhesion to the nasal septum(p=0.47). Data present mean ± SD. F: Representative CXCR3 
immunostaining of fusing palatal shelves without adhesion to the nasal septum of a wt fetus (E15) (magnification: 
x100). The MES (in RED) had higher CXCR3 expression compared to the other epithelial regions (in BLUE) and (in 
YELLOW). G: Some CXCR3 positive cells in the mesenchyme were observed. This was found for the wt sections and 
HO-2 KO sections (black arrow indicates a CXCR3 positive cell in the mesenchyme) (magnification: x400). H: 
Moderate CXCR3 expression in the epithelium of the lateral half of the palatal shelve (in BLUE), and in the 
epithelium of the lateral wall of the nasal cavity (in YELLOW) (magnification: x400). 
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Figure 3.8: CXCR3 positive macrophages were located near the MES. A: Representative immunofluorescent 
histochemical double staining for F4/80 (red) with CXCR3 (green) in HO-2 KO section (E16). Nuclear staining with 
DAPI (Blue). The mesenchyme demonstrates the presence of a F4/80 positive HO-2 KO macrophages, which also 
express CXCR3 (white arrows) (magnification: x200). One CXCR3 F4/80 positive HO-2 KO macrophage was located 
near the disintegrating MES (white arrow within the white square). B: Magnification of a F4/80 positive HO-2 KO 
macrophage located near the MES (area between the dotted white lines) (magnification: x400). C: Magnification 
of a F4/80 positive HO-2 KO macrophage located in the mesenchym of the palate shelf (magnification: x400). D: 
Magnification of a F4/80 positive HO-2 KO macrophage located outside the palatal shelf (magnification: x400). 
 
Figure 
3.9: Macrophages located near the MES phagocytose apoptotic cell fragments.  
A: Representative FragEL™ DNA fragmentation assay (brown) in combination with F4/80 (dark blue) macrophage 
staining. Fusing palatal shelves in a HO-2 KO fetus (E16) (magnification: x100). Multiple macrophages were 
observed in the mesenchyme of the palatal shelves. B: Magnification of the disintegrating MES (magnification: 
x400, black square). Multiple apoptotic DNA fragments are observed within the MES (Red arrows). The only 
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apoptotic DNA fragments in the palatum outside the MES are in macrophages that had taken up epithelial cells 
seen. Two macrophages were located near the MES (green arrows), one macrophage was in close contact with the 
MES (red circle). C: Magnification of the macrophage in close contact with the MES (black square). In this 
macrophage (red circle), two apoptotic cell fragments within its cell body are present (purple arrows). Apoptotic 
DNA fragments near the macrophage were observed (red arrows). These findings were representative for both wt 
and HO-2 KO sections.  
 
More HO-1-positive cells are found in palatal shelves from HO-2 KO fetuses 
As macrophages can express the cytoprotective enzyme HO-1 during the digestion of 
cellular debris (49, 50), we studied whether HO-1-positive macrophages are present within 
the fusing palate. HO-1 mRNA was observed in samples from the heads of both wt and HO-
2 KO fetuses without reaching a significant difference between the two genotypes (p=0.35, 
Figure 3.10A). Double immunostaining for macrophage marker F4/80 and HO-1 showed that 
many F4/80-positive macrophages were positive for HO-1. F4/80 and HO-1-positive cells 
were observed in the fusing palatal shelves and near the disintegrating MES in both wt and 
HO-2 KO fetuses (Figure 3.10B, C).  
The number of HO-1-positive cells in the mesenchyme of the fusing palatal shelves 
was significantly higher in the HO-2 KO group than in the wt group (p=0.02, Figure 3.10D-
G). Almost no HO-1 expression was observed in the epithelium of the palatal shelves in the 
wt and HO-2 KO groups.  
 
Figure 3.10: More HO-1-positive cells are found in palatal shelves from HO-2 KO fetuses. A: HO-1 mRNA 
expression was similar in wt fetuses E15 (n=5) and in HO-2 KO fetuses E15 (n=4) (p=0.35). Data present mean ± SD. 
B: Representative fluorescent immunohistochemical double staining for F4/80 and HO-1 of fusing palatal shelves 
with adhesion to the nasal septum of a wt fetus (E15) (magnification: x400). A part of the mesenchyme around the 
MES, showing a F4/80 positive macrophage (red) expressing HO-1 (green) located (white arrow). Nuclear staining 
with DAPI (Blue). C: Representative fluorescent immunohistochemical double staining for F4/80 with HO-1 of 
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fusing palatal shelves with adhesion to the nasal septum of a HO-2 KO fetus (E16) (magnification: x400). A F4/80 
positive HO-2 KO macrophage (red) expressing HO-1 (green) located near the MES (white arrow). Nuclear staining 
with DAPI (Blue). D: Representative HO-1 immunostaining of palatal shelves of a wt fetus (E15) (magnification: 
x400). This part of the mesenchyme demonstrates the presence of one HO-1 positive cell (black arrow). E: 
Representative HO-1 immunostaining of fusing palatal shelves of a HO-2 KO fetus (E16) (magnification: x400). This 
part of the mesenchyme demonstrates the presence of seven HO-1 positive cells (black arrows). F: Significant 
higher numbers of HO-1 positive cells/mm2 were observed in the HO-2 KO fetuses compared to the wt fetuses in 
the fusing palatal shelves)(p=0.02). Data present mean ± SD. G: Numbers of HO-1 positive cells/mm2 in the 
mesenchyme of wt and HO-2 KO fetuses in the fusing palatal shelves with adhesion to the nasal septum (p=0.60). 
Data present mean ± SD. 
 
Discussion 
Although deletion of HO-2 expression in mice leads to fetal growth restriction, severe 
malformations, and craniofacial anomalies, we found no evidence of disruption of palatal 
fusion in HO-2 KO fetuses. We showed that multiple apoptotic DNA fragments were 
exclusively present in the MES of both genotypes, supporting earlier findings that apoptosis 
of epithelial cells drives MES disintegration (8). We demonstrated that both CXCR3 and its 
ligand, the chemokine CXCL11, were highly expressed by epithelial cells in the MES, 
suggesting that chemokine signaling acts via an autocrine loop to initiate processes involved 
in its own disintegration. Although, probably also other downstream mechanisms play a 
role in this process, such as caspases, other enzymes and apoptotic DNA fragments. We 
demonstrated that apoptotic DNA fragments from the MES were phagocytized by both wt 
and HO-2 KO macrophages. It is likely that CXCR3-positive macrophages were recruited via 
CXCL11 expression by the MES (Figure 3.11). However, we cannot exclude that additionally, 
other mechanisms can in a later phase facilitate macrophage recruitment. For example, 
apoptotic nucleotide fragments derived from the MES have been demonstrated to promote 
macrophage contributed to this recruitment (51). Macrophages near the disintegrating MES 
were positive for HO-1 in both wt and HO-2 KO fetuses, but more HO-1-positive cells were 
found in the palate mesenchyme from HO-2 KO fetuses. Although HO-2 KO macrophages 
have been shown to be dysfunctional in a mouse corneal epithelial debridement model (38), 
HO-2 KO macrophages phagocytosis of apoptotic DNA fragments still function, possibly with 
help of HO-1 overexpression.  
Adult HO-2-deficient mice are morphologically indistinguishable from wt mice (42), 
but only full-grown mice have been studied thus far. To the best of our knowledge, this is 
the first study of HO-2 KO embryonic development. Down-regulation of HO-2 is associated 
with spontaneous abortion in humans (18). We did not find that the absence of HO-2 
expression resulted in an increased fetal loss rate or decreased implantation rate in mice. 
However, non-viable and hemorrhagic embryonic implantations were frequently observed 
in both genotypes. Homozygote HO-2 KO mice were recently demonstrated to be viable 
(37), though they demonstrated delayed wound repair (37, 52) and an exaggerated 
inflammatory response after corneal epithelial wounding (53). Fetal growth retardation is 
associated with down-regulation of HO-2 in human pathologic pregnancies (18), which is in 
line with our findings that HO-2 deletion leads to a developmental growth delay at E15 of 
approximately 1 day. Among the HO-2 KO fetuses, one was severely malformed and another 
presented a head anomaly, but no anomalies or malformations were found in wt fetuses.  
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Figure 3.11: MES mediated chemokine signaling facilitates MES disintegration and palatal fusion.  
Conceptual model: Autocrine and paracrine MES signaling facilitates palatal fusion. CXCL11/CXCR3 autocrine 
signaling controls migration and/or apoptosis of epithelial cells during disintegration of the MES. CXCL11-CXCR3 
paracrine signaling recruits macrophages to clean up the MESs. HO-2 KO macrophages are still able to phagocytize 
apoptotic DNA fragments from the MES due to induction of HO-1. 
 
Environmental factors, such as maternal diabetes, oxidative stress, and infections 
can have a disturbing influence on palatal fusion and lead to clefting of the lip and palate 
(16). HO-2 is essential for regulating physiological levels of reactive oxygen species (ROS) 
(54, 55). Although we found growth restriction and morphological anomalies in HO-2 KO 
fetuses, proper fusion of the palatal shelves was observed. In the absence of additional 
stresses, HO-2 KO fetuses can thus develop into mice with a normal palate, possibly due to 
compensation by elevated HO-1 expression. Next, we studied palatogenesis in HO-2 KO 
mice in more detail.  
We demonstrated increased expression of chemokine CXCL11 and its receptor 
CXCR3 within the disintegrating MES in both genotypes. CXCR3-CXCL11 signaling serves as 
a coordinator in wound repair (56, 57) and is involved in the process of re-epithelialization 
and epidermis maturation (37). In keratinocytes, CXCR3 signaling activated μ-calpain to 
loosen the adhesions for migration (29). Scars in CXCR3 KO mice exhibited hyperkeratosis 
and hypercellularity (30), features that are also observed in hypertrophic scar formation in 
humans (56). CXCR3 plays a key role in coordinating the switch from regeneration of the 
epithelial compartment towards maturation (58) and modulates cell proliferation and 
apoptosis (59, 60). In the disintegrating MES CXCL11-CXCR3 signaling is therefore likely 
involved in controlling processes, such as migration and apoptosis of epithelial cells.  
We found many apoptotic DNA fragments throughout the disintegrating MES, 
supporting apoptosis as a driving mechanism in MES disintegration (7-10). No apoptotic 
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DNA fragments were found in the other epithelial regions of the palatal shelves or the 
mesenchyme of the palatal shelves. Blocking cell death with z-VAD, an inhibitor of caspases, 
leads to persistence of the MES structure, which interferes with fusion of the palatal shelves 
in vitro (61), suggesting that this could lead to cleft palate. However, a role of epithelial 
migration in MES disintegration cannot be excluded. 
In addition to CXCR3 expression in the epithelial MES layer, we also demonstrated 
CXCR3 expression in the mesenchyme of the fusing palatal shelves. We found CXCR3-
positive and phagocytosing macrophages near the disintegrating MES, suggesting that 
macrophages are actively recruited by CXCL11. This demonstrates that the MES actively 
participates in its disintegration via chemokine signaling. However, we cannot exclude that 
other mechanisms play a role, such as caspases, other enzymes and enzyme inhibitors. 
Recruitment of CXCR3-positive macrophages by CXCL11 paracrine signaling was 
demonstrated previously also in other models (35, 36).  
Although HO-2 deletion impaired macrophage function in corneal epithelial wound 
repair (38), in our study both wt and HO-2 KO macrophages phagocytosed apoptotic DNA 
fragments and, thus, were still functional. Although impairment of macrophage function by 
HO-2 deletion was found in a wound repair study in adult mice (38), we studied macrophage 
function in a non-pathological environment during embryonic development. However, our 
findings contradict another wound healing study, demonstrating that HO-2 deletion was 
associated with impaired HO-1 induction (52). Significantly more HO-1-positive cells were 
found in the palatal mesenchyme of HO-2 KO fetuses compared to wt fetuses, in which HO-
1-positive cells were scarce. We suggest that the higher HO-1 expression during embryonic 
development is a compensating mechanism for HO-2 deletion in recruited macrophages in 
the fusing palatal shelves. An increased HO-1 induction could explain in part the discrepancy 
in function between HO-2 KO macrophages in adult and embryonic mice.  
A limitation of the present study was the relatively small number of fetuses. 
However, among the 23 HO-2 KO fetuses, one demonstrated severe malformations and 
another viable fetus had a craniofacial anomaly, suggesting that HO-2 supports fetal growth 
and development.  
In conclusion, we determined that HO-2 deletion leads to fetal growth restriction 
and craniofacial anomalies. In contrast to our hypothesis, no disturbance was observed in 
palatal fusion in HO-2 KO fetuses. However, CXCL11 and CXCR3 were highly expressed in 
the disintegrating MES in both wt and HO-2 KO animals. Both wt and HO-2 KO CXCR3-
positive macrophages were functional since apoptotic cells from the disintegrating MES 
were phagocytosed. Increased numbers of HO-1-positive cells were found within the 
mesenchyme of the fusing palatal shelves of the HO-2 KO fetuses. It is tempting to speculate 
that HO-2 deletion leads to up-regulation of HO-1 expression in macrophages, protecting 
them from oxidative stress following ingestion of apoptotic epithelial fragments from the 
disintegrating MES. Our data supports the hypothesis that chemokine signaling by the MES 
orchestrates its disintegrating by epithelial apoptosis and macrophage recruitment via 
CXCL11-CXCR3 signaling. However, also alternative pathways may have contributed to 
these processes. Further research is needed to investigate whether hampered palatal fusion 
can be the result of disrupted chemokine signaling  and whether reduced protection against 
oxidative and inflammatory stresses promote craniofacial malformations.  
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Chapter 4   
 
Mechanical stress changes the complex interplay 
between heme oxygenase-1, inflammation and fibrosis 
during excisional wound repair.  
 
Cremers NA, Suttorp M, Gerritsen MM, Wong RJ, van Run-van Breda C, van Dam 
GM, Brouwer KM, Kuijpers-Jagtman AM, Carels CE, Lundvig DM, Wagener FA. 
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Abstract  
Mechanical stress following surgery or injury can promote pathological wound healing and 
fibrosis, and lead to functional loss and esthetic problems. Splinted excisional wounds can 
be used as model for inducing mechanical stress. The cytoprotective enzyme heme 
oxygenase-1 (HO-1) is thought to orchestrate the defense against inflammatory and 
oxidative insults that drive fibrosis. Here, we investigated the activation of the HO-1 system 
in a splinted and non-splinted full thickness excisional wound model using HO-1-luc 
transgenic mice. Effects of splinting on wound closure, HO-1 promoter activity, and markers 
of inflammation and fibrosis were assessed. After seven days, splinted wounds were more 
than 3 times larger than non-splinted wounds, demonstrating a delay in wound closure. HO-
1 promoter activity rapidly decreased following removal of the (epi)dermis, but was induced 
in both splinted and non-splinted wounds during skin repair. Splinting induced more HO-1 
gene expression in 7-day wounds; however, HO-1 protein expression remained lower in the 
epidermis, likely due to lower number of keratinocytes in the re-epithelialization tissue. 
Higher numbers of F4/80-positive macrophages, αSMA-positive myofibroblasts, and 
increased levels of the inflammatory genes IL-1β, TNF-α, and COX-2 were present in 7-day 
splinted wounds. Surprisingly, mRNA expression of newly-formed collagen (type III) was 
lower in 7-day wounds after splinting; whereas, VEGF and MMP-9 were increased. 
Summarizing, these data demonstrate that splinting delays cutaneous wound closure and 
HO-1 protein induction. The pro-inflammatory environment following splinting, may 
facilitate higher myofibroblast numbers and increases the risk of fibrosis and scar formation. 
Therefore, inducing HO-1 activity against mechanical stress-induced inflammation and 
fibrosis may be an interesting strategy to prevent negative effects of surgery on growth and 
function in patients with orofacial clefts or in burns patients. 
 
Keywords: cleft palate, burns, mechanical stress, wound healing, heme oxygenase-1, 
inflammation, fibrosis. 
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Abbreviations 
ABC Avidin-biotin-peroxidase complex 
ANOVA Analysis of variance 
αSMA Alpha smooth muscle actin 
AU Arbitrary units 
CL/P Cleft lip with or without cleft palate 
CO Carbon monoxide 
COX-2 Cyclooxygenase-2 
CXCL1 Chemokine (C-X-C) ligand 1 
DAB Diaminobenzidine-peroxidase 
DPX Distyrene plasticizer xylene 
ECM Extracellular matrix 
HO-1 Heme oxygenase-1 
ICAM-1 Intercellular adhesion molecule-1 
IL-1β Interleukin-1 beta 
MCP-1 Monocyte chemotactic protein-1 
MMP-9 Matrix metalloproteinase-9 
NDS Normal donkey serum 
PBS-G Phosphate buffered saline with glycin 
ROI Regions of interest 
TNF-α Tumor necrosis factor-alpha 
VEGF Vascular endothelial growth factor 
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Introduction 
Cleft lip with or without cleft palate (CL/P) is a developmental craniofacial disorder that is 
characterized by an opening in the upper lip and/ or palate and alveolar bone (1). Patients 
with CL/P need multiple surgeries that inevitably result in scar formation (Figure 4.1A) (2, 
3). Especially, the scars on the palate may disrupt normal midfacial growth and impair 
dento-alveolar development (4, 5). Also, patients with severe burns can exhibit excessive 
scar formation (Figure 4.1B) (6). Scarring can be exaggerated by mechanical tension, such 
as due to the growth of the child and by tension of the wound during wound repair (7). 
Overall, pathological wound healing following mechanical stress can result in hypertrophic 
scars and subsequently lead to functional, psychosocial, and esthetical problems for 
patients (8, 9). 
A).               B). 
            
Figure 4.1. Mechanical stress may promote excessive scar formation following injury 
(A) An intra-oral photo of the maxillary arch of a patient of our clinic with an operated complete bilateral cleft lip 
and palate is shown. Mechanical stress-induced scar formation impairs development of the upper jaw and the 
dentition. (B) Also, burns can result in excessive scar formation leading to cosmetic and functional problems as 
exemplified by scar formation near the wrist.  
Mechanical load, together with cytokine expression and the composition of the 
extracellular matrix (ECM), promote the differentiation of fibroblasts into myofibroblasts 
(10-12). During wound repair, myofibroblasts play a key role in the deposition of ECM and 
in wound contraction, thereby reducing wound size and preventing invasion by pathogens 
(10, 12). When a wound closes, myofibroblasts normally disappear by apoptosis. However, 
during pathologic wound healing, extended presence of myofibroblasts may result in 
excessive wound contracture and ECM deposition, leading to excessive scar formation and 
functional problems (5, 13). Mechanical stress during wound repair can trigger a continued 
expression of the myofibroblast marker alpha smooth muscle actin (α-SMA), and a 
prolonged survival of myofibroblasts (5, 14-17).  Prolonged inflammatory and oxidative 
stress may also increase myofibroblast survival (18). A better understanding of the effects 
of mechanical stress during the wound healing process is warranted to develop novel 
adjuvant therapies.  
Rodents, in contrast to humans, possess a subcutaneous muscle layer (m. 
panniculus carnosus), which can cause wound contraction (19). In these animals, the use of 
splinting can induce static mechanical stress to healing wounds (5, 14, 20), interfere with 
this muscle contraction, and thus better simulate human wound healing that is mainly 
dependent on granulation and re-epithelialization of tissues (19). The effects of static 
mechanical stress, caused by splinting, on the different phases of wound healing remains to 
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be unraveled. In addition, the involvement of cytoprotective mechanisms needs further 
exploration. Activation of the cytoprotective heme oxygenase (HO) system has shown 
protective effects in both inflammatory and fibrotic models (6, 18, 21). 
HO is an enzyme that catabolizes heme, yielding the gasotransmitter carbon 
monoxide (CO), free iron, which is scavenged by co-induced ferritin, and biliverdin that is 
rapidly converted into the antioxidant bilirubin by biliverdin reductase (22). The HO system 
possesses antioxidative, anti-inflammatory, anti-fibrotic, and anti-apoptotic properties (18, 
23) and can influence cell proliferation, differentiation, and migration. When these 
processes are disrupted, wound repair may be hampered (24). There are two isoforms of 
HO, the inducible HO-1 and the constitutively-expressed HO-2. It has been shown that HO-
1 is rapidly induced in wounded tissues (25, 26). Decreased HO-1 or HO-2 expression and 
enzyme activity in mice results in slower cutaneous wound closure; whereas, induction of 
HO-1 expression or administration of the HO effector molecule bilirubin attenuates the 
inflammatory response and accelerates wound healing in HO-1-deficient mice (27-29).  
In this study, we investigated the expression of HO-1 during wound repair in both 
non-splinted and splinted wounds using transgenic HO-1-luc mice. Because mechanical 
stress has been shown to induce HO-1 expression in different experimental settings in a 
time- and force-dependent manner (30-32), we therefore postulated that mechanical stress 
by splinting would induce HO-1 expression during wound healing. In addition, we 
investigated the effects of mechanical stress on markers of inflammation, ECM remodeling, 
and fibrosis. 
 
Material and Methods 
Animals 
The Committee for Animal Experiments of Radboud University Nijmegen approved all 
procedures involving mice (RU-DEC 2010-248). Twelve mice (strain: HO-1-luc FVB/ N-Tg 
background), 4 to 5 months of age and weighing 30± 5 g, were provided with food and water 
ad libitum. Mice were maintained on a 12h light/dark cycle and specific pathogen-free 
housing conditions at the Central Animal Facility Nijmegen. More details on the housing 
conditions have been previously described (33). Mice were originally derived from Xenogen 
Corporation (Alameda, CA, USA) and generated as previously described (34).  
The mice were euthanized with a standard CO2/O2 protocol seven days after 
wounding, after which control skin, and wounded skin were isolated. Half of the tissue was 
fixed for 24h in 4% paraformaldehyde and then embedded in paraffin following regular 
histosafe procedures and the other half was snap-frozen in liquid nitrogen and stored at -
80°C until isolation of mRNA.  
 
Excisional non-splinted and splinted wound model 
Splinted (n=6) and non-splinted (n=6) full-thickness excisional wounds 4 mm in diameter 
were created on the dorsum of the mice after shaving as previously described (35). In brief, 
excisional wounds were created using a sterile disposable 4-mm skin biopsy punch (Kai 
Medical, Seki City, Japan) on the dorsum to either side of the midline, and halfway between 
the shoulders and pelvis. Circular silicone splints of 6-mm inner- and 12-mm outer-diameter 
made from silicone sheets (3M, Saint Paul, Minnesota, USA) were glued to the skin around 
the wound. Mice receiving splinted excisional wounds were wrapped with semi-permeable 
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dressing (Petflex; Andover, Salisbury, MA, USA) around their torso, to cover the wound. One 
mouse in the splinted group died due to pulmonary failure as a result of respiratory 
obstruction by the bandage during the recovery from anaesthesia. 
Photographs of the wounds were taken immediately after wounding and then 1h 
and 1, 3, 5 and 7 days thereafter with a reference placed perpendicular next to the wounds 
for wound size normalization. The area of the wounds was blindly measured in triplicates 
using ImageJ (NIH) v1.44p software.  
 
HO-1 promoter activity measurements 
HO-1 promoter activity was determined at baseline, immediately after wounding and 1h 
and 1, 3, and 7 days thereafter in the HO-1-luc-Tg mice by in vivo bioluminescence imaging 
using the IVIS Lumina system (Caliper Life Sciences, Hopkinton, MA, USA) as previously 
described (36). Images were quantified using Living Image 3.0 software (Caliper Life 
Sciences) by selecting regions of interest (ROI). The amount of emitted photons per second 
(total flux) per ROI was measured, and then calculated as fold change from baseline levels.  
 
Immunohistochemical staining 
Immunohistochemical staining for HO-1, macrophages (F4/80), and myofibroblasts (α-SMA) 
were performed on paraffin sections of the wounds as previously described (35). In short, 
paraffin-embedded tissues were cut into 5-μm sections, which were then de-paraffinized, 
quenched for endogenous peroxidase activity with 3% H2O2 in methanol for 20 min, and 
rehydrated. Sections were post-fixed with 4% formalin, and washed with PBS containing 
0.075 μg/ mL glycine (PBSG). Antigens were retrieved with citrate buffer (0.01 M, pH 6.0) at 
70°C for 10 min, followed by incubation in 0.075 g/mL trypsin in PBS at 37°C for 7 min. Next, 
the sections were pre-incubated with 10% normal donkey serum (NDS) in PBS-G. First 
antibodies (HO-1 from Stressgen #SPA-895 1:600 dilution, α-SMA from Sigma-Aldrich 
#A2547 1:600 dilution, and F4/80 from AbD Serotec #MCA497R 1:200 dilution) were diluted 
in 2% NDS in PBSG and incubated overnight at 4°C. After washing with PBSG, sections were 
incubated for 60 min with a biotin-labeled secondary antibody against host species (1:5000 
dilution). Next, the sections were washed with PBSG and treated with avidin-biotin-
peroxidase complex (ABC) for 45 min in the dark. After extensive washing with PBSG, 
diaminobenzidine-peroxidase (DAB) staining was performed for 10 min. After rinsing with 
water, staining was intensified with Cu2SO4 in 0.9% NaCl and rinsed with water again. Finally, 
the nuclei were stained with hematoxylin for 10 s and sections were rinsed for 10 min in 
water, dehydrated and embedded in distyrene plasticizer xylene (DPX). 
 Immunoreactivity was evaluated by blindly scoring the wounds. For the HO-1 
staining, we scored both the epidermal and dermal region of the wounds separately, since 
there were two different positively-stained populations. A single section per wound was 
semi-quantitatively scored, by two assessors independently of each other, as previously 
described according to the following scale: 0 (minimal), 1 (mild), 2 (moderate), and 3 
(marked) (35). 
 
RNA isolation and quantitative-RT-PCR 
Non-wounded control skin and wounds were pulverized in TRIzol (Invritrogen) using a 
micro-dismembrator (Sartorius BBI Systems GmbH, Melsungen, Germany) and RNA was 
further extracted as previously described (37). Quantitative-Real-Time-PCR was performed. 
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mRNA expression levels were calculated as minus delta delta Ct (-∆∆Ct) values, normalized 
to the reference gene GAPDH, and corrected for non-wounded control skin. Fold change 
were calculated by 2^(-∆∆Ct). The sequences of the mouse-specific primers are shown in 
Table 4.1.  
 
Table 4.1. Mouse primers  
Marker Gene name Forward primer (5’-3’) Reverse primer (5’-3’) 
Reference gene GAPDH GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCCTG 
Inflammation IL-1β TGCAGCTGGAGAGTGTGG TCCACTTTGCTCTTGACTTCTATC 
 TNF-α CTCTTCTCATTCCTGCTTGTG GGGAACTTCTCATCCCTTTG 
 COX-2 CCAGCACTTCACCCATCAGTT ACCCAGGTCCTCGCTTATGA 
 MCP-1 ACTGAAGCCAGCTCTCTCTTCCTC TTCCTTCTTGGGGTCAGCACAGAC 
Cytoprotection HO-1 CAACATTGAGCTGTTTGAGG TGGTCTTTGTGTTCCTCTGTC 
 HO-2 AAGGAAGGGACCAAGGAAG AGTGGTGGCCAGCTTAAATAG 
Angiogenesis VEGF GGAGATCCTTCGAGGAGCACTT GGCGATTTAGCAGCAGATATAAGAA 
Fibrosis α-SMA (acta2) CAGGCATGGATGGCATCAATCAC ACTCTAGCTGTGAAGTCAGTGTCG 
 MMP-9 TGCCCATTTCGACGACGAC GTGCAGGCCGAATAGGAGC 
 Collagen 3a1 ATCCCATTTGGAGAATGTTG AAGCACAGGAGCAGGTGTAG 
Keratinocytes Krt-6 GACGACCTACGCAACACC AGGTTGGCACACTGCTTC 
 
Statistics 
Data were analyzed using GraphPad Prism 5.01 software (San Diego, CA, US). No outliers 
were detected using the Grubbs’ test. Data was analyzed by a paired t-test for comparisons 
of two groups and a one- or two-way analysis of variance (ANOVA) for the comparison of 
multiple groups with a post-hoc Bonferroni correction for multiple comparisons. The non-
parametrical one-tailed Mann-Whitney U-test was used to compare the arbitrary scored 
immunohistological sections. Results were considered significant different when p<0.05 
(*p<0.05, **p<0.01, ***p<0.001). 
 
Results 
Static mechanical stress induced by splinting delays excisional wound closure  
Because mechanical stress can lead to excessive scar formation (Figure 4.1AB), we used 
both splinted and non-splinted excisional wound healing to assess the effects of static 
mechanical stress on wound closure. Wound sizes of non-splinted and splinted wounds 
were monitored over time and representative photos are shown in Figure 4.2A. After 
quantification of the wound area the wound closure time in relation to t= 0h was displayed 
(Figure 4.2B). All wounds closed gradually, but there were differences in wound closure 
between splinted and non-splinted wounds. After three days, significant differences 
between the groups were found. Non-splinted wounds were already closed for 45%; 
whereas, splinted wounds had only closed for 10%. After seven days, closure of non-splinted 
wounds was 75% of the wound area, while that for splinted wounds was only 23%. This 
corresponds to a 3.3 times faster wound closure when no mechanical stress was applied. 
This demonstrates that splinting effectively delays wound closure.  
 
 
 
 
 
94 
A). 
  
B). 
 
Figure 4.2: Splinted and non-splinted excisional wound closure over time  
(A) Representative pictures of non-splinted and splinted wounds immediately following injury, and 1h, and 1, 3, 5 
and 7 days after wounding (black bars = 4 mm). (B) Quantification of closures of non-splinted (n=6) and splinted 
(n=5) wounds over time (0-7 days). Each mouse had two wounds. Time point 0h was used as 100%. Data represent 
mean±SD. * is significantly different between non-splinted and splinted wounds (***p<0.001).  
 
The HO system is affected by mechanical stress during excisional wound healing  
HO-1 is thought to be a critical regulator and expressed in distinct cell types during the 
different phases of wound repair. In order to investigate the role of HO-1 following 
mechanical stress (splinting) during excisional wound healing, we used HO-1-luc mice to 
monitor HO-1 promoter activity (Figure 4.3A). HO-1 promoter activity was already present 
in the kidneys in non-injured HO-1-luc mice. In the wound area, HO-1 promoter activity was 
evident especially at days 3 and 7 after splinting.  
Surprisingly, we found that following wounding, there was an initial significant 
decrease in HO-1 promoter activity after 1h in both splinted as well as non-splinted wounds 
(Figure 4.3B). This decrease of HO-1 promoter activity returned to basal levels at day 1 and 
further increased at days 3 to 7, independent of splinting. Three days following wounding, 
the splinted wounds showed a significant increase of HO-1 promoter activity compared to 
basal levels.  
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To further elucidate the role of splinting on HO-1 expression during wound repair, 
we measured both HO-1 mRNA and protein expression in day-7 wounds. Using RT-PCR, HO-
1 mRNA expression was assessed in the wounds and corrected for expression in non-
wounded control skin (Figure 4.4A). Here, we found significantly higher (2.6 times) HO-1 
mRNA expression in splinted wounds compared to non-splinted wounds. As expected, the 
constitutively-expressed HO-2 levels were not significantly different after induction of 
mechanical stress. 
Immunohistochemical staining demonstrated that HO-1 levels were severely 
affected by wounding when compared to non-wounded skin. The number of HO-1-positive 
cells 7 days after wounding was increased in the dermal region of the wounds; also, more 
HO-1-positive cells were present in the epidermal region when compared to non-wounded 
skin.  
 
A). 
 
B). 
 
Figure 4.3: HO-1 promoter activity in splinted and non-splinted wounds 
(A) Representative images of HO-1 promoter activity of non-splinted and splinted wounds over time using the IVIS 
system to measure in vivo bioluminescence in HO-1-luc mice. The rainbow colored bar at the right side indicates 
the amount of luciferase signal represented in each group with a high signal in red and low signal in blue. The red 
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circles surround the wounds in the mice and indicate the measured region of interest (ROI). Note: black triangle (
) with black arrows shows that there is basal HO-1 promoter activity around the kidneys. (B) Quantification of 
HO-1 promoter activity during non-splinted (n=6) and splinted (n=5) wound healing. Each mouse had two wounds. 
Data represent mean±SD. * is significantly different within the non-splinted or splinted group when compared to 
the baseline at the start of the experiment (*p<0.05). # is significantly different within the non-splinted or splinted 
group when compared to 1h after wounding (#p<0.05).  
 
HO-1 protein was particularly evident in the epithelial cells at the leading edge of 
the wound in the epidermis and in recruited inflammatory leukocytes in the dermis (Figure 
4.4B). Since, we observed two different populations of HO-1-positive cells depending on 
their region, the wounds were scored for the level of HO-1 protein expression in both the 
epidermal and dermal regions, which were compared between the different treatment 
groups (Figure 4.4C). Importantly, non-splinted wounds showed significantly higher HO-1 
protein expression in the epidermal region compared to splinted wounds. In the dermal 
region, HO-1 was slightly higher after mechanical stress compared to the non-splinted 
wounds; however, this did not reach statistical significance (p=0.21). Variation in HO-1 
protein expression was found between animals, but was independent of the wound model.  
Thus, wounding initially decreased HO-1 promoter activity in the wound, after 
which HO-1 levels were restored and further induced by recruitment of inflammatory cells 
and keratinocytes. Surprisingly, although splinted wounds delay HO-1 expression, as shown 
by an increased HO-1 promoter activity and HO-1 mRNA expression, HO-1 protein 
expression was, in contrast to in the dermis, lower in the epidermis when compared to non-
splinted wounds.  
 
Interplay between HO-1 and inflammation in non-splinted and splinted wound healing 
Since there was a clear delay in wound closure and HO-1 protein expression in splinted 
wounds, we investigated whether this delay correlated with altered levels of inflammatory 
gene expression. Because HO-1 has anti-inflammatory and antioxidative properties, we 
expected that the delayed HO-activity in the skin would result in increased levels of 
inflammation. Therefore, we quantitated the number of F4/80-positive macrophages using 
immunohistochemical staining in sections of non-splinted and splinted wounds (Figure 
4.5A).  
We found that there were indeed significantly more macrophages present in 7-day 
splinted wounds compared to non-splinted wounds (Figure 4.5B). Next, we investigated 
whether mRNA expression of monocyte chemotactic protein (MCP-1), the main chemokine 
to attract monocytes/ macrophages, was altered by mechanical stress. We observed that 
MCP-1 was elevated 1.8 fold in splinted wounds compared to non-splinted wounds, 
however, this difference did not reach statistical significance (p=0.10). 
 Finally, when we examined the gene expression of several other inflammatory 
markers, we found that mRNA expression levels of the pro-inflammatory cytokines IL-1β, 
TNF-α, and COX-2 in splinted wounds were significantly higher when compared to non-
splinted wounds (36.9-, 24.4-, 8.8-fold, respectively) (Figure 4.5C).  
In summary, we showed that delayed wound closure and reduced HO-1 protein 
expression following mechanical stress was clearly associated with elevated levels of 
macrophages and several other inflammatory genes. 
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A). 
  
B). 
 
C). 
 
Figure 4.4: HO expression in wounds  
(A) HO-1 and HO-2 mRNA expression levels in non-splinted and splinted wounds were determined in 7-day wounds 
and compared to control unwounded skin. Data represent mean±SD. * is significantly different between non-
splinted and splinted wounds (**p<0.01). (B) HO-1 protein expression in control and non-splinted and splinted 
wounds after 7 days of healing. Region above the marked blue line is the epidermis and underneath the line is the 
dermal layer (bars = 1 mm). Note: black triangle ( ) in the non-wounded control skin shows HO-1-positive 
keratinocytes at the front of the epithelial layer, and HO-1 positive hair follicles. Black arrows (→) shows HO-1-
positive cells in the epidermis and dermis of non-splinted and splinted wounds. (C) Quantification of scored HO-1 
protein staining in epidermis and dermis of the wounds after 7 days in arbitrary units (AU). Data represent 
mean±SD. * is significantly different between non-splinted and splinted wounds (*p<0.05). 
A). 
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B). 
 
C). 
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Figure 4.5: Effects of splinting on markers of inflammation 
(A) Immunohistological staining of macrophages (F4/80) in control skin and non-splinted and splinted 7-day 
wounds (bars = 1 mm). Black arrow (→) shows F4/80-positive macrophages in non-splinted and splinted wounds. 
(B) Quantification of scored F4/80 protein staining of the wounds after 7 days in arbitrary units (AU). Data 
represent mean±SD. * is significantly different between non-splinted and splinted wounds (**p<0.01). (C) mRNA 
expression levels of inflammatory markers in 7-day non-splinted and splinted wounds normalized to levels in 
control unwounded skin (MCP-1, IL-1β, TNF-α, and COX-2). Data represent mean±SD. * is significantly different 
between non-splinted and splinted wounds (*p<0.05, **p<0.01). 
 
Effects of mechanical stress on remodeling and fibrotic genes 
Because increased levels of inflammation by mechanical stress during wound repair may 
also affect markers of fibrosis, we investigated the effects of splinting on markers of ECM 
remodeling and fibrosis. 
 During wound healing, fibroblasts can transform into myofibroblasts. These 
myofibroblasts cause wound contraction and produce ECM. Normally, these myofibroblasts 
go into apoptosis after wound repair has finished. When these myofibroblasts fail to 
become apoptotic, ECM production continues, and pathologic wound healing with 
excessive scarring follows. The presence of myofibroblasts is dependent on the phase of 
wound healing. To investigate the role of splinting on myofibroblasts, we stained 7-day 
wound sections with the myofibroblast marker α-SMA. In non-wounded skin, α-SMA 
staining was already evident in the muscles of the vascular wall and the arrector pili muscles 
of the hair follicles (Figure 4.6A). Following injury, myofibroblasts were present both in non-
splinted as well as splinted wounds. However, quantification of arbitrarily scored α-SMA-
positive myofibroblasts showed significantly increased levels in splinted wounds when 
compared to non-splinted wounds (Figure 4.6B). 
 Next, we measured mRNA expression levels of genes involved in remodeling and 
fibrosis (Figure 4.6C). Vascular endothelial growth factor (VEGF) is an important regulator 
of angiogenesis, and was 2.9 times higher in splinted wounds compared to non-splinted 
wounds. Also matrix metalloproteinase (MMP)-9, an important enzyme that helps remodel 
the provisional ECM following wounding, was increased (4-fold). 
 Surprisingly, collagen type 3 gene expression, which is produced by 
(myo)fibroblasts, and forms the major collagen type expressed in granulation tissue, was 
almost 3 times lower in splinted wounds compared to non-splinted wounds (p=0.0544). 
 Interestingly, we found significantly more (5.8-fold) gene expression of 
keratinocyte marker krt-6 in non-splinted wounds compared to splinted wounds.  
 Thus, there were more myofibroblasts and higher expression of VEGF and MMP-9 
in day-7 wounds following mechanical stress. 
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Figure 4.6: Effects of splinting on markers of fibrosis 
(A) Immunohistological staining of α-SMA-positive myofibroblasts in control skin and non-splinted and splinted 7-
day wounds (bars = 1 mm). Note: black triangle ( ) in the non-wounded control skin shows α-SMA-positive 
muscles in the vascular wall and the arrector pili muscles of the hair follicles. Black arrow (→) shows α-SMA-
positive myofibroblasts. (B) Quantification of scored α-SMA protein staining of wounds after 7 days in arbitrary 
units (AU). Data represent mean±SD. * is significantly different between non-splinted and splinted wounds 
(**p<0.01). (C) mRNA expression levels of VEGF, MMP-9, collagen type 3, and krt-6 in 7-day non-splinted and 
splinted wounds normalized to levels in control unwounded skin. Data represent mean±SD. * is significantly 
different between non-splinted and splinted wounds (*p<0.05). 
 
Discussion 
We found that splinting effectively delayed wound closure. Interestingly, HO-1 promoter 
activity initially decreased upon wounding, but was followed by induction of HO-1 mRNA 
and protein. However, HO-1 protein expression was delayed in the splinted wounds. Since 
HO activity attenuates inflammatory and oxidative stress and is thought to reduce fibrosis, 
we postulated that the splinting-mediated delay in HO-1 protein expression could result in 
a reduced defense against inflammatory and fibrotic processes. Indeed, more F4/80-
positive macrophages, α-SMA-positive myofibroblasts, and pro-inflammatory cytokines 
were present in splinted wounds at day 7 when compared to non-splinted wounds. 
Normally, the wound healing cascade is characterized by three distinct phases: 
inflammation, proliferation and remodeling (9, 38, 39). This suggests that mechanical stress 
causes delayed wound closure, a prolongation of the inflammatory phase, and an altered 
remodeling phase, and may promote fibrosis.  
 
Mechanical stress and HO-1  
We found that mechanical stress by splinting delays wound closure 3.3 times in comparison 
to non-splinted wounds after 7 days. This was likely largely mediated by inhibiting the 
contraction of the subcutaneous muscle layer in mice; however, it may also be caused by 
interfering with other processes involved in wound healing, such as inflammation, 
proliferation or remodeling.  
 Previously, it was shown that in vitro administration of mechanical stress with a 
Flex-cell strain unit induces HO-1 mRNA and protein expression in periodontal ligament cells 
in a time- and force-dependent manner (30). HO-1 mRNA levels are also upregulated in vitro 
after mechanical stress in human aortic endothelial cells (40) and human dental pulp cells 
(41). Aortic smooth muscle cells also respond to mechanical stress, and induce HO-1 
expression in a time-dependent response to laminar shear stress (32). In an in vivo model 
with inflammatory, oxidative and mechanical stress, HO-1 mRNA was induced after 6 and 
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12h as a result of unilateral urethral obstruction (31). We therefore postulated that splinting 
would induce HO-1 as a protective response.  
We have shown that within the first hour of wounding, HO-1 promoter activity at 
the place of the wound decreases. This may be related to the removal of the HO-1-positive 
skin layer. This suggests that there is basal HO-1 promoter activity present in normal skin, 
which we previously validated in the epithelium of the skin (6). More precisely, 
keratinocytes in the hyperproliferative epithelium express high levels of HO-1 as normal 
physiology (25, 26). After the initial decrease in HO-1 promoter activity in both groups, HO-
1 promoter activity significantly increased within one day, which may be due to the 
attraction of HO-1-positive macrophages during the inflammatory phase, and the influx of 
HO-1-positive epithelial cells during the re-epithelialization of the wounds (22, 26, 42). This 
rapid HO-1 induction is in line with a previous study in mouse excisional wounds, showing 
increased HO-1 mRNA and protein at day 1 after wounding (24). Additionally, the 
constitutively-expressed HO-2 was also not affected by wounding in this previous study, 
which was similar to our current results. We found that effects on HO-1 promoter activity 
were independent of the wound model, since both splinted and non-splinted wounds 
showed similar activity. However, at day 3, there was only a significant increase in the 
splinted model compared to the baseline level. Increased HO-1 expression was also found 
for both models in 7-day wounds at the mRNA level when compared to non-wounded skin. 
This increase was significantly higher after mechanical stress.  
On the protein level, we saw contradictory results with significantly more HO-1 
protein staining in the epidermis of non-splinted wounds and a slight, non-statistically 
significant, increase of HO-1 protein in the dermis in splinted wounds after 7 days. Thus, 
although HO-1 induction was shown in diverse models of mechanical stress, we found only 
HO-1 promoter activation and HO-1 mRNA induction. HO-1 protein expression was, in fact, 
reduced by the static mechanical stress of the splint in the epidermal region.  
When comparing protein levels in the epidermis, HO-1-positive cells were 
clustered in re-epithelialized tissue underneath the wound crust and were likely newly-
formed keratinocytes (25, 26). It is likely that the highly increased keratinocyte gene 
expression in non-splinted wounds account for the observed increase in HO-1 protein 
expression. 
In the dermis, HO-1-positive cells in inflamed tissues were individually spread, and 
based on their location and morphology, appeared to be macrophages (25, 42). We and 
others demonstrated previously that HO-1-positive macrophages can be recruited during 
the wound repair process (6, 25, 26).   
It is, however, striking that splinted wounds exhibited similar levels of HO-1-
positive cells in the dermis when compared to non-splinted wounds, while there were 
higher levels of F4/80-positive macrophages in splinted wounds.  
 
Mechanical stress by splinting enhances inflammation; the role of HO-1 
Macrophages promote strong inflammatory responses through secretion of cytokines, such 
as IL-1β and TNF-α (43). It is thought that during the wound repair process, first pro-
inflammatory M1 macrophages enter the wound site to clear cellular debris and destroy 
invading pathogens. Besides pro-inflammatory M1 macrophages, there are other 
macrophage subsets, including the anti-inflammatory M2 macrophages and the Mhem, 
Mox, and M4 macrophages (44-46). To enter the proliferation phase, resolution of 
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inflammation is necessary. Under the right conditions, M1 macrophages may therefore 
skew into other anti-inflammatory macrophage subsets (45, 46). The presence of large 
numbers of macrophages in the splinted wounds and the increased levels of pro-
inflammatory mediators IL-1β, TNF-α and COX-2 suggests that in the splinted wounds there 
were mainly M1 macrophages present. Prolonged inflammation and high levels of oxidative 
stress may result in excessive deposition of ECM, leading to fibrosis and excessive/ 
hypertrophic scarring (18, 47). Cytokines that mediate inflammation, such as IL-1β and TNF-
α, are well known to be involved in mechanical stretch-induced inflammation. For example, 
in vitro administration of mechanical stress induces both IL-1β and COX-2 in fibroblast-like 
synoviocyte cells (48), epithelial cells (49), chondrocytes (50), and cardiac muscle cells (51) 
in a time- and force-dependent manner. This increased expression of inflammatory markers 
corresponded to our findings. Moreover, we found a trend in MCP-1 mRNA induction 
(p=0.10) after mechanical stress, matching the enhanced protein staining for macrophages 
after mechanical stress. 
HO-1-positive macrophages are thought to protect the wound environment 
against oxidative stress (25, 52). Following injury, the HO substrate heme is abundantly 
released at the edges of the wound site and can stimulate recruitment of leukocytes (6, 25, 
53). In contrast, HO activity inhibits leukocyte recruitment via down-regulation of vascular 
adhesion molecules (6). Moreover, HO-1 activity inhibits production of various pro-
inflammatory cytokines, including IL-1β and TNF-α (54, 55). In 7-day wounds, the 
inflammation levels were high in both non-splinted and splinted wounds, but however were 
much higher after mechanical stress in the splinted wounds.  
The expression of HO-1 may facilitate resolution of inflammatory and oxidative 
stress at the wound site. When mechanical stress delays HO-1 protein expression, this may 
also delay resolution of inflammation, and lead to fibrogenesis. 
 
Mechanical stress results in more fibrosis by a prolonged survival of myofibroblasts; the 
relation between inflammation, remodeling and HO-1 
Mechanical stress, which is present in CL/P patients following palatal surgery and in patients 
with wounds in the vicinity of joints, increases the risk of excessive scar formation. In our 
splinting model, we demonstrated the increased presence of pro-inflammatory and pro-
fibrotic cells and markers, suggesting that mechanical stress interferes with resolution of 
inflammation, which may ultimately lead to hampered wound repair and excessive scar 
formation. Application of mechanical loading to healing wounds in mice can cause 
hypertrophic scarring, through decreased apoptosis of myofibroblasts (56). It is tempting to 
speculate that the delayed HO-1 protein expression in the splinted model contributes to the 
delay in resolution of inflammation and allows the pro-inflammatory environment and the 
myofibroblast survival that we observed in the wound area at day 7. 
When myofibroblasts fail to go into apoptosis, this leads to continuation of 
contraction and production of ECM, and ultimately to fibrosis (5, 13, 17, 18). We found an 
increased presence of myofibroblasts after splinting, suggesting that either more 
myofibroblasts are formed upon mechanical stress, less myofibroblasts die, or splinting 
causes a delay in the myofibroblast formation when compared to non-splinted wounds. This 
corresponds to other reports, which showed that mechanical tension induces myofibroblast 
differentiation in wound granulation tissue in 6-day splinted wounds compared to non-
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splinted wounds (14, 20). These processes may be fine-tuned by HO-1 and its effector 
molecules as is shown in vitro by regulating the apoptosis of fibroblasts (18, 57). 
Pathological cutaneous wound healing resulting in excessive scarring and fibrosis 
is the consequence of an imbalance between ECM synthesis by myofibroblasts and 
degradation and remodeling by MMPs (13). We found that remodeling marker MMP-9 was 
increased after mechanical stress, which was also observed by other groups (58-60). VEGF 
is an important promoter of angiogenesis and therefore microvessel density might be 
increased by mechanical tension. Chemokine and cytokine processing by MMPs affects the 
progression of inflammatory responses and leukocyte migration (61). For example, MMP-9 
can inactivate/ degrade CXCL1, CXCL4, CXCL9, and CXCL10, resulting in anti-inflammatory 
effects (62, 63). Increased MMP-9 may be indicative of inflammation and poor wound 
healing (64). The interplay between VEGF and HO-1 is complex and it was demonstrated 
that they can both inhibit or induce each other (65-68). Induction of HO-1 in a rat excisional 
wound model enhanced wound healing by increased cellular proliferation and collagen 
synthesis (28). HO-1 induction also reduced the inflammatory response by inhibition of pro-
inflammatory molecules TNF-α, and ICAM-1 and an induction of the anti-inflammatory 
cytokine IL-10 (28). 
 In summary, mechanical stress leads to delayed wound closure, increased 
inflammation, and altered remodeling during the wound healing process. Since more 
myofibroblasts are present after splinting, mechanical stress may result in more scar 
formation. This was associated with a delayed anti-inflammatory and anti-fibrotic HO-1 
protein expression in splinted wounds compared to non-splinted wounds. Since HO-1 
attacks multiple targets that play an important role during fibrogenesis, pharmacologic 
induction of HO-1 may facilitate resolution of inflammation and attenuate fibrosis.  
 
Conclusion 
We demonstrated that splinting significantly delays wound closure and potentiates the 
influx of pro-inflammatory leukocytes and myofibroblasts in day-7 wounds, which may 
promote fibrosis. The cytoprotective HO-1 gene is increased upon wounding, but HO-1 
protein was lower in the epidermis after mechanical stress, probably as a result of the 
increased number of HO-1-positive keratinocytes in the re-epithelialization tissue of non-
splinted wounds. Therefore, targeted pharmacologic induction of cytoprotective 
mechanisms, including HO-1, as preventive therapy against mechanical stress-induced 
inflammation and fibrosis must be considered. 
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Chapter 5 
 
Curcumin-induced heme oxygenase-1 expression 
prevents H2O2-induced cell death in wild type and heme 
oxygenase-2 knockout adipose-derived mesenchymal 
stem cells.  
 
Cremers NA, Lundvig DM, van Dalen SC, Schelbergen RF, van Lent PL, Szarek WA, 
Regan RF, Carels CE, Wagener FA. 
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Abstract 
Mesenchymal stem cell (MSC) administration is a promising adjuvant therapy to treat tissue 
injury. However, MSC survival after administration is often hampered by oxidative stress at 
the site of injury. Heme oxygenase (HO) generates the cytoprotective effector molecules 
biliverdin/bilirubin, carbon monoxide (CO) and iron/ferritin by breaking down heme. Since 
HO-activity mediates anti-apoptotic, anti-inflammatory, and anti-oxidative effects, we 
hypothesized that modulation of the HO-system affects MSC survival. Adipose-derived 
MSCs (ASCs) from wild-type (WT) and HO-2 knockout (KO) mice were isolated and 
characterized with respect to ASC marker expression. In order to analyze potential 
modulatory effects of the HO-system on ASC survival, WT and HO-2 KO ASCs were pre-
treated with HO-activity modulators, or downstream effector molecules biliverdin, bilirubin, 
and CO before co-exposure of ASCs to a toxic dose of H2O2. Surprisingly, sensitivity to H2O2-
mediated cell death was similar in WT and HO-2 KO ASCs. However, pre-induction of HO-1 
expression using curcumin increased ASC survival after H2O2 exposure in both WT and HO-
2 KO ASCs. Simultaneous inhibition of HO-activity resulted in loss of curcumin-mediated 
protection. Co-treatment with glutathione precursor N-Acetylcysteine promoted ASC 
survival. However, co-incubation with HO-effector molecules bilirubin and biliverdin did not 
rescue from H2O2-mediated cell death, whereas co-exposure to CO-releasing molecules-2 
(CORM-2) significantly increased cell survival, independently from HO-2 expression. 
Summarizing, our results show that curcumin protects via an HO-1 dependent mechanism 
against H2O2-mediated apoptosis, and likely through the generation of CO. HO-1 pre-
induction or administration of CORMs may thus form an attractive strategy to improve MSC 
therapy. 
 
Keywords: adipose-derived mesenchymal stem cells, oxidative stress, apoptosis, heme 
oxygenase, carbon monoxide. 
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Abbreviations 
ASC Adipose-derived MSCs 
BM Bone marrow 
BR Bilirubin 
BV Biliverdin 
CO Carbon monoxide 
CORM-2 CO Releasing molecule-2 
GPX Glutathione peroxidase 
GSH Glutathione  
H2O2 Hydrogen peroxide  
HO Heme oxygenase 
IL Interleukin 
iPSC Induced pluripotent stem cells 
KO Knockout 
MAPK Mitogen-activated protein kinase 
MSC Mesenchymal stem cell 
MEF Murine embryonic fibroblasts 
NAC N-acetyl-L-cysteine 
nrf2 Nuclear factor-erythroid 2-related factor 2 
PI Propidium iodide 
qPCR Quantitative Reverse-Transcriptase PCR 
SDF-1 Stromal cell-derived factor-1 
WT Wild-type 
  
116 
Introduction 
Administration of mesenchymal stem cells (MSCs) forms a promising novel adjuvant 
treatment to improve tissue repair (1-4). MSCs have been shown to accelerate dermal 
wound healing and can regenerate diverse injured organs, such as kidney, lung and heart 
(5-9). MSCs are a heterogeneous population of fibroblast-like, multipotent stem cells 
characterized by their ability to differentiate into mature cells of the mesodermal lineage, 
like osteoblasts, chondrocytes, adipocytes, endothelial cells, and myocytes, and into cells 
outside the mesodermal lineage, such as keratinocytes, and fibroblasts (3, 10-12). Adipose 
tissue forms an easy accessible source for isolating MSCs for the use in (autologous) 
regenerative medicine and may therefore be a better alternative than MSCs isolated from 
other sources, such as bone marrow (BM) (13-16). These adipose-derived MSCs (ASCs) are 
abundantly present in adipose tissue, easy to isolate, and highly proliferative. In addition, 
they secrete extensively regenerative factors, such as hepatocyte growth factor, vascular 
endothelial growth factor, basic fibroblast growth factor, interleukin (IL)-6, -7, -8, and -11, 
and stromal cell-derived factor-1 (SDF-1) (14-16).  
Despite the promising utilization of MSCs in regenerative medicine, the low 
survival after administration and the limited migration of MSCs to the site of injury limits 
their therapeutic efficacy (17, 18). Local administration to the site of injury may attenuate 
the problems with MSC migration. However, MSC administration in vicinity to the injured 
tissue may also affect MSC survival, as the wound microenvironment harbors excessive 
levels of inflammatory and oxidative mediators, hypoxia, and limited blood flow (19). 
Oxidative and inflammatory stresses are known causes of MSC death (17, 18, 20). Cells have 
several mechanisms to protect themselves against inflammatory and oxidative insults, 
including cytoprotective enzyme systems (e.g., glutathione S-transferase, dismutases, 
catalases, and peroxidases) or anti-oxidants (vitamin A, C, and E, urate, glutathione, and 
bilirubin) (21). In addition, MSCs may upregulate anti-apoptotic and anti-oxidative genes 
(16, 19). Pre-induction of cytoprotective pathways in the ASCs may improve their 
therapeutic potential by protecting them against the harsh microenvironment (22, 23).  
The cytoprotective enzyme heme oxygenase (HO) is important for (stem) cell 
survival and functioning (17, 18, 24, 25). HO breaks down heme into biliverdin, free iron 
(Fe2+) and carbon monoxide (CO). Biliverdin (BV) is rapidly converted into bilirubin (BR) by 
biliverdin reductase (26, 27). The iron scavenger ferritin is co-induced by HO-derived iron 
and is important for protection against iron-mediated reactive oxygen species (ROS) 
formation (28). Two distinct isoforms (HO-1 and HO-2) exist. HO-2 is mainly constitutively 
expressed whereas HO-1 is highly inducible by a variety of patho-physiological stimuli, such 
as free heme, cytokines, hypoxia, and oxidative stress (29). HO-2 is responsible for 
maintaining normal metabolic cellular functions, and regulating physiological levels of ROS 
(30-32).  
Induction of HO-1 has been demonstrated to improve MSC therapy in vivo by 
improving tissue functioning of the damaged organ, whereas inhibition of HO-activity 
worsened MSC therapy outcome in diverse pathologic conditions, such as ischemia-
reperfusion injury of the heart, pulmonary arterial hypertension, diabetes, and dermal 
wound healing (31, 33-40). It has been shown in vitro that HO-1 overexpression increases 
BM-derived MSC survival against oxidative stress, but the exact mechanism remains 
unknown (17, 34). By contrast, induced pluripotent stem cells (iPSCs) and murine embryonic 
fibroblasts (MEFs) derived from HO-1 knockout mice accumulate higher levels of 
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intracellular ROS after exposure to oxidative stress (41, 42). Moreover, HO-1 KO iPSCs and 
MEFs are more sensitive to hydrogen peroxide (H2O2)-induced cell death (41, 42). Since, the 
effects of HO-1 are extensively studied in stem cells, we investigate here the role of the HO-
2 isoform in protection against oxidative stress. HO-2 has been shown to act protective 
against inflammatory and oxidative injury and cell apoptosis in diverse cell types (43-51).  
In the present study we postulated that HO-2 WT ASCs would be better protected 
against oxidative stress when compared to HO-2 deficient ASCs. Additionally, we aimed to 
investigate the role of HO-activity and HO-effector molecules BR/BV and CO on ASC survival 
after H2O2-induced oxidative stress.  
 
Experimental Section  
Reagents 
Biliverdin and bilirubin were purchased from Frontier Scientific, Carnforth, UK. Curcumin, 
N-acetyl-L-cysteine (NAC), tricarbonyldichlororuthenium(II)dimer (CO releasing molecule: 
CORM-2), and Ruthenium(III)chloride (CORM-2 control) were purchased from Sigma-
Aldrich, Zwijndrecht, the Netherlands. Biliverdin, and bilirubin were prepared by dissolving 
this together with Trizma base in 2 mL 0.1M NaOH and 5 mL H2O. The pH was adjusted to 
pH 8 with HCl, and further diluted till 10 mL with H2O. An end concentration of 1 µM was 
used in the experiments (52). Curcumin was dissolved in 99.5% ethanol at a concentration 
of 2 mM. The stock solutions were filter-sterilized (0.2 μm filter), protected from light and 
directly used at a final concentration of 5- 15 µM. NAC was dissolved in PBS and used at a 
final concentration of 6 mM (52). CORM-2, and CORM-2 control were both dissolved in 
DMSO, and diluted 1000x in work solution to 50 μM. QC15 was produced by Dr. Szarek; 
Department of Chemistry, Queen’s University, Kingston, Ontario, Canada (53, 54), and used 
at an end concentration of 50 µM. Hydrogen peroxide (H2O2) (30%) was purchased from 
Merck, Hohenbrunn, Germany. 
 
Mice 
The Committee for Animal Experiments of the Radboud University Nijmegen approved all 
procedures involving animals. Mice (HO-2 KO and WT with a mixed C57BL/6_129/Sv 
background (55)) of 6-12 weeks in age were housed under standard specific pathogen-free 
housing conditions.  
 
Isolation and culture of ASCs 
Adipose-derived mesenchymal stem cells (ASCs) were routinely isolated from WT and HO-
2 KO mice as described previously (56). In brief, adipose tissue surrounding the mouse 
inguinal lymph nodes were isolated and cut up using scalpels, followed by 30 min of 
incubation at 37 °C with digestion buffer [30 wt/v%, fat/digestion buffer]. Digestion buffer 
consisted of complete ASC culture media: DMEM/F12 (Gibco, New York, USA) 
supplemented with 2 % Penicillin/Streptomycin (Pen/Strep) (Invitrogen, Carlsbad, CA, USA), 
0.5% Amphotericin B (Invitrogen, Carlsbad, CA, USA), 16 μM Biotin (Sigma Aldrich, St. Louis, 
USA), 18 μM Panthotenic Acid (Sigma Aldrich, St. Louis, USA), 100 μM Ascorbic Acid (Sigma 
Aldrich, St. Louis, USA), and 10% Newborn Calf Serum (Sigma Aldrich, St Louis, USA, ref. 
N4762), with additionally 2 mg/ml collagenase A (Roche, ref. 10103586001) and 2 wt/v % 
Bovine Serum Albumin (Sigma Aldrich). Digested adipose tissue was filtered over a 25 μm 
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filter and the filtrate was centrifuged 10 min at 500g. Pellet was resuspended in 1 mL culture 
media and red blood cells were lysed with 7 mL ammonium chloride solution (Stem Cell 
technologies, ref. 07850). Next, the cells were counted (Beckman coulter Z2: >4 μm <25 μm) 
and seeded at a concentration of 8.000 cells/cm2 in complete culture media.  
Genotypes were confirmed using qPCR showing that HO-2 KO ASCs were in contrast to WT 
ASCs, negative for HO-2 mRNA expression (data not shown). In order to phenotypically 
analyze the ASC population we further used a panel of specific ASC markers and exclusion 
markers expressed on macrophages, endothelial cells, and hematopoietic cells to exclude 
non-ASCs. Cells (passage 3) isolated from WT and HO-2 KO mice were tested for six different 
stem cell markers using flow cytometry. The adipose-derived cells were stained with the 
MSC markers Sca-1, CD44 and CD105 (BD Bioscience, Breda, the Netherlands; Biolegend, 
San Diego, CA, USA and eBioscience, San Diego, CA, USA, respectively) and exclusion 
markers CD11b, cKit and CD34 (Biolegend, San Diego, CA, USA; BD Bioscience, Breda, the 
Netherlands and eBioscience, San Diego, CA, USA, respectively). In addition, we chose a 
subset of cell markers for Quantitative Reverse-Transcriptase PCR (qPCR), analysis (Table 
5.1). ASCs up to passage number 5 were used for the different experiments. 
Table 5.1. Primer sequences of mouse ASC cell surface markers and cytoprotective enzymes.  
 Sense Antisense 
Cell surface marker 
CD45 5'-GACAGAGTGCAAAGGAGACC-3' 5'-ATCACTGGGTGTAGGTGTTTG-3' 
Sca1 5'-AGCAGTTATTGTGGATTCTC-3' 5'-TAGTACCCAGGATCTCCATAC-3' 
CD105 5'-TTGTACCCACAACAGGTCTC-3' 5'-GGTGGTAAACGTCACCTCAC-3' 
CD29 5'-AAATTGAGATCAGGAGAACCAC-3' 5'-GGTAATCTTCAGCCCTCTTG-3' 
CD11b 5'-CTGGTCACAGCCCTAGCC-3' 5'-TTTGCATTCTCTTGGAAGGTC-3' 
CD31 5'-CTGGTGCTCTATGCAAGC-3' 5'-GCTGTTGATGGTGAAGGAG-3' 
CD34 5'-TGAGTCTGCTGCATCTAAATAAC-3' 5'-CTCATTGGTAGGAACTGATGG-3' 
CD117 5'-GCCAGACAGCCACGTCTC-3' 5'-CTGATTGTGCTGGATGGATG-3' 
CD106 5'-CGTGGACATCTACTCTTTCC-3' 5'-TGTAAACTGGGTAAATGTCTGG-3' 
CD86 5'-GTCAGTGATCGCCAACTTC-3' 5'-TCTTCTTAGGTTTCGGGTGAC-3' 
Housekeeping gene 
Gapdh 5'-GGCAAATTCAACGGCACA-3' 5'-GTTAGTGGGGTCTCGCTCCTG-3' 
Cytoprotective enzymes 
HO-1 5’-CAACATTGAGCTGTTTGAGG-3’ 5’-TGGTCTTTGTGTTCCTCTGTC-3’ 
HO-2 5’-AAGGAAGGGACCAAGGAAG-3’ 5’-AGTGGTGGCCAGCTTAAATAG-3’ 
 
Heme oxygenase protein expression by In-Cell Western  
ASCs were cultured in a 96-well plate, fixated with 4% PFA for 15 minutes, and 
permeabilized with 0.1% Triton X-100 in PBS for 30 minutes. The cells were blocked with 5% 
ELK (Campina skimmed milk powder) in PBS for 90 minutes. First antibody (rabbit-anti-HO-
1 polyclonal antibody; Stressgen Biotechnologies, Victoria, BC, Canada; cat# SPA895: 6,7 μg/ 
mL in 2.5% ELK and mouse-anti-β-actin monoclonal antibody; Sigma-Aldrich, St. Louis, MO, 
US, cat# A5441: 5 μg/ mL in 2.5% ELK) treatment was performed overnight at 4 °C. 
Secondary antibody treatment (goat-anti rabbit Alexa fluor 680; Invitrogen: Molecular 
Probes, Eugene, US, cat# A21109: 2.5 μg/ mL in 2.5% ELK, and goat-anti-mouse InfraRedDye 
800; Rockland, US, cat# 610-132-121: 1.25 μg/ mL in 2.5% ELK) was performed for one hour. 
The plate was measured using the Odyssey Imager with detection in both 700 nm and 800 
nm channels at an intensity of 5 and 7.5, respectively, and was analyzed using Odyssey 
software (LI-COR Biosciences; version 2.1.12). The amount of HO-1 protein expression was 
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quantified in relation to the expression of β-actin protein. Since the Western blot shows 
only one single band following induction with curcumin, the SPA895 antibody specifically 
recognizes HO-1 (see supplemental figure 5.1). Therefore, we used this antibody for 
immuno-fluorescent and In-Cell Western techniques. 
 
A). 
 
B). 
 
Supplemental figure 5.1. HO-1 protein expression was induced with [0-10 µM] curcumin after 24 hour 
treatment in isolated WT and HO-2 KO ASCs. 
(A). WT and HO-2 KO ASCs were treated with curcumin for 24 hours and HO-1 protein expression was analyzed 
using Western blot, and housekeeping protein β-actin was used to correct for the amount of cells. Experiment was 
performed once. (B). Quantification of the HO-1 protein expression of the Western blot, corrected for the amount 
of cells with β-actin and related to untreated control. 
 
Heme oxygenase protein expression by Western blot 
ASCs were cultured in a 6-well plate in the presence of 0, 5, and 10 μM of curcumin for 24 
hours. After treatment, cells were harvested using trypsin-EDTA, pelleted by centrifugation 
and protein was extracted by resuspending the cell pellet for 30 minutes on ice in lysis buffer 
consisting of 1 mM EDTA, 0.5% triton-X-100, 100 μM phenylmethylsulfonyl fluoride (PMSF) 
in ethanol, and 1:100 complete mini protease inhibitor (Roche complete mini: 11 836 153 
001). Cell lysates were centrifuged for 2 minutes at 13000 rpm at 4°C and 7.5 μg total 
protein was separated by SDS/PAGE using a 10% gel. Subsequently, proteins were blotted 
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onto a nitrocellulose membrane using the iBlot system (Invitrogen). The membrane was 
blocked for 30 minutes in 5% ELK in PBS and overnight incubated with first antibodies 
(rabbit-anti-HO-1 polyclonal antibody; Stressgen Biotechnologies, Victoria, BC, Canada; cat# 
SPA895: 1:5000 and mouse-anti-β-actin monoclonal antibody; Sigma-Aldrich, St. Louis, MO, 
US, cat# A5441: 1:100000) in 2.5% ELK containing 0.1% Tween-20. Afterwards, the 
membrane was briefly washed three times with PBS and twice with PBS containing 0.1% 
Tween-20 for 10 minutes. The secondary antibodies (goat-anti rabbit Alexa fluor 680; 
Invitrogen: Molecular Probes, Eugene, US, cat# A21109: 1:10000, and goat-anti-mouse 
InfraRedDye 800; Rockland, US, cat# 610-132-121: 1:10000) dissolved in 2.5% ELK 
containing 0.1% Tween-20 and 0.01% SDS were incubated for 45 minutes at room 
temperature. After thorough washing, the membrane was measured using the Odyssey 
Imager with detection in both 700 nm and 800 nm channels at an intensity of 3.5 and 7.5, 
respectively. The intensity of the bands of the Western blot was analyzed using Odyssey 
software (LI-COR Biosciences; version 2.1.12). The amount of HO-1 protein expression was 
quantified in relation to the expression of β-actin protein. 
 
Heme oxygenase protein expression by immuno-fluorescent staining 
HO-1 protein expression was also evaluated by immuno-fluorescent staining of ASCs treated 
with curcumin on plastic chamberslides (Nunc, Lab-Tek: permanox 8-well chamberslides: 
Thermo scientific, Rochester, NY, US). In the chambers, cells were fixated with 4% PFA for 
15 minutes, permeabilized with 0.5% Triton X-100 in PBS for 20 minutes, and washed with 
0.05% Tween in PBS (PBS-T). Next, the cells were incubated with blocking buffer consisting 
of 2% bovine serum albumin, 2% normal goat serum, 0.1% Triton X-100, 0.05% Tween, and 
100 mM glycin in PBS for 30 minutes. First antibody (Rb-a-HO-1; Stressgen Biotechnologies, 
Victoria, BC, Canada; CAT#SPA895) was diluted 1:600 in blocking buffer without glycine and 
incubated on cells for 60 minutes. After washing with PBS-T, cells were incubated with 
secondary antibody goat-anti-rabbit alexa 594 (Life Technologies, cat# A-11037 diluted 
1:200 in blocking buffer without glycin) for 60 minutes. Next, the cells were washed with 
PBS-T, followed by washing with PBS, and nuclei were stained with DAPI for 10 minutes. 
Finally, cells were washed with PBS, 1:1 PBS:MQ, and MQ and sealed with DABCO. The Zeiss 
Imager Z1 microscope was used to make fluorescent pictures of the cells using Axiovision 
software version 4.8. 
 
mRNA isolation and Quantitative-Reverse-Transcriptase-PCR 
Cells were lysed and homogenized in TRIzol (Invitrogen) and RNA was further extracted with 
the RNeasy mini kit (Qiagen, Venlo, The Netherlands). DNase treatment (Qiagen: RNase-
Free DNase Set) was performed between the first washing steps with RW1 buffer. RNA 
concentration was determined using the nanodrop 2000 spectrophotometer (Thermo 
Scientific). For the reverse transcriptase treatment 1 µg sample RNA together with total RT 
mix (iScript cDNA Synthesis kit from Bio-Rad Laboratories) in a total volume of 20 µL was 
incubated for 5 minutes at 25 °C, 30 minutes at 42 °C and 5 minutes at 85 °C. Hereafter the 
cDNA was diluted 10x and used for Quantitative Reverse-Transcriptase PCR (qPCR), using 
CFX96 Real-Time System (Bio-Rad Laboratories). The reaction was performed in 25 μL 
containing 5 μL cDNA, 0.6 μM primers, 12.5 μL iQ SYBR Green Supermix (Bio-Rad 
Laboratories). After incubation of 3 minutes, amplification was carried out for 40 cycles of 
15 s at 95°C and 30 s at 60°C. The melting temperature of the products was defined to 
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indicate amplification specificity. All values were normalized to the housekeeping gene 
Gapdh. Data of the ASC characterization were presented as 2-ΔCt. HO-1 mRNA expression 
was evaluated after treatment with curcumin for 24 hours and related to untreated control 
(2-ΔΔCt). All used primers are summarized in table 5.1. 
 
Determination of cell viability  
Cells were seeded into a 96 wells plate at 2000 cells/ well and after overnight culturing of 
the cells were pre-treated with HO-activity modulators or HO-system related molecules for 
24 hours, followed by a co-treatment with 350 µM hydrogen peroxide (selected from a 100-
500 µM H2O2 dose range) for 24 hours in 100 μL media. Hereafter, media was removed and 
replaced by media containing 10% AlamarBlue® Cell Viability Reagent (Invitrogen) and 
further incubated at 37°C for three hours. The oxidized form of this Alamar blue (resazurin) 
enters the cytosol where it is converted into the reduced form (resorufin) by mitochondrial 
enzyme activity. The amount of resorufin is directly proportional to the amount of 
proliferating viable cells and was measured fluorescently at 530/ 590 nm using the Universal 
Microplate reader FL600 (Bio-TEK instruments Inc., Winooski, VT, USA). Viability was 
calculated as percent of the difference in reduction of Alamar blue in treated versus non-
treated cells, corrected for background signal of Alamar blue: Viability = (Ex-Eblanc)/ (Ec-
Eblanc)*100; where Ex = extinction treatment, Ec = Extinction untreated control, and 
Eblanc= extinction Alamar blue background.  
 
Detection of Apoptosis by Flowcytometric Analysis 
Flowcytometry was used to study the effects of H2O2 on apoptotic signals, by double 
staining with fluorescein isothiocyanate (FITC) labeled – Annexin V and propidium iodide 
(PI). Untreated and H2O2-treated ASCs were resuspended in binding buffer and stained with 
Annexin V-FITC and PI for 15 minutes at RT in the dark, according to manufacturer’s protocol 
(BioVision Inc, ITK Diagnostics, Uithoorn, the Netherlands). Cells treated with 4% 
paraformaldehyde containing 0.1% saponine and stained with Annexin V and PI were used 
as positive control. Detection of Annexin V-FITC and PI binding was performed by a 
FACSCalibur (Becton Dickinson Biosciences, San Jose, CA, USA) using channels FL-1 (Annexin 
V-FITC) and FL-3 (PI). Viable cells (Annexin V -/ PI-), early apoptotic cells (Annexin V+/ PI-), 
late apoptotic cells (Annexin V+/ PI+), and necrotic cells (Annexin V-/ PI+) were quantified 
as a percentage of the gated population, using FlowJO software (version 7.6.5 for windows, 
Tree Star, Inc.). 
 
Determination of cell amount 
The influence of pre- and co-treatment with HO-modulators and effector molecules on cell 
loss after H2O2-treatment was determined using PicoGreen dsDNA Quantification reagent 
(Molecular Probes Inc, Eugene, OR, USA). The amount of double stranded DNA can be 
quantified using this assay and this correlates to the amount of cells. After measuring the 
Alamar plate, the media was removed and the plate was washed twice with PBS. Cells were 
lysated by adding 0.1% Triton X-100 and frozen (-80°C) and thawed (37°C) for three 
consecutive times. The assay was performed according to the protocol of the manufacturer. 
The fluorescent signal was measured in a FL600 Microplate Fluorescence Reader (Bio-Tek 
Instruments Inc., Winooski, VT, USA) at excitation 485 nm, emission 520 nm. DNA standards 
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ranging from 0 to 2000 ng DNA /mL were used. The total amount of DNA after treatment 
was calculated using the standard curve. 
 
Statistical analysis 
Data were analyzed using GraphPad Prism 5.01 software (San Diego, CA, US). Outliers were 
tested using the Grubbs' test. In Alamar blue experiments, one outlier was detected in a 
control untreated group of WT ASCs in two experiments. In picogreen experiments, one 
outlier was found in a control treated group of WT ASCs and one outlier was found in NAC 
treated group of HO-2 KO ASCs, in single experiments. Data was analyzed by one- or two 
way analysis of variance (ANOVA) with Bonferroni’s multiple comparison post test. One-
way ANOVA was used in survival studies and picogreen studies and two-way ANOVA was 
used in other experiments. Results were considered significant different when p<0.05 
(*p<0.05, **p<0.01, and ***p<0.001).  
 
Results and Discussion 
Isolation and characterization of adipose-derived MSCs (ASCs) 
ASCs were isolated from mouse (WT and HO-2 KO) adipose tissue around the inguinal lymph 
nodes and cultured in defined media as described in the materials and methods section. 
The cells adhered to plastic and had, as expected for ASCs, a fibroblast-like morphology. 
Passage three of the isolated cell populations were characterized for the expression of 
mesenchymal, endothelial, and hematopoietic markers by immunophenotyping (Figure 
5.1A) and qPCR (Figure 5.1B). Surface antigen expression of the isolated cells, using flow 
cytometry, was consistent with literature data and our previous results (56). The cells 
expressed ASC surface markers Sca-1, CD44, and CD105 and were negative for the exclusion 
markers CD117 (hematopoietic stem cells), CD11b (macrophages) (Figure 5.1A), and 
showed low expression of CD34 (endothelial/ hematopoietic progenitor cells)(16, 57-62). 
No significant differences in ASC marker expression was detected between WT and HO-2 
KO ASCs. These phenotypic observations at the protein level were further corroborated at 
the mRNA level using common MSC markers (Figure 5.1B). The isolated cells expressed high 
mRNA levels of ASC markers Sca-1, CD29 (16, 58-60, 62), CD105, and CD106 (16, 58), 
whereas cells were negative for exclusion markers CD11b, CD31 (16, 57-61), CD34, 
hematopoietic marker CD45 (16, 57-62), antigen-presenting cell marker CD86 (62), and 
CD117 showing low levels of mRNA expression, compared to housekeeping gene GAPDH. 
No significant difference in marker expression was found between WT and HO-2 KO ASCs. 
We conclude that the isolated cells are ASCs, since the marker expression profile 
corresponded well with literature data of earlier reported isolated murine ASCs. 
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Figure 5.1. Phenotypic analysis of isolated WT and HO-2 KO ASCs. 
(A). Percentage of positive cells for ASC exclusion markers (negative) and ASC cell surface markers 
(positive) of isolated WT and HO-2 KO ASCs, measured using flow cytometry. (B). mRNA levels of negative 
and positive ASC markers of isolated WT and HO-2 KO ASCs, analyzed by qPCR and presented as 2-ΔCt.  
No significant differences were observed between in the expression of selected markers between WT and 
HO-2 KO ASCs using both flow cytometry and qPCR. Data represent mean ± SD of three independent 
experiments. 
 
H2O2 induces cell death in ASCs in a dose-dependent manner independently from HO-2 
expression 
ASCs were exposed to increasing concentrations of H2O2 (0 - 500 µM) to investigate the 
effect of oxidative stress on ASC survival. H2O2 is a strong oxidant that can cause cell death 
and apoptosis. Compared to other ROS, H2O2 is a relatively long-lived molecule commonly 
used in models of oxidative stress (63). Exposing cells to H2O2 results in deleterious effects 
of hydroxyl and peroxyl radicals on membrane lipids and proteins, resulting in loss of 
mitochondrial membrane potential, mitochondrial dysfunction, and eventually apoptosis 
(64, 65).  
ASCs were exposed for 24 hours to increasing concentrations of H2O2 and cell 
viability was assessed using the Alamar blue assay. This assay is based on the ability of 
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metabolically active cells to convert the Alamar blue reagent into a fluorescent signal, which 
is directly proportional to the cellular viability. Damaged and non-viable cells have lower 
innate metabolic activity, and generate thus a proportionally lower signal. 
ASC viability decreased gradually after exposure to increasing concentrations of 
200-500 µM H2O2 for 24 hours (Figure 5.2A). Exposure to doses of 250 µM H2O2 and higher 
had a significant cytotoxic effect for both WT and HO-2 KO ASCs compared to controls (all 
p<0.001). No ASCs survived at concentrations of 450 µM H2O2 and higher. In parallel, the 
amount of cells after 24 hours treatment with H2O2 were analyzed using the picogreen 
assay. This assay quantifies the amount of double stranded DNA and is directly proportional 
to the amount of cells. These results were similar and corroborated our findings with the 
Alamar blue assay. The amount of cells decreased significantly at H2O2 concentrations of 
250 µM and higher in a dose-dependent fashion for both WT and HO-2 KO ASCs (Figure 
5.2B). After treatment with 350 µM H2O2 24% ± 2.5% of WT and 19.5% ± 4.9% of HO-2 KO 
ASCs survived. At this concentration, we found increased apoptotic signals in WT and HO-2 
KO ASCs as measured by the increased levels of phosphatidylserine flip-flops and membrane 
disruption, using AnnexinV-FITC and propodium iodide (PI) staining (see Supplemental 
figure 5.2). Surprisingly, no significant difference could be observed between WT and HO-2 
KO ASCs in sensitivity towards H2O2-induced cell death at any measured concentration. This 
suggests that HO-2 does not protect against H2O2-induced ASC death. Probably, the HO-2-
activity level in naïve ASCs is too low. Although HO-2 has been demonstrated to protect 
against a wide range of oxidative insults in diverse cells, the role of HO-2 may be cell and 
stressor dependent (43, 44, 46, 49). HO-2 can either protect or augment apoptosis (45, 50). 
In this setting, ASCs were not dependent on HO-2 for their protection against H2O2-induced 
cell death.  
Based on the above data, 350 µM H2O2 was chosen as cytotoxic dose since it offers 
an analytical window to assess whether the HO-system could mediate protection against 
oxidative stress-induced cell death in ASCs.  
 
A). 
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B).  
 
Figure 5.2. Survival and cell amount of isolated WT and HO-2 KO ASCs after exposure to increasing doses of H2O2 
[0-500 µM] for 24 hours.  
(A) WT and HO-2 KO ASC survival and (B) amount of ASCs after H2O2-treatment were analyzed using the Alamar 
blue assay and picogreen assay, respectively. 
Doses of 250 µM H2O2 and higher resulted in a significant decreased survival and, subsequently, lower cell amounts 
(all p<0.001) compared to untreated control. No significant differences were observed between WT and HO-2 KO 
ASCs at any concentration. A dose of 350 µM H2O2 was chosen in further experiments to induce ASC death. 
Data represent mean ± SD of three independent experiments with four samples per condition.  
 
 
Supplemental figure 5.2. Apoptosis of WT and HO-2 KO ASCs after treatment with 350 µM H2O2 or control for 24 
hours using AnnexinV-FITC (FL-1) and PI (FL-3) labeling. It was found that both WT and HO-2 KO ASCs showed 
similar induction of apoptosis following H2O2 treatment. 
 
Can curcumin induce HO-1 expression in ASCs? 
Next, we studied if we could induce the expression of HO-1 in ASCs to provide protection 
against oxidative damage. Therefore, ASCs were treated with increasing curcumin 
concentrations for 24 hours and HO-1 gene transcription was subsequently assessed by 
qPCR (Figure 5.3A).  
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C).  
 
D).  
  
Figure 5.3. HO-1 mRNA and protein expression was induced with increasing doses of curcumin [0 - 25 µM] for 
24 hours in isolated WT and HO-2 KO ASCs.  
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(A). WT and HO-2 KO ASCs were treated with curcumin for 24 hours and HO-1 mRNA expression was evaluated 
with QPCR, corrected for the housekeeping gene GAPDH and normalized to untreated control. HO-1 mRNA 
expression was significantly (p<0.05) induced at every concentration in comparison to untreated control. Data 
represent mean ± SD of three independent experiments. No significant differences between WT and HO-2 KO ASCs 
were found. (B). WT and HO-2 KO ASCs were treated with curcumin for 24 hours and HO-1 protein expression was 
evaluated with In-Cell Western (green: β-actin, and red: HO-1). (C). Quantification of the In-Cell Western signal, 
corrected for the amount of cells with β-actin and related to untreated control. HO-1 protein expression was 
significantly (p<0.05) induced at every concentration in comparison to untreated control. Data represent mean ± 
SD of three independent experiments. Four samples were analyzed per condition. No significant differences 
between WT and HO-2 KO ASCs were found. (D). WT and HO-2 KO ASCs were untreated or treated with 10 µM 
curcumin for 24 hours and HO-1 protein expression was evaluated using immuno-fluorescent staining of 
chamberslides (green is HO-1, blue is nuclear staining with DAPI). Representative of three independent 
experiments.  
 
Exposure to curcumin for 24 hours induced HO-1 mRNA levels dose-dependently 
in WT and HO-2 KO ASCs compared to untreated control. No significant differences in HO-1 
induction were found between the two genotypes. 
Next, the HO-1 protein expression after treatment with different concentrations of 
curcumin was assessed using In-Cell Western (Figure 5.3B). HO-1 protein expression was 
quantified in relation to β-actin protein expression (Figure 5.3C). We observed that HO-1 
protein expression was significantly and dose-dependently induced after 24 hours 
treatment with increasing doses of curcumin compared to untreated control in both WT 
and HO-2 KO ASCs. HO-1 protein expression after induction with curcumin was not 
significantly different between WT and HO-2 KO ASCs at any of the used concentrations. 
Furthermore, a plateau in expression was reached as we did not detect any difference in 
HO-1 expression levels at concentrations of 10 and 15 µM. For our next experiments we 
used 10 µM curcumin, since high concentrations of curcumin (25 µM) may cause cell death 
in vitro (54). Treatment with 10 µM curcumin did not result in cytotoxic effects and induced 
HO-1 mRNA expression 20-fold and HO-1 protein levels roughly 7-fold compared to 
untreated cells. 
The HO-1 protein induction in WT and HO-2 KO ASCs was also measured using 
immuno-fluorescent staining (Figure 5.3D). In accordance with the mRNA and In-Cell 
Western expression data we demonstrated that HO-1 protein expression was highly 
upregulated in ASCs from both genotypes after treatment with 10 µM curcumin in 
comparison with untreated control.  
There were no significant differences observed in HO-1 induction at either mRNA 
or protein level between WT and HO-2 KO ASCs after treatment with 10 µM curcumin. We 
demonstrated that curcumin acts as a potent inducer of HO-1 in both WT and HO-2 KO ASCs 
after treatment for 24 hours.  
 
HO-1 inducer curcumin protects against H2O2-mediated ASC death in a HO-2 independent 
manner 
Pre-conditioning of MSCs with cytoprotective factors can improve MSC survival against 
several injurious stressors in vitro, such as serum-free conditions, hypoxia and oxidative 
stress (14, 66). It has been shown that pre-conditioning of MSCs with melatonin (65), NO-
donor SNAP (67), or overexpression of transcription factor nuclear factor-erythroid 2-
related factor 2 (nrf2) (18) can prevent MSC death caused by H2O2. Interestingly, these 
preconditioning factors are also potent inducers of HO-1 (68-70). Since HO-1 can protect 
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against oxidative stress in diverse models (17, 34), we investigated if HO-1 induction can 
also protect against oxidative stress-induced ASC death. Since HO-1 transfection is difficult 
to introduce safely into the clinic, we investigated the use of the safe pharmaceutical HO-1 
inducer curcumin. Curcumin is a natural product that is already used in daily life as a spice 
in the Indian kitchen (71, 72), acts as an anti-oxidant (73), and provides protection against 
a wide variety of diseases and conditions (74-76). Moreover, a protective role for 
polyphenols, including curcumin, on BM-derived MSC survival against oxidative stress was 
recently demonstrated (21). However, any relation to the HO-system was not investigated, 
and the survival was thought to relate to the induction of ROS-reducing enzymes glutathione 
peroxidase (GPX) and catalase (21).  
In order to investigate the role of curcumin on H2O2-induced cell death in more 
detail, ASCs were pre-treated for 24 hours with 10 µM of curcumin followed by co-
treatment with 350 µM H2O2 for 24 hours after which the cell viability was assessed using 
the Alamar blue assay. Pre-conditioning with curcumin significantly improved ASC survival 
during oxidative stress (Figure 5.4). Pre-treatment with 10 µM curcumin increased ASC 
survival 2.7 and 3.6 fold in WT (Figure 5.4A) and HO-2 KO ASCs (Figure 5.4B), respectively, 
compared to cells exposed to solely 350 µM H2O2. This is further supported by picogreen 
data that showed significant more WT and HO-2 KO ASCs when pre-treated with curcumin 
(Figure 5.5). Vehicle control ethanol did not increase ASC survival and cell amount compared 
to H2O2-treated control cells. Since we found that curcumin acts as a strong inducer of HO-
1 this suggests a possible role for HO-1 in ASC survival from oxidative stress. 
 
A).      B). 
   
Figure 5.4. Curcumin treatment rescues WT and HO-2 KO ASCs against H2O2-induced cell death.  
(A) WT ASC and (B) HO-2 KO ASC survival after 24 hour pre-treatment with curcumin, vehicle control, or untreated 
(control) and 24 hour co-treatment together with 350 µM H2O2 following an Alamar blue assay and fluorimetric 
quantification, related to untreated control.  
Vehicle consisted of 0.5% ethanol (curcumin solvent) in culture media. * is significant different from H2O2-treated 
control. (*p<0.05, ***p<0.001). Data represent a representative of three independent experiments and present 
mean ± SD. For each condition six samples were analyzed. 
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A).       B). 
   
Figure 5.5. Cell amount of WT and HO-2 KO ASCs after treatment with HO-system related molecules and H2O2-
induced cell death. 
(A) WT ASC and (B) HO-2 KO ASC after 24 hour pre-treatment with several substances, and 24 hour co-treatment 
together with 350 µM H2O2 following a picogreen assay and fluorimetric quantification, related to untreated 
control.  
DMSO control represents the vehicle for CORM-2 and CORM-2 control and consisted of 0.1% DMSO in culture 
media. Ethanol control is the vehicle for curcumin and consisted of 0.5% ethanol in culture media. * is significant 
different from treated control (**p<0.01, and ***p<0.001). Experiments are performed in triplicate with samples 
in sextet. Representative graph is shown. Data are presented as mean ± SD.  
NAC: N-acetylcysteine; CORM-2: CO-releasing molecule-2; BR: Bilirubin; BV: Biliverdin. 
 
Interestingly, transient overexpression of the human HO-1 gene in BM-derived 
MSCs has been shown to protect against oxidative stress-induced cell death (17, 34). HO-1 
transfected BM-derived MSCs were more resistant to cell death than non-transfected MSCs 
after exposure to H2O2 (34). Survival at 500 µM H2O2 for two hours was higher after HO-1 
transfection and HO-1 induction could thus protect BM-MSCs to a short exposure of high 
concentrations H2O2. At a lower concentration of H2O2 but longer treatment time with H2O2 
we showed also protection for ASC following curcumin exposure, suggesting that HO-1 
induction plays a role. We further investigated the downstream mechanism of protection 
after pre-conditioning with the clinically more relevant curcumin towards an exposure of 
H2O2 for 24 hours. 
In summary, curcumin provides similar protection against H2O2-induced cell death 
both in WT and HO-2 KO ASCs. A possible involvement of HO-activity will be further 
evaluated. 
 
Is rescue from H2O2-induced ASC death by curcumin mediated by HO-activity? 
We have shown that curcumin can prevent from ASC death caused by oxidative stress. Since 
we demonstrated that curcumin induces HO-1 expression in ASCs, we next examined 
whether the protective mechanism of curcumin is HO-dependent using a specific HO-
activity inhibitor. We used the synthetic isozyme-selective non-porphyrin HO-activity 
inhibitor QC-15 to test its effect on ASC survival. QC-15 is an imidazole-dioxolane compound 
that binds to the distal side of the heme-binding place in the HO protein and is a highly 
selective HO-1 activity inhibitor and has less potency to inhibit HO-2 activity (52, 77-79). 
Specifically, we investigated whether HO-1 activity inhibition would reduce ASC 
survival, and in addition, if the protecting effect of curcumin could be attenuated by co-
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treatment with QC-15. ASCs were therefore pre-incubated for 24 hours with HO-activity 
modulators followed by a co-treatment with 350 µM H2O2 for 24 hours, after which the ASC-
survival was assessed using the Alamar blue assay.  
Surprisingly, we found that co-exposure of 50 µM QC15 together with H2O2 did not 
influence cell survival when compared to cells treated with only H2O2 in both WT and HO-2 
KO ASCs (Figure 5.6). This suggests that the basal levels of both HO-1 and HO-2 are not 
sufficient for protection. However, the increased survival of ASCs after 10 µM curcumin 
treatment, and subsequent induced HO-1 expression, against H2O2 was completely 
abrogated (p<0.001) following co-treatment with 50 µM QC15 in both WT as HO-2 KO ASCs. 
These results clearly demonstrate the protective potential of pre-induction of HO-1-activity 
in preventing oxidative stress-induced ASC death. Surprisingly, this is likely independent 
from HO-2, since no differences in survival were found between WT and HO-2 KO ASCs. In 
addition, picogreen data also showed a decline in cell amount after co-treating curcumin 
with QC15 (Figure 5.5). However, this decrease in cell amount was not always significant for 
both WT and HO-2 KO ASCs in replicate experiments. Similar protective effects of HO-
activity from injurious insults have also been demonstrated in other cell lines (80, 81). 
Induction of HO-activity by flavonoid baicalcin and HO-1 transfection protected raw 264.7 
macrophages and vascular smooth muscle cells against H2O2-induced cell death. Also here, 
inhibition of HO-activity attenuated this protection (80, 81). 
Thus, curcumin-induced protection against H2O2-induced ASC death acts via 
induction of HO-1, whereas inhibition of HO-activity abrogates this protective effect. 
 
A).        B). 
      
Figure 5.6. Inhibition of HO-activity abrogated the protective effect of curcumin against H2O2-induced cell death 
in isolated WT and HO-2 KO ASCs. 
(A) WT ASC and (B) HO-2 KO ASC survival after 24 hours pre-treatment with HO-modulators or untreated (control) 
and 24 hours co-treatment together with 350 µM H2O2 as measured by Alamar blue assay and fluorimetric 
quantification, related to untreated control.  
Vehicle consisted of 0.5% ethanol (curcumin solvent) in culture media. * is significant different from treated 
control.  (*p<0.05, and ***p<0.001).  
Data represent a representative of three independent experiments and present mean ± SD. For each condition six 
samples were analyzed.  
 
Do anti-oxidants bilirubin, biliverdin, and NAC rescue from H2O2-induced ASC death? 
Since HO-activity protects against H2O2-mediated cell death, we investigated whether the 
anti-oxidative properties of HO-effector molecules BR and BV, or anti-oxidant N-actyl 
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cysteine (NAC) could mediate a protective effect. It has previously been reported that NAC; 
a precursor of glutathione (GSH) synthesis, and BR and BV can protect cells from ROS-
induced cell death (54, 82, 83). GSH serves as electron donor for glutathione peroxidase to 
catalyze the reduction of H2O2 into H2O, and is together with catalase the only defense 
available to metabolize H2O2 (84, 85). GSH and BR are both prominent endogenous anti-
oxidant molecules, protecting against oxidative stress on a complementary basis and have 
a distinct antioxidant mechanism (86). Therefore, we investigated the possible contribution 
of the different anti-oxidants NAC, BR, and BV on ASC survival. Pre-treatment for 24 hours 
with 10 µM BR, 10 µM BV, and 6 mM NAC and co-exposure for another 24 hours with 350 
µM H2O2 was performed to investigate the effects on ASC survival. This was assessed using 
the Alamar blue assay. Anti-oxidant NAC significantly increased cell survival compared to 
H2O2-treated control in WT and HO-2 KO ASCs 6.3- and 7.1- fold, respectively (Figure 5.7). 
NAC may also influence mitochondrial biogenesis (87), and thus might cause bias in the 
Alamar blue assay, since this assay is a measure of mitochondrial activity. However, NAC 
significantly increased the cell amount compared to H2O2-treated control as confirmed by 
the picogreen assay, suggesting that NAC does not only promote mitochondrial biogenesis 
but also cell survival (Figure 5.5). Since NAC can interfere with several cell viability test 
methods (88), we corroborated that cell-free NAC containing media did not influence the 
Alamar blue signal (data not shown). Increasing GSH formation results in a more reduced 
intracellular environment, and promotes cell proliferation and survival (89). NAC has been 
demonstrated to promote the proliferation of different cell types, including adipose derived 
stem cells and BM stromal cells (90, 91). Surprisingly, the anti-oxidants BR and BV did not 
improve ASC survival in both WT and HO-2 KO ASCs (Fig. 6.5 and 6.7). Treatment with BR 
and BV in the absence of H2O2 did not result in increased cell death, as measured by the 
Alamar blue assay (data not shown). The observed differences between NAC and BR/BV 
may be related to the different targets that these anti-oxidants have (86). GSH is hydrophilic 
and protects mainly water-soluble proteins in the cytosol, while BR and BV are more 
lipophilic and protect against lipid peroxidation of cell membranes (86). The 
microenvironment largely determines which mechanism is needed to sustain redox 
homeostasis (89). H2O2 can easily penetrate the cell membrane, and form hydroxyl radicals 
with intracellular metal ions. Treatment with H2O2 results in cytosolic release of cytochrome 
c as well as activating caspase-9 and caspase-3 and works through the intrinsic/ 
mitochondrial apoptotic pathway in several cell types, including MSCs (92-97). And hence, 
H2O2 scavenging is likely more dependent on GSH, rather than BR and BV.  
Our results show that H2O2-induced cytotoxicity can be prevented by NAC, but not 
BR and BV. This suggests that HO-1-mediated ASC survival following H2O2-treatment is 
independent from HO-effector molecules BR and BV and independent of intrinsic HO-2 
expression. 
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A).        B). 
     
Figure 5.7. Survival of WT and HO-2 KO ASC against H2O2-induced cell death after treatment with anti-oxidants. 
(A) WT ASC and (B) HO-2 KO ASC survival after 24 hour pre-treatment with anti-oxidant NAC or HO-effector 
molecules BR and BV, and 24 hour co-treatment together with 350 µM H2O2 following an Alamar blue assay and 
fluorimetric quantification, related to untreated control. 
* is significant different from treated control. (***p<0.001). Data represent a representative of three independent 
experiments and present mean ± SD. For each condition six samples were analyzed. 
NAC: N-acetylcysteine; BR: Bilirubin; BV: Biliverdin. 
 
Does HO-effector molecule carbon monoxide influence H2O2-induced ASC death? 
Since we have shown that HO-activity is responsible for ASC survival, and is independent 
from the effector molecules BR and BV, we next investigated the effects of the HO-effector 
molecule CO. The HO-effector molecules also provide protection through different 
mechanisms; BR and BV are anti-oxidants, whereas CO is thought to work on regulating 
downstream signaling pathways. Furthermore, CO may produce mitochondrial ROS 
initiating intracellular protective signaling pathways and maintain cells in homeostasis (98-
100).  
In order to determine whether CO could mediate the HO-induced protection 
against H2O2-induced ASC death, we treated the cells with CO releasing molecules-2 (CORM-
2), and found that this resulted in significantly higher ASC survival in WT and HO-2 KO ASCs 
compared to H2O2-exposed ASCs (Figure 5.8). The absence of HO-2 expression in the ASCs 
in our experimental setup did not have any significant influence on its survival against H2O2-
induced cell death. In addition, CORM-2 control and solvent control (DMSO) treated cells 
showed no protection and survival were comparable to cells treated with H2O2. Thus, the 
HO-mediated protection mechanism is likely dependent on the effects of CO-release. This 
was partly confirmed by our picogreen data (Figure 5.5). Here, we found that more cells 
were present after CORM-2 treatment in WT ASCs (p<0.001) exposed to H2O2. However, in 
HO-2 KO ASCs this protective effect of CORM-2 on cell amount was not always significant in 
replicate experiments. A decrease in viability may therefore not always mean a decrease in 
cell amount. In line with our results, Lin et al. also demonstrated that CO, but not BR and 
BV administration inhibited H2O2-induced cytotoxicity in macrophages (80), suggesting that 
CO is responsible for the protective effect caused by HO-1 overexpression in both 
macrophages and ASCs. Furthermore, the ruthenium-based CORM-2 and CORM-2 control 
have been demonstrated to be potent inducers of HO-1, which could have further boosted 
the protective effects of CORM-2 via a positive feedback loop (101, 102). Preliminary 
experiments show indeed induction of HO-1 following exposure to CORM-2 and to a lower 
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extent for CORM-2 control. This positive feedback between HO-1 and CO (and nrf2) has 
previously been demonstrated in hepatocytes (103) and vascular endothelium cells (104).  
The down-stream protective effects of CO can be mediated by several protective 
signaling pathways. Pre-treatment with CORM-2 increases mitochondrial ROS signaling, 
which leads to pre-conditioning of the cells, making them more resistant to secondary 
stresses with H2O2 (105, 106). In addition, CO may activate diverse other downstream 
signaling pathways, including nrf2, guanylate cyclase, p38 mitogen-activated protein kinase 
(MAPK), PI3K-Akt, and iNOS (104, 106, 107). Finally, CO can reduce the production of ROS 
in cells treated with H2O2, probably by preventing the formation of hydroxyl radicals by 
binding to ionized iron (108).  
More research is warranted to unravel the exact mechanism by which CORM-2 exerts its 
protective effects. These results suggest that CO is responsible for the observed HO-
mediated ASC survival from oxidative stress.  
 
A).        B). 
      
Figure 5.8. CORM-2 increases WT and HO-2 KO ASC survival against H2O2-induced cell death. 
(A) WT ASC and (B) HO-2 KO ASC survival after 24 hour pre-treatment with CORM-2, or its controls, and 24 hour 
co-treatment together with 350 µM H2O2 following an Alamar blue assay and fluorimetric quantification, related 
to untreated control.  
Vehicle consisted of 0.1% DMSO (CORM-2 and CORM-2 control solvent) in culture media. * is significant different 
from treated control. (***p<0.001). Experiments are performed in triplicate with samples in sextet. Representative 
graph is shown. Data are presented as mean ± SD. 
CORM-2: CO-releasing molecule-2. 
 
In summary, 
Administrating MSCs forms a promising therapy following pathologic tissue injury. 
However, the poor survival of MSCs following administration limits their therapeutic 
efficacy. In this study, we demonstrated that exposure of adipose-derived MSCs (ASCs) to 
oxidative stress results in ASC death and that induction of the HO-system by curcumin can 
attenuate this. Simultaneous inhibition of HO-activity could abrogate the protective effects 
of curcumin, demonstrating an essential role for HO-1. We found that also NAC improved 
ASC survival, whereas BR or BV did not demonstrate a protective effect, and thus suggest 
differential anti-oxidative protective mechanisms. Since administration of the HO-effector 
molecule CO also attenuated H2O2-induced ASC death, it is likely that CO mediates in part 
the protective effects of HO-1 induction. All these effects were independent from HO-2 
expression, as the results for WT and HO-2 KO ASCs were similar.  
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Clinical Relevance 
Increased levels of ASCs at the site of injury may ameliorate tissue repair by their 
differentiation capacity and the excretion of paracrine factors into the tissue environment 
further promoting wound repair (109-112). The clinical relevance of HO-1 induction in MSCs 
is further supported by in vivo models of tissue injury, improving MSC survival and tissue 
function (33-35, 112-115).  
Our results further emphasize on the important role of HO-1 and CO as target for 
improved ASC survival and therapy in tissue repair. We also show that HO-2 expression is 
less important in mediating protection against oxidative insults in ASCs.  
 
Conclusions  
Survival from H2O2-induced apoptosis was similar for WT and HO-2 KO ASCs, suggesting that 
the HO-2 isoform is not able to provide protection in this specific setting. ASC survival was 
ameliorated following pre-induction of HO-1 using the cytoprotective flavonoid curcumin. 
This protection by curcumin was mediated by HO-1 activity since simultaneous inhibition of 
HO-activity abrogated this curcumin-mediated protection. HO-effector molecules BR/ BV 
did not provide protection, whereas CO protected against H2O2-induced cell death, 
suggesting involvement of CO in HO-1 mediated protection. HO-1 pre-induction by 
curcumin or CO exposure could therefore form a novel promising adjuvant strategy to 
promote stem cell survival during therapy.  
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Abstract 
Skin wounds may lead to scar formation and impaired functionality. Remote ischemic 
preconditioning (RIPC) can induce the anti-inflammatory enzyme heme oxygenase-1 (HO-1) 
and protect against tissue injury. We aim to improve cutaneous wound repair by RIPC 
treatment via induction of HO-1. RIPC was applied to HO-1-luc transgenic mice and HO-1 
promoter activity and mRNA expression in skin and several other organs were determined 
in real-time. In parallel, RIPC was applied directly or 24h prior to excisional wounding in 
mice to investigate the early and late protective effects of RIPC on cutaneous wound repair, 
respectively. HO-1 promoter activity was significantly induced on the dorsal side and locally 
in the kidneys following RIPC treatment. Next, we investigated the origin of this RIPC-
induced HO-1 promoter activity and demonstrated increased mRNA in the ligated muscle, 
heart and kidneys, but not in the skin. RIPC did not change HO-1 mRNA and protein levels 
in the wound 7 days after cutaneous injury. Both early and late RIPC did not accelerate 
wound closure nor affect collagen deposition. RIPC induces HO-1 expression in several 
organs, but not the skin, and did not improve excisional wound repair, suggesting that the 
skin is insensitive to RIPC-mediated protection. 
 
Keywords: remote ischemic preconditioning, heme oxygenase-1, tissue injury, wound 
repair. 
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Abbreviations 
H&E Hematoxylin and eosin 
HO-1 Heme oxygenase-1 
HO-1-luc Tg HO-1-luciferase transgenic 
I/R Ischemia/Reperfusion 
IPC Ischemic preconditioning 
IRI Ischemia/Reperfusion injury 
RIPC Remote ischemic preconditioning 
ROS Reactive oxygen species 
RPCT Remote preconditioning by trauma 
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Introduction 
Severe skin wounds following burns, trauma, or surgery often lead to scar formation 
and impaired functionality (1). Cutaneous wound repair is a dynamic and highly regulated 
process, involving several overlapping phases: inflammation, proliferation, and remodelling 
(2). Aberrant wound repair and scarring occurs following prolongation of the inflammatory 
phase that together with oxidative stress fuels (myo)fibroblast proliferation and interferes 
with myofibroblast apoptosis (2). This leads to excessive deposition of extracellular matrix 
proteins, subsequently promoting excessive scar formation (3, 4). Unfortunately, 
conventional therapies to accelerate wound repair and to prevent scarring are insufficient 
(5-7). Therefore, adjuvant therapies aimed at resolving inflammation are warranted. 
Pharmacological preconditioning has been shown to improve wound repair, as exemplified 
by heme and curcumin that also induce the cytoprotective protein heme oxygenase-1 (HO-
1) (8-14). HO-1 is one of the most important enzymes protecting against oxidative and 
inflammatory insults (15). HO catabolizes heme to biliverdin, free iron, and carbon 
monoxide (CO). Biliverdin is then rapidly converted to the antioxidant bilirubin by biliverdin 
reductase (16, 17). The iron scavenger ferritin is co-induced by HO-1 and renders iron 
inactive (18). Recent studies have shown that induction of HO-1 expression attenuates the 
inflammatory response and accelerates wound healing in HO-1-deficient mice; whereas, 
decreased HO activity in mice results in slower cutaneous wound closure (9, 19). In addition, 
intraperitoneal administration of the HO-effector molecule bilirubin accelerates wound 
repair (20). Since increased HO-1 expression improves wound repair, its induction may be a 
good candidate for preventing aberrant cutaneous wound repair. 
A promising novel preconditioning strategy is ischemic preconditioning (IPC), hereby, 
short cycles of ischemia/reperfusion to an organ protects against subsequent more harmful 
insults to the same organ. In remote ischemic preconditioning (RIPC), the target organ is not 
subjected to the initial stress, but a remote organ, e.g., the hind limb, is exposed (21, 22). 
Interestingly, RIPC protects against injury in the liver (23-26), lung (27), intestines (28), heart 
(29, 30), and kidneys (31, 32) often via the induction of HO-1, since inhibition of HO-activity 
abrogates the protective effects of RIPC (23, 26, 33). Following RIPC, there exists both a 
rapid phase of protection initiated within 1h after preconditioning, and a later phase after 
one to several days (21, 34). In addition, different modes of action have been reported 
between single and repeated RIPC procedures, as demonstrated by differential expression 
of genes involved in autophagy, endoplasmic reticulum stress, mitochondrial oxidative 
metabolism, and cell survival (35, 36). 
Successful translation towards its clinical use was recently established by inducing 
temporary occlusion and restoration of blood flow in arm or thigh of patients (29, 30, 37). 
Patient outcome after myocardial surgery was significantly improved when RIPC was 
applied before surgery (27). However, recently conflicting results have been reported 
showing that RIPC does not always mediate protection (38-41). Data from animal and 
human studies demonstrated the need for careful interpretation because of translational 
differences (38-43). RIPC improves microcirculation by an increase in tissue oxygenation and 
capillary blood flow in the skin (44) and skin flaps (45), and forms a novel target for skin flap 
transplantation (46) and the healing of diabetic foot ulcers (47, 48). Although RIPC has been 
shown to protect in several models of tissue injury, its role in cutaneous excisional wound 
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healing is still unclear. We postulated that RIPC induces HO-1 expression and improves skin 
repair following excisional skin injury. 
Materials and Methods 
Animals 
The Committee for Animal Experiments of the Radboud University Nijmegen approved 
all procedures involving animals (RU-DEC 2010-248) on 1 February 2011. Fifty mice (strain: 
HO-1-luc FVB/N-Tg background; see Table 6.1) of 4–5 months in age, and weighing 21–35 g 
were provided with food and water ad libitum and maintained on a 12 h light/dark cycle 
and specific pathogen-free housing conditions at the Central Animal Facility Nijmegen. The 
transgene consists of the full-length mouse HO-1 promoter fused to the reporter gene 
luciferase (luc). More details on the housing conditions are previously described (49). Mice 
were originally derived from Stanford University (Stanford, CA, USA) as previously described 
(50). An overview of the animals used for the different experiments can be found in Table 
6.1. No animals died during the experiments and no animals were excluded during the 
experiments or data analyses. All mice were randomly divided over the experiments, and 
split evenly over their sex and age. All outcomes were measured by an observer who was 
blinded for the allocation of the animals to the experimental groups, when possible. 
Table 6.1. Overview animal experiments. 
Aim Experiment Read Out 
Animals  
(n: ♂/♀) 
Investigate the effects of RIPC 
on HO-1 promoter activity 
HO-1 promoter activity at 1, 6 and 24 h after 
RIPC treatment 
6: 0/6 
Investigate the effects of RIPC 
on HO-1 gene expression in 
different organs during time 
HO-1 mRNA levels at 0, 1, 6, and 24 h after RIPC 
treatment 
24: 0/24  
(6 per time point) 
Investigate the effects of RIPC 
on dermal wound healing 
Early (5 min before wounding) and late (24 h 
before wounding) effects of RIPC on wound 
healing compared to controls without receiving 
RIPC treatment (endpoint: day 7) 
6: 4/2 (early RIPC)  
6: 4/2 (late RIPC)  
8: 4/4 (controls) 
RIPC Treatment 
RIPC by brief hind limb ischemia was induced by applying elastic latex-free O-rings 
(Miltex Integra: 28–155) using a hemorrhoidal ligator (Miltex McGivney: 26–154B) 
bilaterally around the most upper position of the proximal thigh (Supplemental figure S6.1). 
Reperfusion was accomplished by cutting the elastic rings with scissors, confirmed by the 
disappearance of blue color to the limbs (Supplemental figure S6.1) as described previously 
(51-53). The mice were anesthetized with isoflurane in O2/N2O (5% isoflurane for induction 
and 2%–3% to maintain anesthesia) during RIPC treatment and treatment consisted of three 
cycles of 4-min ischemia interspersed with 4-min reperfusion. This RIPC regime is based on 
a previous study in which we found that bilateral repetitive (3 times 4 min) 
ischemia/reperfusion gave the most potent protection in a kidney injury model (32). 
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Supplemental figure S6.1. Hind limb ischemia by ligation using elastic ring (red arrow). Note the difference in the 
color of the legs after obstruction of the blood flow, confirming RIPC treatment was successful. 
Measuring of HO-1 Promoter Activity 
In order to monitor HO-1 promoter activity after RIPC treatment in time, HO-1-luc Tg 
mice underwent RIPC treatment as described above. HO-1-luc expression was measured in 
vivo and the mice were sacrificed at 24 h. In vivo bioluminescence imaging was performed 
as described before on the IVIS Lumina System (Caliper Life Sciences, Hopkinton, MA, USA) 
(54). Images taken were quantified using Living Image 3.0 software (Caliper Life Sciences) 
by selecting the regions of interest (ROI). ROIs included both the dorsal images 
encompassing the back region below the head and above the tail to cover the area where 
the wounds would be made and the renal area. Emitted photons per second (or total flux) 
per region of interest (ROI) was measured, and then calculated as fold change from baseline 
levels and related to 1 h after RIPC. 
Excisional Wound Model 
Wounds were made 24 h or 5 min after RIPC. Control mice did not receive RIPC, but 
underwent the same anesthetic procedure 1h before wounding. Two full-thickness 
excisional wounds of 4 mm in diameter were made on the shaved dorsal side of 
anesthetized mice using a sterile disposable biopsy punch (Kai Medical, Seki City, Japan), as 
previously described by our group (55). The wounds were created on the dorsum to either 
side of the midline, with approximately 1cm between the wounds, and just below the 
shoulders and pelvis. Skin biopsies taken to create the 4-mm wounds served as control skin. 
Wounds were photographically documented immediately, and 1, 3 and 7 days after 
wounding with a ruler placed perpendicular to the wounds for wound size normalization. 
The area of the wounds was blindly measured twice using ImageJ v1.44p software 
(http://imagej.nih.gov/ij; NIH, Bethesda, MD, USA). 
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Sample Collection 
At day 7, the mice were anesthetized with 5% isoflurane in O2/N2O and sacrificed by 
exsanguination, followed by cervical dislocation. Kidney and muscle (m. quadriceps femoris) 
were dissected, and wound tissue was collected using a 4-mm biopsy punch. Half of the 
tissue was fixated with 4% paraformaldehyde and processed for paraffin embedding and 
(immuno-)histochemistry, and the other half was snap frozen in liquid nitrogen and stored 
at −80 °C until use for RT-PCR. 
(Immuno-)histochemical Staining and Analyses 
Standard H&E, Weigert-AZAN staining (azo carmine and aniline blue), and 
immunohistochemical HO-1 staining were performed on paraffin sections of the wounds as 
previously described (55). Stained sections were analyzed and photographed using the Zeiss 
Imager Z1 microscope (Zeiss, Sliedrecht, The Netherlands) and Axiovision software version 
4.8 (Zeiss). 
Analysis of collagen deposition in AZAN stained wound sections was performed by 
image analysis using a macro built in Image J (56). The wound area was manually defined 
using the edges of the m. panniculus carnosus and epithelium as boundaries before running 
the macro. Measurements were averaged per mouse and mean intensity/mm2 was used for 
further analysis. 
HO-1 immunoreactivity was evaluated by blindly scoring the epidermal zone and the 
dermal region of the wounds. A single section per wound of each animal was semi-
quantitatively scored as previously described using the following scale: 0 (minimal), 1 (mild), 
2 (moderate), and 3 (marked). 
RNA Isolation and Quantitative-RT-PCR 
Tissue was pulverized in TRIzol (Invitrogen, Carlsbad, CA, USA) using a micro-
dismembrator (Sartorius BBI Systems GmbH, Melsungen, Germany) and RNA was further 
extracted as previously described (13). All values were normalized to the household gene 
gapdh, which is often used in RIPC experiments (57, 58) according to the comparative 
method (2−ΔΔCt). Gapdh mRNA expression levels were stable and were not affected by RIPC 
treatment. The sequences of the mouse-specific primers for gapdh are forward 
5′GGCAAATTCAACGGCACA3′, and reverse 5′GTTAGTGGGGTCTCGC 
TCCTG3′, and for Hmox1 (HO-1) forward 5′CAACATTGAGCTGTTTGAGG3′, and reverse 
5′TGGTCTTTGTGTTCCTCTGTC3′. 
Statistics 
Data were analyzed using GraphPad Prism 5.01 software (San Diego, CA, USA). Outliers 
were tested using the Grubbs’ test, but no outliers were found (except for the data in 
supplemental figure S6.3 where one outlier was found in the skin and one in the kidney 
group). Data were analyzed using two-sided t-tests to compare two variables or a one-way 
analysis of variance when comparing multiple variables. Bonferroni’s multiple comparison 
post hoc test was applied as correction for multiple comparisons when investigating 
multiple dependent research questions. Results were considered significantly different at 
p<0.05 (*p<0.05, **p<0.01, and ***p<0.001). 
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Results 
Effects of RIPC on HO-1 Promoter Activity and HO-1 mRNA Expression in Mice 
RIPC can induce HO-1 expression in different organs. In order to evaluate if RIPC can 
induce HO-1 expression, we used a combination of HO-1 promoter activity and HO-1 mRNA 
analyses in HO-1-luc transgenic (Tg) mice. We previously demonstrated that treatment with 
cadmium chloride (CdCl2) potently induced HO-1 promoter activity in the liver and kidney 
using the HO-1-luc Tg model (59). To validate the RIPC model, we corroborated that blood 
flow was indeed hampered after applying elastic rings (Supplemental figure S6.1). After RIPC 
treatment, HO-1 promoter activity was measured using the In Vivo Imaging System at 1, 6, 
and 24 h. Measurements of HO-1 promoter activity were acquired at the dorsal aspect of 
each mouse (Figure 6.1A). Because of variations in HO-1 promoter activity, each mouse 
served as its own control. Relative HO-1 promoter activity of the dorsal side of the mice 
after RIPC treatment is shown over time (Figure 6.1B). We found a significant increase in 
HO-1 promoter activity after 6 and 24 h of RIPC treatment compared to 1 h after RIPC. HO-
1 promoter activity was strongly observed in the renal area, suggesting RIPC induced HO-1 
promoter activity in an organ-specific manner 6 and 24 h after RIPC treatment when 
compared to 1 h after RIPC treatment (Figure 6.1C). 
To discriminate whether the skin or underlying organs were responsible for the 
increase in HO-1 promoter activity, and to test whether RIPC induced HO-1 expression in a 
tissue-specific manner, we measured HO-1 mRNA expression levels in the skin and several 
organs 1, 6 and 24 h after RIPC using RT-PCR and then compared these results to untreated 
controls. First, HO-1 mRNA expression in the hind limb muscles that had been exposed to 
repeated ischemia/ reperfusion cycles were measured and significantly increased 6 h after 
RIPC treatment when compared to untreated controls and other time points after RIPC 
(Figure 6.1D). We then analyzed the effects of RIPC on HO-1 mRNA levels in remote organs 
like kidney, heart, and skin. We also observed a significant increase in HO-1 mRNA 
expression in the kidney 6h after RIPC treatment when compared to untreated controls and 
other time points after RIPC (Figure 6.1E). Similarly, in the heart, HO-1 mRNA levels 
significantly increased 6h after RIPC treatment when compared to untreated controls 
(Figure 6.1F). No significant induction was found at other time points compared to 
untreated controls. After 24 h, HO-1 mRNA levels returned to control levels. However, no 
significant induction in HO-1 mRNA expression was detected in the skin at any time point 
(Figure 6.1G). In conclusion, we demonstrated a tissue- and time-specific induction of HO-1 
promoter activity and HO-1 mRNA expression after RIPC treatment. 
 
A).     B). 
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Figure 6.1. Heme oxygenase-1 (HO-1) promoter activity (A–C) and mRNA expression (D–G) after remote ischemic 
preconditioning (RIPC) treatment. (A) Representative dorsal images of HO-1 promoter activity after RIPC over time. 
Both the overall dorsal side (inserted orange rectangles) and the specific regions of the kidneys (inserted red 
circles) were analyzed and the total flux of emitted photons per second was quantified. Quantification of HO-1 
promoter activity in the overall dorsal area after RIPC treatment (B); and locally in the regions of the kidneys (C), 
and HO-1 mRNA expression in muscle at the place of ligation (D); kidney (E); heart (F); and dorsal skin (G), 1, 6 and 
24 h after RIPC treatment compared to untreated controls (n = 6 animals per group). Data are expressed as mean 
± SD of six individual mice. *p<0.05, **p<0.01, ***p<0.001. 
Effects of Early or Late RIPC on Excisional Cutaneous Wound Closure in Mice 
Since RIPC was observed to improve the cutaneous microcirculation (44), we next 
investigated whether RIPC could also modulate cutaneous wound repair. RIPC induced HO-
1 expression in several organs, but not in the skin. Interestingly, HO-1 can also promote 
regeneration in a paracrine fashion via its versatile effector molecules biliverdin/bilirubin, 
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CO, and ferritin (20, 60-64), which are increased following (R)IPC (65-68). Moreover, RIPC-
mediated protection can act via various alternative signaling pathways, including humoral, 
neuronal, and systemic mechanisms (22, 69). Since there are early and late protective 
effects of RIPC, we evaluated whether early (5 min) and/or late (24 h) RIPC treatment before 
wounding improved full-thickness excisional wound closure. Examples of untreated 
excisional wounds are shown in Figure 6.2A. Wound sizes were normalized to the wound 
size at day 0 (Figure 6.2B). As expected, after quantification of the wound surface area, we 
found a reduction in the wound size over time. However, no significant differences were 
observed in wound closures between early or late RIPC treatment mice and controls. 
A).
 
B). 
 
Figure 6.2. Excisional wound closure in time after RIPC treatment 24 h and directly after wounding compared to the 
control group. Representative images of the wounds of a single mouse receiving no RIPC treatment at day 0, and at 1, 
3, and 7 days after wounding (ruler is incorporated in the pictures and each bar represent 1 mm) (A) and their relative 
wound sizes after different treatments in time, compared to control group at day 0 (B). Data are expressed as mean ± 
SD. No significant differences were observed between the different groups: no RIPC (n = 8), RIPC 5 min (n = 6) and RIPC 
24 h (n = 6). 
HO-1 mRNA and Protein Expression in Wounds After RIPC 
To further elucidate the role of RIPC-induced HO-1 expression during wound repair, 
we investigated whether RIPC modulates HO-1 mRNA and protein expression in day-7 
wounds. Using RT-PCR, HO-1 mRNA expression was assessed in the wounds and compared 
to non-wounded day-0 skin (Figure 6.3A). Here, we found no significant differences 
between the wounds and their corresponding control skins for both RIPC-treated and 
control groups as well as between the different treatment groups. 
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HO-1 protein was found in the epithelial cells of the epidermis and in recruited 
leukocytes in the dermis (Figure 6.3B). In the epidermis, HO-1-positive cells were clustered 
in the re-epithelialized tissue underneath the wound crust and were likely newly-formed 
keratinocytes (70, 71). In the dermis, HO-1-positive cells in inflamed tissues were 
individually spread, and based on their location and morphology, they appear to be 
macrophages (70-73). Moreover, in unpublished data from a previous experiment on 
excisional wound healing in C57Bl/6 mice at day-2 post-wounding, fluorescent staining for 
HO-1 (red) and F4/80 (green) clearly showed co-localization (orange) of HO-1 and 
macrophages in a majority of cells (Supplemental figure S6.2). 
The wounds were scored for the levels of HO-1 expression in the epidermal and dermal 
regions, and compared between the different treatment groups (Figure 6.3C). RIPC 
treatment did not modulate HO-1 protein expression in either region of day-7 wounds when 
compared to controls. Variations in HO-1 expression was found between animals, but was 
independent of RIPC treatment. In summary, RIPC treatment does not appear to alter HO-
1 mRNA and protein expression in day-7 wounds. 
 
A). 
 
B). 
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Figure 6.3. HO-1 expression in wounds. (A). HO-1 mRNA expression in unwounded (control) skin at day 0 and 
wounds after 7 days for the different treatments compared to control skin; (B) HO-1 protein expression in control, 
and early and late RIPC-treated wounds after 7 days of healing. Region above the marked blue line is the epidermis 
and underneath the blue line is the dermal layer (bars represent 1 mm); (C) Scored HO-1 protein staining in 
epidermis and dermis of the wounds after 7 days in arbitrary units (AU). Data are expressed as mean ± SD. No 
significant differences were observed between the different groups: no RIPC (n = 8), RIPC 5 min (n = 6) and RIPC 
24 h (n = 6). 
 
Supplemental figure S6.2. Co-localization of HO-1 and macrophages during excisional wound healing. Fluorescent 
staining from a previous experiment on excisional wound healing in C57Bl/6 mice at day 2 post wounding, showing 
cell nuclei stained with DAPI (blue), HO-1 (red), macrophages stained for F4/80 (green), and an overlay. The overlay 
picture clearly shows co-localization (orange) of HO-1 and macrophages. 
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Effects of RIPC on Wound Morphology and Collagen Deposition 
To determine if RIPC modulates other processes during wound repair, we performed 
H&E staining to examine wound morphology, and AZAN staining to investigate the effects 
on collagen deposition. 
H&E staining revealed that the wound area could be easily distinguished from non-
injured skin by a disruption of the epidermis, subcutaneous fat, and muscle layers. Figure 
6.4A shows H&E staining of day-7 wounds from mice treated with early and late RIPC, and 
control mice (left). At the surface of the wound, the re-epithelialized tissue had marked 
epithelial hyperplasia under the crust of the wound. More distally, the highly cellularized 
granulation tissue was less organized, and consisted of inflammatory cells, such as 
macrophages, granulocytes, and (myo)fibroblasts. Variations in the thickness and size of the 
wounds were observed between the tissue sections of the animals. When comparing the 
different treatment groups, no differences were found in morphology and in the presence 
of different cell types in day-7 wounds. 
Figure 6.4A (right) shows collagen deposition by AZAN staining. The wound regions 
were marked after which the level of collagen deposition in the wounds were measured 
and corrected for the total wound area (Figure 6.4B). No significant differences were 
observed between the different groups. Summarizing, RIPC did not affect wound 
morphology and collagen deposition of day-7 wounds. 
Discussion 
We postulated that RIPC increases HO-1 induction and improves cutaneous wound 
repair. RIPC induced HO-1 in kidney, heart, and skeletal muscles, but not in the skin. 
Although RIPC had previously been shown to target the skin (44-46, 48), both early and late 
RIPC did not affect cutaneous wound closure. In addition, skin morphology and collagen 
deposition at day-7 wounds did not change after early or late RIPC. 
RIPC-mediated protection to organs seems therefore tissue-specific and/or dependent 
on the insult. Organ- and time-specific protective effects of RIPC have also previously been 
demonstrated. For example, RIPC does not improve wound healing in small bowel 
anastomoses (74, 75). Although late RIPC (24 h) attenuates ischemia/reperfusion injury (IRI) 
in muscle flaps, it is ineffective in adipocutaneous flaps (76). In contrast, early RIPC (30 min) 
enhances adipocutaneous flap survival (77). IPC improves the survival of myocutaneous and 
skin flaps subjected to secondary ischemia of 1h in rats (78, 79). Since these RIPC protocols 
vary from ours, and IPC and RIPC are different procedures, these studies cannot be directly 
extrapolated to our study. The protective actions of RIPC are thus dependent on the 
targeted organ and the type of RIPC treatment (80). Remote preconditioning by trauma 
(RPCT) by abdominal incision, has previously been reported to improve cardiac outcome 
following induced heart infarcts by coronary artery occlusion in murine and canine models 
(81-83). Similarly, the inflicted injuries in our study could have led to the induction of 
overlapping cytoprotective pathways. When these RPCT-induced protective pathways were 
stronger than the effects by RIPC or used similar pathways, this could explain in part the 
observed lack of protective effects by RIPC on cutaneous wound repair. Similar protective 
pathways of RIPC and RPCT include the activation of protein kinase C, mitogen-activated 
protein kinases and mitochondrial potassium ATP channels, bradykinin and adenosine (81, 
83, 84). 
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Figure 6.4. Effects of early and late RIPC on morphology of 7-day-old excisional wounds. (A) H&E and AZAN staining 
were performed to evaluate wound morphology (bars represent 1 mm); (B) Quantification of collagen deposition 
to assess the level of wound remodeling using AZAN staining. Data are expressed as mean ± SD. No significant 
differences were observed between the different groups: no RIPC (n = 8), RIPC 5 min (n = 6) and RIPC 24 h (n = 6). 
Previously, the stress enzyme HO-1 was found to be important in wound repair and is 
generally expressed at wound sites (70, 85, 86). HO-1 and HO-2 knockout mice showed a 
delayed wound repair; whereas, induction of HO-1 or administration of its effector molecule 
bilirubin accelerated wound repair (19, 20, 55). Since some of the protective effects of RIPC 
were shown to be dependent on HO-1 expression in IRI of diverse organs, like the liver (23, 
24, 26), lungs (33), and intestines (28), we further evaluated the role of RIPC on HO-1 in 
excisional wound healing. HO-1-luc Tg mice allowed monitoring the effects of RIPC on HO-
1 promoter activity levels in different organs in real-time. 6 and 24 h after RIPC treatment, 
HO-1 promoter activity was significantly induced compared to 1h after RIPC. This correlates 
well with our RT-PCR data showing significantly increased endogenous HO-1 mRNA levels in 
muscle, heart, and kidney 6h after RIPC treatment. However, despite RIPC improving 
cutaneous microcirculation (44), no HO-1 mRNA induction was found in the skin, and may 
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thus not affect the skin directly. HO-1 induction in the skin is possible using pharmacological 
preconditioning since we previously observed that i.p. administration of the HO-1 inducer 
cobalt protoporphyrin at a concentration of 25 mg/kg body weight in HO-1 luc Tg mice 
induced HO-1 mRNA specifically in the skin after 24 h (Supplemental figure S6.3). This 
underscores the tissue- and time-dependent effects of RIPC, which is probably due to the 
structural and physiological differences between different organs. Since organs that have 
induce HO-1 expression upon RIPC treatment correlate with the organs that are protected 
by RIPC, it is tempting to speculate that HO-1 facilitates these protective effects. 
 
 
Supplemental figure S6.3. Pharmacological preconditioning with cobalt protoporphyrin (25 mg/kg body weight) 
in HO-1 luc Tg mice (n = 6) induced HO-1 mRNA expression in both the skin and kidney 24 h after treatment when 
compared to saline-injected control mice (n = 6). Dashed line represents the mRNA expression levels in the 
corresponding control organs after saline injection, which are set at 1. Data represents the relative mean ± SD. 
One significant outlier was found in both skin and kidney group and therefore excluded in the graph. 
Also the long-term protective effects of RIPC via activation of HO-1 were absent in the 
skin. Both HO-1 mRNA and protein expression levels were observed to be independent of 
RIPC treatment in the epidermal and dermal regions of day-7 wounds. Like others, we found 
HO-1-positive keratinocytes in the hyperproliferative epithelia of the wound margins 
covering the wound (70, 71, 87). In the dermis, we also observed HO-1-positive infiltrating 
leukocytes that are likely macrophages (70, 72, 88). HO-1-positive macrophages are thought 
to protect the wound environment against oxidative stress (70, 89). The pro-inflammatory 
HO substrate heme is abundantly released at the edges of the wound site and stimulates 
recruitment of leukocytes (70, 73, 87). HO-1 is thought to attenuate these inflammatory 
and oxidative triggers at the wound site. 
The effect of both early and late RIPC on wound closure was monitored regularly. 
However, the (immuno-)histochemical and PCR analysis was only performed on day 7 
wounds, which limits our insight in wound repair processes, like inflammatory signaling, 
during the first days. Using the HO-1-luc Tg mice we previously found that HO-1 promoter 
activity was indeed significantly induced on day 3 post-wounding, however the level of HO-
1 promoter activity did not decline significantly at day 7 compared to day 3 (88). Although 
no effects in wound closure, collagen deposition, or HO-1 expression in the skin were 
observed, we cannot exclude that paracrine effects of HO-1 or other protective signaling 
pathways may have been triggered by RIPC. HO-effector molecules biliverdin, bilirubin, CO, 
and ferritin, have all shown to improve wound repair (20, 61-64), suggesting that RIPC-
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induced HO-1 induction in various organs stimulate wound repair in a paracrine fashion. 
Interestingly, increased systemic levels of bilirubin augment vascular function (90, 91) and 
may contribute to the reported RIPC induced improvement of cutaneous microcirculation. 
In a previous study, no adverse effects of HO inhibition following RIPC were observed in a 
kidney injury model, suggesting that other mediators may have been protective (31). 
Alternative protective pathways triggered by RIPC include humoral, neural, or systemic anti-
inflammatory, anti-apoptotic responses (22, 69). In addition, RIPC may have more effects in 
more stringent wound repair models where there is a shortage of cytoprotective molecules, 
such as in diabetic wound repair models and pressure ulcers (47). Although our method has 
shown to be effective in diverse animal models (32), other RIPC regimens may enhance 
these protective effects such as combinations with remote ischemic postconditioning (35, 
36, 47). Recently, it was found that the sex of the animal may play a role in the efficacy of 
RIPC treatment, and was observed to be lower in experimental groups of mixed sexes, which 
we also used in our wound repair study (92). 
Conclusions 
RIPC treatment induced HO-1 mRNA expression in kidney, heart, and ligated muscle, 
and may therefore directly contribute to enhanced protection to injurious stressors and/or 
microcirculation in these tissues. However, RIPC did not alter HO-1 in the skin and was not 
modulated in day-7 skin wounds, demonstrating organ- and time-specific effects. Both early 
and late RIPC treatment did not affect dermal wound closure time, collagen deposition, or 
wound morphology. A better understanding of the mechanistic insight by which RIPC 
mediates organ protection is needed.  
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and immune activation. 
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Abstract  
Following injury, the immune system gets activated by released danger signals, including 
heme, to eliminate injurious stressors. However, how the surrounding tissue is protected 
from collateral damage remains still unclear. Better understanding the protective 
mechanisms following remote ischemic preconditioning (RIPC) may give us clues. When a 
small local injury is inflicted to a remote tissue as the leg, organs as the heart and kidney 
get protected from subsequent injuries. High amounts of danger signals activate immune 
cells, whereas low levels may promote tissue protection. Since low levels of heme are 
directly scavenged by hemopexin (hpx), we postulate that RIPC-mediated protection acts 
via the formation of heme-hpx complexes, activating cytoprotective genes including heme 
oxygenase 1 (HO-1). Serum heme levels, HO-1 promoter activity, and HO-1 expression were 
measured following RIPC in HO-1-luc transgenic mice. After RIPC, free heme levels increase 
rapidly but mildly. HO-1 expression gets induced both locally in the ligated skeletal muscle 
and remotely in the kidney and heart. The majority of HO-1-positive cells also expressed 
LRP-1, the only known receptor for heme-hpx complexes. Systemic protection may be 
mediated by the formation of tissue survival factors (TSFs). Heme-hpx complexes bind to 
LRP-1, subsequently activating nrf2-responsive cytoprotective genes, including HO-1. We 
propose therefore a “tissue survival model” next to the “danger model” where TSFs as the 
heme-hpx complex prepares the tissue for injurious insults by inducing cytoprotective 
genes. When the tissue is warned, hpx is depleted and free heme can no longer form TSFs, 
but acts as danger signal by binding to TLR4 and alerting the immune system. 
 
Keywords: RIPC, heme, heme oxygenase-1, hemopexin, LRP-1, tissue survival factor, danger 
signals. 
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Abbreviations 
CoPP Cobalt protoporphyrin 
DAMP Damage-associated molecular patterns 
Hb Hemoglobin 
Hp Haptoglobin 
hpx Hemopexin 
HO-1 Heme oxygenase-1 
iNOS Inducible nitric oxide synthase  
IRI Ischemia-reperfusion-injury 
LRP-1 LDL receptor-related protein-1 
nrf2 Nuclear factor erythroid 2-related factor 2 
RIPC Remote ischemic preconditioning 
ROS Reactive oxygen species 
SnPP Tin protoporphyrin 
TLR Toll-like receptors 
TSF Tissue survival factor 
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Introduction 
Following injury, endogenous alarm signals (1) activate the immune system to eliminate 
possible pathogenic invaders. Unfortunately, the resulting immune response can also cause 
considerable collateral damage (1, 2), both locally and distally (via the elaboration of soluble 
cytokines, chemokines and other signaling entities) that can result in tissue injury, organ 
failure and fatality (3-5). Therefore, harnessing tissue damage is as important for survival as 
activating immunity (3, 6, 7), and a powerful, but little known, aspect of physiology is the 
bodily response that protects distant organs from such damage. This can be seen in studies 
on remote ischemic preconditioning (RIPC), where short ischemic insults are induced in 
remote non-vital tissues (e.g., skeletal muscle of the legs) leading to enhanced tolerance 
against a subsequent stress in vital organs (e.g. heart, brain, kidney) (8). RIPC protects 
different organs and tissues in pre-clinical models. For example, RIPC has been shown to 
reduce myocardial injury after ischemia-reperfusion injury (IRI) in models of surgery and 
organ transplantation (9). Although the potential for clinical use is obvious, the responsible 
molecular mechanisms remain elusive (10). If the underlying mechanisms could be found, 
it might be possible to mimic them, rather than do the damage that elicits them. 
One intriguing possibility arises from the “Danger model” (1). Given that high local 
concentrations of alarm signals act as immune stimulators, we postulated that lower 
concentrations of some of those same molecules might act distally to elicit tissue-protective 
mechanisms. In effect, they might act as “Tissue Survival Factors” (TSFs) to trigger tissue 
protection. This is commonly accepted for exogenous alarm signals, such as LPS, where 
pretreatment with low doses is well known to protect against the effects of subsequent 
higher doses (11).  We postulated that this may also be true of endogenous alarm signals.  
To test this idea, we studied the alarm properties of heme. 
Heme is the prosthetic group of various hemoproteins and indispensable for many 
cellular processes. However, heme is also involved in the pathology of many different 
pathologies, including sickle cell disease, malaria, sepsis and kidney failure. Excess of free 
heme can be detrimental to tissues by mediating oxidative injury (by catalyzing the 
formation of reactive oxygen species (ROS) via the Fenton reaction). Previously, we and 
others have shown that heme is released following injury (12) and acts as an alarm signal to 
induce inflammatory responses (13-16). We also demonstrated that heme induces ICAM-1 
expression in vascular endothelial cells and causes recruitment of granulocytes and 
macrophages (12, 15, 16). Based on these findings, we were the first to postulate that heme 
could act as a danger molecule and promote inflammation (12). Later it was found that 
heme can indeed activate TLR-4 (17), and induce NLRP3 inflammasome formation, thus 
promoting pro-inflammatory signaling (18, 19). Heme has also been described to be part of 
the damage-associated molecular patterns (DAMP)-family and alarmins (18, 20). Thus, in 
high local concentrations, heme can act as a danger signal and alert the immune system.  
In lower concentrations, heme has also been shown to mediate protective effects. 
For example, several in vitro and in vivo pre-clinical studies showed that administration of 
low doses of heme resulted in protection against diabetes, human immunodeficiency virus 
replication, and heart injury (21-26). In addition, administration of hemoglobin before 
provoking rhabdomyolosis in rats prevented kidney failure and drastically reduced 
mortality, and was dependent on HO activity. Induction of HO-activity may be generally 
beneficial for oxidative and inflammatory diseases and immuno-suppressed states (27, 28). 
169 
To test whether heme can also act as a TSF, and to elucidate the mechanisms 
involved, we assessed whether heme gets released following RIPC treatment and whether 
this was associated with induction of cytoprotective pathways. 
Several protective pathways of RIPC have been proposed, including the release or 
induction of erythropoietin, bradykinin, adenosin, glucagon, endogenous opioids, IL-10, 
nitrates, CXCL12, HIF-1α, or heme oxygenase (HO)-1 (29). When cardiac infarction was 
induced in rabbits, RIPC was found to attenuate the cardiac infarction size compared to 
naive rabbits. Most likely, RIPC-mediated protective factors are released into the serum, as 
transfer of serum from RIPC-treated rabbits to naive rabbits still protected induced cardiac 
infarct size in the recipient naive rabbits (30). 
Pharmacological preconditioning with low levels of heme may lead to tissue 
protection. Interestingly, in IRI models of the heart, liver, and lung, RIPC-mediated 
protection was dependent on the expression of the cytoprotective enzyme HO-1, 
emphasized by abrogated protection when HO activity was inhibited (31-34). HO is one of 
the most important cytoprotective enzymes involved in the protection against oxidative 
stress and resolution of inflammation (35, 36). HO degrades heme into biliverdin/bilirubin, 
free iron, and carbon monoxide (CO). Ferritin is co-induced by HO-derived iron and is 
important for protection against iron-induced ROS formation (37). How HO-1 mediates this 
protection is not yet completely understood, but it may be related to its antioxidant 
activities and attenuation of vascular adhesion molecule expression (16, 38-40). The HO-1 
isoform can be induced by a variety of stimuli (41), among which heme, and 
pharmacological induction can be used as preconditioning strategy against subsequent 
stresses (28), such as IRI in the lung, liver, intestine, pancreas, and kidney (42-47).  
Since RIPC protects against heart failure, we aimed to investigate the role of HO-1 
in regulating RIPC-mediated protective effects. Although HO-1 has been demonstrated to 
be important in RIPC-mediated protection in diverse organs, it is not yet clear how this 
protective mechanism is triggered. LRP-1 is ubiquitously expressed in many cell types, 
including fibroblasts, macrophages, and endothelial cells in diverse organs, where it 
activates protective signaling pathways.   
A dual role for heme is proposed with heme in complex with hpx promoting 
protective TSF signaling, whereas free heme acts as danger signal, alerts the immune system 
and promotes inflammation. We postulate that heme gets released following RIPC and acts, 
by binding to hemopexin (hpx), as a TSF signal. This heme-hpx-complex binds to its only 
receptor LRP-1 that next activates tissue protective pathways via nrf2-responsive HO-1 
signaling. 
 
Materials and methods 
 
Animals 
30 female mice (strain: HO-1-luc FVB/ N-Tg background) of 4-5 months in age and weighing 
22-31 g (25.9±2.3 g) were provided with food and water ad libitum and maintained on a 12h 
light/dark cycle and specific pathogen-free housing conditions at the Central Animal Facility 
in Nijmegen. Details on the housing conditions have been previously described (48). In these 
mice, the transgene consists of the full-length mouse HO-1 promoter fused to the reporter 
gene luciferase (luc). Mice were originally derived from Stanford University (Stanford, CA) 
(49). An overview of our experimental design is shown in Table 7.1. All mice were randomly 
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assigned to treatment or control groups. All outcomes were measured by an observer who 
was blinded for the allocation of the animals to the experimental groups, when possible. No 
animals died during the experiments, nor were excluded in our data analyses.  
 
Table 7.1. Overview animal experiments. 
Aim Measurement Animals (n) 
Investigate the effects of 
RIPC on HO-1 promoter 
activity 
HO-1 promoter activity at 1, 6 and 24h after 
RIPC treatment 
6 
Investigate the effects of 
RIPC on gene and protein 
expression during time 
HO-1 mRNA levels at 0, 1, 6, and 24h after 
RIPC treatment 
24 
(6 per time point)  
The Committee for Animal Experiments of the Radboud University Nijmegen approved all 
procedures involving animals (RU-DEC 2010-248). 
 
RIPC treatment 
As previously demonstrated, RIPC was performed by applying brief hindlimb ischemia using 
a hemorrhoidal ligator (Miltex McGivney: 26-154B) to place elastic latex-free O-rings (Miltex 
Integra: 28-155) placed bilaterally around the most upper portion of the proximal thigh 
(Figure 7.1, reproduced with permission) (50). Reperfusion was accomplished by cutting the 
elastic rings and confirmed by the disappearance of blue color to the limbs. During the 
entire RIPC procedure, mice were anesthetized with isoflurane in O2/N2O (5% for induction 
and 2%3% as maintenance) and consisted of three cycles of 4-min ischemia interspersed 
with 4-min reperfusion. This regime is based on a previous study in which we found that 
bilateral repetitive (3x4 min) ischemia/reperfusion resulted in the most potent protection 
in a kidney injury model (8).  
 
 
Figure 7.1: Hind limb ischemia by ligation using the black elastic ring (red arrow). Note the difference in the color 
of the legs after obstruction of the blood flow with the elastic ring. 
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Measuring of HO-1 promoter activity  
In order to monitor HO-1 promoter activity after RIPC treatment in real time, HO-1-luc Tg 
mice underwent RIPC treatment as described above. HO-1-luc expression was measured in 
vivo by bioluminescence imaging (BLI) using the IVIS Lumina System (Caliper Life Sciences, 
Hopkinton, MA, USA) as previously described (51). HO-1 promoter activity in the heart were 
quantified using LivingImage 3.0 software (Caliper Life Sciences), calculated as emitted 
photons per second (or total flux), and then expressed as fold change from baseline levels 
and then compared with levels measured at 1h after RIPC. 
 
Sample collection 
Mice were anesthetized with 5% isoflurane in O2/N2O and sacrificed by exsanguination, 
followed by cervical dislocation. Plasma samples were stored at -80°C until further use. The 
ligated muscle (m. quadriceps femoris), kidneys, and heart were dissected. Half of the tissue 
was fixated with 4% paraformaldehyde and processed for paraffin embedding and 
immunohistochemistry, and the other half was snap frozen in liquid nitrogen and stored at 
-80°C for later RNA isolation and RT-PCR.  
 
Measurement of free heme levels in the circulation using HPLC 
A stock solution of heme (2 mM; 13.4 mg/10 mL pure DMSO) was freshly prepared and 
serially diluted to 2.0, 4.0, 6.0, 8.0 and 10.0 µM heme as standards. An aliquot of 20 µL of 
serum or standards was mixed with 160-µL HCl/acetone (1:40 ratio), and after 2 min cooling 
and centrifugation at 13.400 rpm for 3 min, the upper organic layer was collected and used 
for HPLC analysis. The chromatographic system consisted of a Thermo Separations Products 
(TSP) binary pump (P2000), autosampler (AS3000) and a single wavelength UV detector 
(UV1000). The autosampler was programmed to inject 50 µL of sample. Pump flow-rate was 
1.0 mL/min with mobile phase comprised of degassed 44% methanol, 56% 0.1 M 
ammonium phosphate buffer pH 3.4, v/v (Solvent A) and the sample/ standard (solvent B) 
using the following gradient: Solvent B, 0% at t0 to 100% at 14 min; then isocratic to 15 min; 
down to 0% at 16 min and isocratic to 21 min. The UV detector was set at a wavelength of 
400 nm. Gradient separation of heme was performed on a GraceSmart RP18 column, 
150x4.6 mm i.d., 5-µm particle size at a column temperature of 60°C. 
 
Immunohistochemical staining and analyses 
Immunohistochemical staining was performed on paraffin sections of heart tissues as 
previously described (52). Double stainings were performed to characterize HO-1-positive 
cells as follows: first, fields of HO-1-positive cells were located on stained tissue sections 
using the Zeiss Imager Z1 microscope and Axiovision software version 4.8; and the second 
staining of cell-specific markers was performed on the same tissue section using the “mark 
and find” option to locate the stained HO-1-positive cells. For the co-localization studies of 
HO-1 and LRP-1 expression, we performed immunohistochemical stainings on subsequent 
tissue sections of 5µm in thickness and scanned the complete sections using the automatic 
slide scanner Pannoramic scan II (3DHISTECH), in which co-localization can be studied based 
on tissue morphology. HO-1-positive cells were easily located and matched to cells stained 
with LRP-1. HO-1 immunoreactivity was semi-quantitatively evaluated blindly by two 
independent trained observers for a single section of the whole heart tissue from each 
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animal using the following scoring scale: 0 (minimal), 1 (mild), 2 (moderate), and 3 (marked) 
as previously described (52). 
 
RNA isolation and quantitative-RT-PCR 
Tissue was pulverized in TRIzol (Invitrogen) using a micro-dismembrator (Sartorius BBI 
Systems GmbH, Melsungen, Germany) and RNA was further extracted as previously 
described (35). All values were normalized to the household gene gapdh according to the 
comparative method (2-ΔΔCt). The sequences of the mouse-specific primers for gapdh are 
forward 5’GGCAAATTCAACGGCACA3’, and reverse 5’GTTAGTGGGGTCTCGCTCCTG3’, and 
for Hmox1 (HO-1) forward 5’CAACATTGAGCTGTTTGAGG3’, and reverse 
5’TGGTCTTTGTGTTCCTCTGTC3’. 
 
Statistical analyses 
Data were analyzed using GraphPad Prism 5.01 software (San Diego, CA, US). Outliers were 
tested using the Grubbs' test, but no outliers were found. Data were analyzed using two-
sided t-tests to compare two variables or a one-way analysis of variance when comparing 
multiple variables. Bonferroni’s multiple comparison post hoc test was applied as a 
correction for multiple comparisons when investigating multiple dependent research 
questions. The non-parametrical one-tailed Mann-Whitney U-test was used to compare the 
arbitrary scored immunohistological sections. Results were considered significantly 
different at p<0.05 (*p<0.05, **p<0.01, and ***p<0.001).  
 
Results 
 
Low amounts of heme are released following RIPC 
RIPC has been reported to protect the tissue; however, the mechanism by which this occurs 
is not yet completely understood. In order to investigate the possible involvement of heme, 
we postulated that during RIPC, local mild damage leads to the release of small amounts of 
heme into the circulation, which could then act protectively. To this end, we measured 
plasma levels of free heme after RIPC treatment over time using HPLC analysis (Figure 7.2). 
We observed a significant increase in free heme levels within 1h after RIPC treatment. No 
significant effects were found 6 or 24h after RIPC treatment. This release of low levels of 
heme into the circulation early after RIPC treatment could possibly lead to induction of the 
cytoprotective enzyme HO-1.  
 
 
Figure 7.2: Free heme levels in the plasma are elevated early in mice after RIPC treatment  
Data are expressed as mean±SD of six individual mice. * p<0.05 
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RIPC treatment induces HO-1 mRNA and protein expression locally in the ligated muscle 
Induction of HO-1 expression has been observed previously after RIPC treatment (31-34). 
To determine whether HO-1 is also induced in our model, we isolated total RNA from ligated 
muscles of the hind limbs and performed quantitative RT-PCR (Figure 7.3A). RIPC 
significantly (p<0.05) induced HO-1 mRNA expression a 3.5- and 10.8-fold at 1 and 6h, 
respectively, and non-significantly a 2.4-fold (p=0.11) at 24h, following RIPC compared with 
the no RIPC-treated control group. In addition, HO-1 protein expression was strongly 
enhanced in individual cells in the ligated hind limb muscle; whereas, HO-1-positive cells 
were not found in the muscle of the no RIPC-treated control group. After quantification, 
HO-1 protein expression was significantly elevated at 6 and 24h after RIPC when compared 
with the no RIPC-treated control group (Figure 7.3B). Thus, local HO-1 induction is observed 
after RIPC treatment of the ligated skeletal muscle. 
 
A).      B). 
  
Figure 7.3: HO-1 is induced locally in the skeletal muscle upon RIPC treatment 
Time course of HO-1 mRNA level (A) and protein (B) levels in ligated skeletal muscles of the hind limbs of mice 
after RIPC treatment. Data are expressed as mean±SD of six individual mice. AU, arbitrary units. * p<0.05, ** p< 
0.01, *** p < 0.001 
 
HO-1 expression is induced in kidney and heart after RIPC treatment 
To assess whether HO-1 is also induced in remote organs, we analyzed the HO-1 mRNA 
expression levels of the kidney and heart after RIPC. HO-1 mRNA expression in the kidney 
was significantly elevated (4.2-fold) 6h after RIPC treatment (Figure 7.4A). Next, HO-1 
promoter activity in the heart region of HO-1-luc tg mice after RIPC treatment was 
investigated. We observed that there were significant increases 6h and 24h after RIPC 
treatment in HO-1 promoter activity compared to 1h after RIPC treatment (Figure 7.4B). 
Since measured HO-1 promoter activity may be affected by HO-1 promoter activity in other 
organs that lay near to the heart, we next investigated HO-1 induction in the heart also on 
mRNA and protein level as confirmation. Indeed, also on mRNA level, there was a significant 
induction of HO-1 expression at 1 and 6h after RIPC treatment (a 1.5-fold and 2.4-fold, 
respectively) when compared to no RIPC-treated control. However, significance 
disappeared after 24h (p=0.094) (Figure 7.4C). When we subsequently analyzed HO-1 
protein expression in the heart, we could only find a significant induction 6h after RIPC 
treatment (Figure 4D). Taken together, we show that HO-1 is induced in multiple remote 
organs following RIPC treatment. 
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C).      D). 
   
Figure 7.4: HO-1 is induced in remote organs after RIPC treatment 
A). HO-1 mRNA expression levels in the kidney after RIPC treatment in time compared with those of no RIPC-
treated controls. B). Time course of HO-1 promotor activity in the heart after RIPC treatment compared with the 
1h RIPC time point. Time course of HO-1 mRNA level (C) and protein (D) levels expression levels after RIPC 
treatment compared with that of no RIPC-treated controls. Data are expressed as mean±SD of six individual mice. 
AU, arbitrary units. * p<0.05, ** p< 0.01, *** p < 0.001 
 
HO-1 induction is mediated via LRP-1 activation 
In large amounts, free heme has been demonstrated to bind to TLR-4 and act as danger 
signal activating inflammatory responses. However, shortly following RIPC treatment only 
small amounts of free heme were observed in the circulation. It has been demonstrated 
that free heme in the circulation gets directly scavenged by hpx (53). Since hpx can 
completely scavenge low levels of free heme, we aimed to investigate whether this heme-
hpx complex could induce HO-1 in cells via activation of LRP-1 signaling. To test this, we 
performed HO-1 and LRP-1 immunohistological staining on subsequent tissue sections to 
show that HO-1 and LRP-1 proteins co-localize in the cells of the heart. In Figure 7.5A, a 
representative example of the HO-1 and LRP-1 stainings of the heart, 6h after RIPC 
treatment are depicted, clearly showing HO-1 and LRP-1 double positive cells. After 
quantification of the number of HO-1-positive cells in multiple fields (at least 5) of the heart, 
the number of double positive cells was determined. An average of at least 86% of the HO-
1 positive cells were positive for and LRP-1 in the 6h time-point group (Figure 7.5B) showing 
that HO-1 induction is likely mediated via LRP-1.  
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Figure 7.5: Most of the cells expressing HO-1 protein also express LRP-1 protein 
A). Representative example of double-positive staining of HO-1 and LRP-1 on consecutive stained sections of a 
heart 6h after RIPC treatment. B). Number of HO-1 and LRP-1 double-positive cells in immunohistological sections 
of the heart. Quantification was performed on at least five regions were HO-1-positive cells were present. On 
subsequent tissue sections stained for LRP-1 protein, HO-1-positive cells were identified based on location and 
tissue morphology, and LRP-1 double-positive cells were determined. 
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Discussion 
 
With the “danger theory” we better understand how the immune system is activated 
following injury. Here, we propose to extend this theory with a “tissue survival theory” and 
explain how first the tissue gets warned by TSF-signaling for both injurious stressors and for 
an immune response that may cause collateral damage. The tissue will prepare itself by 
inducing cytoprotective pathways. 
RIPC protects against various forms of tissue injuries (54-56). We postulated that 
RIPC leads to the release of heme that upon binding to hpx activates tissue protective 
pathways via LRP-1 and nrf2-responsive HO-1 signaling. We demonstrated that RIPC 
induced the cytoprotective enzyme HO-1 locally in the ligated muscle, and remotely in the 
kidney and heart. Since serum heme levels are mildly but significantly elevated early 
following RIPC treatment, it is likely that HO-1 is induced via LRP-1 activation by heme-hpx 
complexes (57), which is supported by massive co-localization of HO-1-positive cells with 
LRP-1. Based on these RIPC data, we propose a novel model to explain tissue protective 
effects following injury by the formation of TSFs that can activate cytoprotective genes 
(Figure 7.6A). Following alerting the tissue by TSFs (e.g., heme-hpx complexes), danger 
signals may take over and activate the immune system (Figure 7.6B). 
 
The heme-hpx complex acts as TSF by binding to LRP-1 and inducing protective signaling 
The heme that gets released upon small injuries is directly scavenged by hpx. The only 
receptor described to recognize the heme-hpx complex to date is LRP-1 (CD91) (58), which 
can recognize a wide range of different ligands (59). LRP-1 is ubiquitously expressed 
throughout the body in many cell types, including fibroblasts, macrophages, vascular 
smooth muscle cells, endothelial cells, adipocytes, neurons, and foam cells (60-62), and has 
physiological functions for endocytosis and regulation of signaling pathways (63). LRP-1 is 
an important switch in protective/inflammatory responses, as LRP-1 expression reduces NF-
κB activation of pro-inflammatory genes; whereas, deletion of LRP-1 enhances pro-
inflammatory signals (64, 65). LRP-1 has an atheroprotective effect on the vascular wall (59). 
Interestingly, LRP-1 induction makes the tissue more susceptible to heme-hpx-mediated 
protective signaling as more receptors can be activated. LRP-1 expression is increased in 
several pathologies; hypoxia and IRI as exemplified by the observation that during 
myocardial infarction LRP-1 expression gets induced (66). However, LRP-1 is involved in 
phagocytosis and removal of apoptotic cells, which is critical for development, tissue 
homeostasis, and resolution of inflammation (63, 67-69). LRP-1 and their signaling cascades 
may serve as new target for the treatment of different diseases, such as cardiovascular and 
neuronal disorders (63). LRP-1 overexpression probably makes the tissue more prone to 
hpx-mediated protective signaling as more LRP-1 receptors are available for activation by 
heme-hpx complexes.  
  
177 
A). 
 
 
  
178 
B). 
 
Figure 7.6: Proposed mechanisms of tissue protection by TSFs and immune cell activation by danger signals 
A). Low amounts of heme get scavenged by hpx and bind in complex to LRP-1, which activates cytoprotective nrf2-
responsive pathways, such as HO-1, to promote tissue protection. Excess free heme molecules can bind TLR-4 and 
induce pro-inflammatory pathways (e.g. TNF-α, ICAM-1) and activate immune cells; B). Preconditioning of naive 
cells with RIPC or hpx administration may increase tissue tolerance towards oxidative and inflammatory stress, 
e.g., as experienced during heme overload. Heme overload activates the immune response resulting in cytokine 
and ROS release, and collateral damage. High-tolerant tissue is better protected against injurious insults resulting 
in organ survival, while not protected low-tolerant tissue gets injured and lead to organ dysfunction. 
TLR-4: Toll-like Receptor-4, LRP-1: LDL Receptor-Related Protein-1, TNF-α: Tumor Necrosis Factor-α, IL-1β: 
Interleukin-1β, MCP-1: Monocyte Chemoattractant Protein-1, ICAM-1: Intercellular Adhesion Molecule-1, VCAM-1: 
Vascular Cell Adhesion Molecule-1, HO-1: Heme Oxygenase-1, NQO1: NAD(P)H Quinone Oxidoreductase-1, SOD: 
Superoxide Dismutase, PRX: Peroxiredoxin, ROS: Reactive Oxygen Species. 
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Heme-hpx mediated activation of LRP-1 leads to the induction of the nrf2-responsive gene 
HO-1 and tissue protection 
After oxidative and inflammatory stress, nrf2 balances redox levels by inducing the 
expression of cytoprotective proteins (70, 71). A major nrf2 target is the inducible protective 
enzyme HO-1 (72). Decreased levels of the HO-1 effector molecules bilirubin and CO are 
implicated in ischemic heart disease; whereas, enhanced expression of HO-1 or 
administration of its effector molecules prevents cardiac injury and transplant rejection 
(73). In cultured monocytes, uptake of heme-hpx complexes elevates LRP-1-dependent HO-
1 induction (60).  
The importance of the nrf2/HO-1 axis in cardiac protection is shown by the 
association of RIPC with elevated levels of nrf2 expression in a porcine model of deep 
hypothermic circulatory arrest, which improved cardiac outcome (74). In addition, lack of 
nrf2 leads to rapid development of heart failure after ischemic injury (75). Also, 
administration of cobalt protoporphyrin (CoPP) improved heart function following 
myocardial ischemia via the induction of HO-1 by reducing oxidative stress and apoptosis, 
and preserving mitochondrial membrane potential in cardiomyocytes (76). The protective 
role of nrf2/HO-1 is further supported by studies reporting that preconditioning of cardiac 
stem cells with CoPP induces several cytokines, such as EGF, FGFs, colony-stimulating 
factors, and chemokine ligand, and pro-survival genes that protect against apoptosis via a 
nrf2 and HO-1-dependent manner, as blocking these pathways abrogated the protective 
effects of CoPP (77, 78).  
 
High levels of free hemoglobin and heme can activate the immune system when 
haptoglobin and hemopexin are depleted 
In pathological conditions and tissue injuries, such as sickle cell disease, malaria, IRI and 
severe sepsis, large amounts of hemoproteins, such as hemoglobin and myoglobin are 
released into the circulation (53, 79-82). After exhausting the hemoglobin (Hb) scavenger 
protein haptoglobin (hp), “labile” free heme is released from methemoglobin (53). Free 
heme is subsequently scavenged by hpx and can then warn the tissue for upcoming stress. 
However, when also the binding capacity of hpx is overwhelmed, free heme accumulates in 
the plasma where it can promote oxidative and inflammatory stress and act as danger signal 
(79).  After binding of heme to TLR-4, NF-κB-responsive genes are activated resulting in the 
induction of pro-inflammatory cytokines and activation of the immune system (79). 
Protective mechanisms against free heme are therefore pivotal for cellular survival. 
When the release of heme is massive, the tissue will have only few time left to prepare its 
defense by TSF signaling, because of the limited amount of haptoglobin and hemopexin.  
 
Hpx skews away from danger molecule signaling by promoting tissue survival via TSF 
signaling  
The scavenger hpx binds to free heme and directly prevents oxidative and inflammatory 
insults. Hemopexin is not recycled after the clearance of heme-hpx complexes; and under 
pathologic conditions, e.g., during cardiovascular surgery or hemolysis, hpx levels are 
rapidly exhausted (83). Additional administration of hpx to cell cultures containing high 
levels of free heme prevents heme-induced toxicity (84). This may be possibly due to direct 
scavenging of heme by hpx, but may also likely be the result of induction of HO-1 via LRP-1. 
The latter is supported by reduced protection in the presence of HO-1 inhibitors (85). Also, 
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in diverse pre-clinical models, the protective role of hpx has been demonstrated. 
Administration of hpx protected against heme-induced inflammation in sepsis (86). Studies 
using hpx knockout animals further confirmed the protective role of hpx against heme-
induced toxicity (84, 87, 88). In a model of heme overload using hpx knockout mice, the 
excess accumulation of free heme in the plasma produced ROS, induced adhesion 
molecules, reduced nitric oxide availability (89), and caused severe systolic dysfunction in 
the heart (84). Supplementation of hpx in hpx knockout mice after heme overload in models 
of hemolytic diseases (sickle cell disease and β-thalassemia) resulted in the preservation of 
cardiac function, limited oxidative stress and promoted recovery and hepatic detoxification, 
mainly via the induction of HO-1 (84, 89, 90). The levels of heme and hpx appear to 
determine also disease severity and adverse clinical outcomes in malaria, sepsis, and sickle 
cell disease (91-93). Normally, hpx concentrations in mice range from 0.55–1.25 mg ml−1 
(94). This level is sufficient to scavenge all the heme we observed after RIPC treatment. 
Excess levels of heme contribute to pathogenesis; whereas, increased levels of the heme-
hpx complex has a protective role (86, 95-97). And hence, we propose that heme binding to 
hpx can be considered a systemic protective response complex (TSF). 
 
Sickle cell disease models strongly support a “tissue survival theory” next to a “danger 
theory” 
We previously postulated that heme could play a decisive role in the stasis observed in sickle 
cell disease (93). It was indeed shown that in transgenic sickle cell mice heme can provoke 
vascular adhesion molecule expression and contribute to vascular occlusion via TLR4-
signaling (98-100). Interestingly, the nrf2 inducer dimethyl fumarate was shown to protect 
against oxidative stress and inflammation in sickle cell disease in an HO-1-dependent 
manner (101).    
The hemoglobin scavenger haptoglobin and the heme scavenger hpx get swiftly 
depleted during hemolytic episodes in sickle cell disease (102), abrogating protective TSF 
signaling (Figure 7.6A). Hpx gene transfer in transgenic sickle mice significantly increased 
plasma and hepatic hpx levels compared to controls, and ameliorates heme-induced 
vascular inflammation and occlusion, suggesting that it is possible to abrogate danger 
molecule signaling by promoting TSF formation (61, 90, 103). Administration of hpx 
increased HO-1 in the liver, kidney and skin within 1h, and decreased nuclear NFκB -p65, 
and vaso-occlusion for 48h after infusion. Hpx-induced protection was abrogated when HO-
activity was inhibited with tin protoporphyrin (SnPP) (103).  
In addition, hpx overexpression increased hepatic nuclear nrf2 expression, HO-
activity and HO-1 protein and LRP-1, while decreasing NFκB activation and down-stream 
pro-inflammatory signaling (61). The heme-hpx/LRP-1/nrf2/HO-1 axis was elegantly proven 
by the use of mutant hpx proteins. A hpx missense construct that did not bind heme could 
not prevent heme-induced vascular occlusion, and another hpx missense construct that was 
not able to bind LRP-1 did not prevent heme-induced vascular occlusion, showing that hpx 
can only provide protection when in complex with heme and only when it can activate 
protective LRP-1 signaling (61).  
Free heme was demonstrated to mediate pro-inflammatory effects also in renal 
epithelial cells via TLR-4 signaling; whereas, blocking of TLR-4 did not result in less nrf2 and 
HO-1 activation, indicating that anti-inflammatory effects of heme are not TLR-4 mediated, 
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and thus likely mediated via LRP-1 signaling (104). Heme-hpx binding to the LRP-1 receptor 
may thus activate protective nrf2-responsive pathways.  
Summarizing, these data support our model that heme in the presence of hpx is 
skewed towards the protective TSF-pathway via LRP-1/nrf2/HO-1, whereas in the absence 
of hpx, heme activates TLR4-mediated induction of NFκB responsive inflammatory genes is 
enhanced (see Figure 7.6A). 
 
Clinical relevance of the described RIPC-mediated protective concept 
Patients have an individual predisposition towards oxidative and inflammatory stress. For 
example, patients with sickle cell disease, diabetes, older age or infectious diseases will have 
more depleted antioxidant and anti-inflammatory defenses and be less tolerant to 
subsequent exposure to injurious stressors. The tolerance of tissue may be increased by 
applying preconditioning strategies, e.g., RIPC or hpx administration, which both can 
activate tissue survival factors (Figure 7.6B). Interestingly, it was found that in contrast to 
preconditioning with heme that caused attenuation of inflammatory stress, post-
conditioning with heme exacerbated inflicted kidney injury (105), showing that heme only 
acts protective in the presence of hpx. When hpx is depleted, administration of heme 
aggravates inflammatory conditions. There is a differential response between high and low 
tolerant tissues towards oxidative and inflammatory stressors. For example, heme overload 
cannot be completely scavenged by hpx and will then bind to TLR-4. Next, TLR-4 signaling 
activates an immune response and extensive release of cytokines resulting in collateral 
damage by recruited immune cells. While high tolerant tissue is better protected against 
such damage and results in organ survival, low tolerant tissue is not equipped to deal with 
this stress and may develop towards organ dysfunction. 
However, heme shows dose-dependent effects and can act as a double-edged 
sword. Therefore, quantification of the amount of plasma heme, hpx, hemoglobin-hp, 
heme-hpx, and heme-albumin levels in various disease states may aid the diagnosis and 
treatment of several pathologic conditions (86). High levels of heme often lead to oxidative 
stress and inflammation-induced damage, whereas low levels of heme are essential for 
physiological processes, but can also protect individuals in several diseases (106, 107). 
Pharmacological preconditioning with low levels of heme-hpx or RIPC treatment forms an 
interesting strategy. However, heme is unstable and heme arginate forms a better 
alternative as it is also less toxic (53, 108, 109). 
In addition, the induction of TSFs may not be restricted to the heme-hpx complex 
alone, but may also apply to other factors, such as e.g., the hemoglobin-haptoglobin 
complex by binding to CD163 and activate anti-inflammatory pathways (60). This is 
supported by a study showing that haptoglobin supplementation induces cytoprotective 
cellular responses via a HO-1 dependent mechanism in a murine model of sickle cell 
diseases, as protection is blocked by HO-activity inhibitor SnPP (103).  
With our “tissue survival model” in mind, we may now develop novel strategies to 
skew either towards a pro-inflammatory or anti-inflammatory microenvironment. 
Hemopexin harnesses the pro-inflammatory and oxidative properties of heme, and the 
heme-hpx complex initiates protective pathways. This concept may be beneficial for the 
development of therapeutic strategies in a plethora of conditions, including tissue injury, 
diabetes, transplantations and graft failure, fibrosis, IRI, cardiac diseases, aging, 
pathological pregnancies and heme-mediated pathologies such as sickle cell disease, 
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malaria, hemolytic-uremic syndrome, and thrombotic thrombocytopenic purpura (101). 
Also, patients receiving blood transfusion have elevated levels of free hemoglobin and 
heme, and often suffer from a certain disease. We propose to administer hpx to patients 
suffering from the aforementioned diseases. Also, the induction of nrf2 or HO signaling or 
administration of HO-effector molecules forms an interesting strategy to skew towards 
protection (109, 110).  
Summarizing, the amount of the heme scavenger hpx plays a decisive role in 
discriminating between heme acting as a danger signal or heme-hpx acting as TSF. However, 
the exact role of hpx in the protection against heme-mediated toxicity needs to be further 
confirmed in clinical settings (86). Thus, besides the direct protective effects of hpx in 
shielding the bioreactive and pro-inflammatory heme, the heme-hpx complex can also act 
as secondary messenger (TSF) and activate tissue protective signaling pathways. 
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CO Carbon monoxide 
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Synopsis of the problem 
 
In the Western world, an orofacial cleft is surgically treated at an early age which leads to 
scar formation (1). Unfortunately, exposure of healing wounds to oxidative and 
inflammatory stimuli together with mechanical stress in a growing child may exacerbate 
scar formation (1, 2). Scar formation after CL/P repair may lead to functional problems, 
including hampered growth of the maxilla and velopharyngeal dysfunction resulting in 
speech difficulties (3, 4). Similar biological processes that are important during 
palatogenesis and development of CL/P also play a crucial role in cutaneous wound repair 
(5). Therefore, this thesis aimed to better understand the molecular and cellular 
mechanisms that discriminate between tissue repair and tissue regeneration.  
We postulated that decreased activity of protective pathways impairs wound 
repair and palatogenesis, whereas induction of protective signaling cascades, provides a 
regenerative microenvironment that improves wound repair and regeneration. 
In this thesis, several protective strategies were explored to find the decisive 
factors that determine the outcome of tissue repair by studying developmental, 
inflammatory, preconditioning and wound repair processes. More specifically, in part I, the 
effects of decreased protective mechanisms on wound repair and palatogenesis were 
studied. In part II, the role of inducing protective mechanisms on stem cell survival and 
wound repair was investigated, aiming at new therapeutic strategies towards tissue 
regeneration and developing a novel “tissue survival theory”. 
Next, the main findings of this thesis are discussed, elaborating on the 
consequences for future research and possible therapeutic strategies. 
 
Similarities between processes taking place during wound repair and palatogenesis 
 
Accumulating evidence shows that palatogenesis and the wound healing process 
encompass many overlapping biological processes (5).  
CL/P occurs, as the palatal shelves and/ or lip do not entirely fuse during 
embryogenesis. Processes that orchestrate palatal fusion include the mobilization of (stem) 
cells, cell proliferation and differentiation, migration of cells towards the fusion edge, and 
disintegration of the midline epithelial seam (MES) by epithelial-to-mesenchymal transition, 
migration or apoptosis of the epithelial cells, followed by remodeling of the extracellular 
matrix (ECM) (6-9). During cutaneous wound repair, leukocytes, mesenchymal cells (e.g., 
fibroblasts), and stem cells are recruited into the wound area, and keratinocytes migrate 
and re-epithelialize the damaged tissue (10). Fibroblasts can proliferate and differentiate 
into myofibroblasts, and subsequently, synthesize and remodel the ECM and eventually go 
into apoptosis. And hence, similar processes that are crucial for palatogenesis also control 
cutaneous wound repair (5). Epithelial-mesenchymal crosstalk and chemokine signaling 
play an important role herein. In both palatogenesis and wound repair, the final aim is to 
(re)generate the tissue. Not surprisingly, many genes associated with CL/P development are 
also essential during wound repair and scar formation (e.g., IRF6, PDGF-C, TGF-β3, 
RhoGTPase activating protein 29, and Sonic hedgehog) (5).  
Inflammatory and oxidative stress both promote CL/P and scar formation (11-16). 
The importance of suppressing inflammatory and oxidative stress for both preventing CL/P 
and improving wound repair is further strengthened by observations that embryos heal 
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wounds with reduced scar formation by an attenuated inflammatory response (17-19). 
Controlling the inflammatory and oxidative components may therefore be crucial during 
hampered palatogenesis and wound repair (1). Likely, the importance of this control will 
not be limited to these indications, but probably also plays a role in patients with higher 
levels of oxidative stress and inflammation, such as diabetes, infections, obesity, or elderly 
people (20-22). We postulated that decreased activity of protective pathways exacerbates 
wound repair and developmental problems, whereas induction of protective signaling 
pathways, with a focus on the resolution of oxidative and inflammatory stress, will provide 
a regenerative environment leading to improved wound repair. 
 Notably, there are environmental differences between skin and oral tissue, e.g., 
temperature, moisture environment, and microflora. Although both the oral mucosa and 
skin consist of stratified epithelium, anatomical differences exist with the oral mucosa 
covering bony tissue (hard palate) and muscle (soft palate) and the presence of taste buds, 
whereas the skin epithelium holds sweat glands and hair follicles (19, 23). Despite these 
differences, inflammation and oxidative stress remain important in the healing process of 
both tissues. However, the inflammation phase is less pronounced in oral wound repair with 
less influx of neutrophils, macrophages, and T-cells and differential expression of cytokines 
such as TGF-β and VEGF (24, 25). Interestingly, oral wounds heal more rapidly than skin 
wounds and with less scar formation (19, 24-29). Additional factors that could explain this 
include the moisture microenvironment in the oral tissue with saliva, accompanied by the 
presence of pro-healing factors such as histatin and growth factors, or enhanced cellular 
proliferation resulting in a quicker re-epithelialization in oral tissue, supporting a more 
regenerative environment (19, 24-29).  
 
Part I: Decreased protective pathways during natural wound repair and palatogenesis 
 
HO during excisional wound repair 
 
The important role of HO-1 has been demonstrated in models of tissue injury and HO 
improves tissue repair by its anti-oxidative and anti-inflammatory effects (30-32). Inducing 
HO-1 expression accelerates cutaneous wound repair, whereas absence or inhibition of HO-
1 attenuates wound repair (33, 34). Although the role of HO-2 has been much less 
investigated than HO-1, it was shown that the absence of HO-2 leads to slower corneal 
wound repair (35-38).  
The role of HO-2 in excisional skin wound repair was not yet investigated and is 
discussed in Chapter 2 of this thesis.  
We reported that excisional skin wound repair was delayed in HO-2 knockout mice, 
despite the absence of differences in inflammation, and independent of HO-1 expression. 
Reduced collagen deposition and angiogenesis was found in HO-2 KO mice, and may be 
associated with the delay in CXCL11 expression in these mice compared to WT mice. 
Decreased expression of CXCL11 and its receptor CXCR3 has been demonstrated to result 
in delayed wound healing and disturbed angiogenesis (39-43). Our study is the first 
describing basal HO-2 expression to be important for cutaneous wound repair and provides 
critical insight into the wound healing mechanism. Analyzing genetic polymorphisms of HO-
2 or whether the expression is down-regulated in patients suffering from impeded wound 
repair may give insight into what is going wrong. Since HO-2 is hardly pharmacologically 
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inducible, the inducible HO-1 isoform or HO-effector molecules can be used as an 
alternative for therapeutic application (44). To translate our findings to embryogenesis, we 
next studied the role of HO and CXCL11/CXCR3 in craniofacial and palatal development. 
 
Palatogenesis  
 
To gain more insight into the etiology of CL/P, we need to understand the biological 
mechanisms during palatogenesis better.  
In Chapter 3, the molecular process of palatogenesis was studied in more detail 
using WT and HO-2 KO mice. Since the palate normally develops between day 10-15 of 
intrauterine gestation in mice, we investigated the development and palatogenesis at day 
15 and 16 of the embryos since the palates then usually should have been fused. 
We showed that the offspring of HO-2 KO mice had more malformations compared 
to WT mice and are behind in growth at day 15 of embryological development. In both WT 
and HO-2 KO mice, multiple apoptotic fragments were found within the MES, which were 
taken up by macrophages, indicating that apoptosis plays a principal role in the 
disintegration of the MES. CXCL11 was strongly expressed in the MES, suggesting that this 
caused the recruitment of CXCR3-positive macrophages. Since macrophages in HO-2 KO 
mice located around the MES have increased expression of HO-1 compared to those in WT 
mice, a compensatory mechanism is suggested, dealing with the oxidative stress as a result 
of the absence of HO-2.  
The lack of effect in the absence of HO-2 on palatogenesis may be related to the 
absence of an inflammatory trigger. There is no need for the fire brigade when there is no 
fire. It would be interesting to follow this up with research in a more stringent model (e.g., 
following the induction of diabetes), since this may lead to a more substantial effect on 
palatogenesis. Taken together, HO and the CXCL11/CXCR3 axis play an important role in 
embryogenesis and facilitating palatal fusion. Previously, it was demonstrated that HO-2 is 
down-regulated in murine and human pathological pregnancies and may lead to enhanced 
levels of free heme that subsequently elevates an inflammatory response (45, 46). HO was 
proposed as a putative therapeutic target in immunological pregnancy complications (47). 
Whether the induction of HO-1 can be used as a therapeutic approach to prevent CL/P 
formation is under active investigation. Currently, our research group evaluates whether 
administration of different doses of heme during pregnancy in mice leads to craniofacial 
malformations and whether this can either be worsened by inhibition of HO-activity or be 
rescued by HO-1 induction. When successful, this could give new therapeutic strategies 
preventing CL/P formation. 
 
Mechanical stress during excisional wound repair 
 
Understanding the wound healing process is important for different patient groups with 
tissue injuries, such as those with diabetes, obesity, trauma injuries, burn wounds, cancer, 
and CL/P after cleft surgery (48). Experimental wound healing studies in humans are limited 
due to ethical and practical obstacles, such as scarcity of wound biopsies due to the painful 
procedure and risk of infection and scarring (49). Wound repair models in animals are 
therefore often used to investigate the molecular mechanisms behind wound repair.  
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There are several in vivo models that can be used to study the different aspects of 
wound repair. Although the skin characteristics of humans are more related to the pig (48, 
50), murine models have many advantages. Rodents are small, easy to handle, and relatively 
cheap, but most importantly their genome is similar to the human genome and transgenic 
rodents are widely available and relatively easy to develop due to the short reproduction 
time (50, 51). Using knockout or transgenic rodents, e.g., HO-2 KO mice and HO-1 luc tg 
mice, makes it possible to investigate molecular mechanisms in more detail. A difference 
between murine and human wound healing is that wound contraction in mice is primarily 
mediated by the musculus panniculus carnosus underneath the murine skin which is lacking 
in humans (50, 52, 53). Wound healing in humans is mainly based on granulation tissue 
formation and re-epithelialization (50, 52, 53).  
In Chapter 4 of this thesis, we described a splinted excisional wound model in mice, 
which is more closely related to human wound repair. In this model wound contraction by 
the musculus panniculus carnosus is inhibited by a splint, which leads to static mechanical 
stress on the healing wound by the difference in force between the muscle and the splint. 
Similarly, mechanical stress is also experienced on the healing palate in surgically operated 
CL/P patients and wound repair, which is exacerbated during growth and results in scar 
formation. The basal expression of the protective HO-1 enzyme in this mechanical stress-
induced splinted wound repair was investigated using HO-1 luciferase mice.  
In brief, splinting delayed excisional wound repair. Splinting-induced mechanical 
stress induced more HO-1 gene expression in 7-day wounds; however, HO-1 protein 
expression remained lower in the epidermis, likely due to a lower number of keratinocytes 
in the re-epithelialization tissue. Higher numbers of macrophages, myofibroblasts, and 
increased levels of inflammatory genes in 7-day splinted wounds, indicate an elevated or 
extended pro-inflammatory microenvironment. Mechanical stress because of splinting 
delays wound repair and induces a pro-inflammatory environment that may explain the 
higher number of myofibroblasts and subsequently increases the risk of fibrosis. This 
splinted wound model simulates surgically-treated cleft palate wound repair. Although HO-
1 was expressed in both splinted and non-splinted wounds, the lower HO-1 protein 
expression in splinted wounds suggests that inducing HO-1 activity may form an interesting 
strategy for attenuating inflammatory and fibrotic processes caused by mechanical stress. 
Also, administration of HO effector molecules may form a possible therapeutic option, as 
both CO and bilirubin can enhance wound repair (54-56).   
 
Part II: Activation of protective mechanisms to enhance tissue regeneration 
 
Part II was divided into three chapters. Chapter 5 showed that pharmacological 
preconditioning can improve mesenchymal stem cell survival. In Chapter 6, we investigated 
the effects of remote ischemic preconditioning (RIPC) on wound repair. Lastly, Chapter 7 
describes the possible molecular mechanism that discriminates between tissue survival and 
activation of the immune system. 
 
Mesenchymal stem cells in tissue repair 
 
A novel therapeutic approach in a plethora of disease settings is the administration of stem 
cells. Administration of mesenchymal stem cells (MSC) forms a promising adjuvant 
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treatment to improve wound repair and to prevent scarring (12, 57-60). Stem cells can 
differentiate into different cell types and are crucial during embryogenesis, palatogenesis, 
and repair of injured tissue. In addition to their pluripotency, stem cells excrete paracrine 
factors that improve wound repair (61-63). Many studies are showing that MSC 
administration during wound healing is effective and contributes to an enhanced wound 
repair and proper skin restoration during all phases of wound healing in both pre-clinical 
and clinical settings (64-67). The exact mechanism is unknown, but paracrine effects are 
likely more important than cell replacement and differentiation for the therapeutic effects 
(68, 69). Injection of solely the conditioned media derived from MSCs can already improve 
wound repair, suggesting that the paracrine factors exert the principal protective 
mechanism of action (70-72). Since the administration of MSCs to one side of a two-sided 
excisional wound model, improved wound repair to both sides, this suggests a systemic 
effect, which could not be explained by cell differentiation (73). Protective paracrine factors 
of MSCs improve wound repair by enhancing cell viability and proliferation, attenuating 
oxidative and inflammatory signals, improving angiogenesis, and improving mobilization/ 
attraction of reparative cells (69, 70, 74, 75). 
Unfortunately, administered MSCs die quickly upon administration and are only 
limited incorporated into the injured tissue due to the hostile wound environment 
consisting of oxidative and inflammatory mediators (66, 67).  
Improving MSC survival at the place of injury may further enhance the protective 
effects as these cells can continue to produce paracrine factors for prolonged periods and 
create a pro-healing regenerative wound microenvironment. 
 
HO-1 is a promising target to improve MSC therapy in tissue repair 
 
Systemic administration of MSCs may reduce the direct lethal effects of the hostile wound 
environment on the cells and chemokines from the injury site may direct the cells by cell 
migration (66, 76, 77). However, less than 1% of systemically administered MSCs may 
persist at the injury site after seven days (59, 78), maybe because access from the circulation 
to the wound site may be hampered by damaged blood vessels and disorganized tissue and 
inhibit MSC therapy efficacy (66). The limited migration of stem cells to the site of injury 
after systemic administration, together with the low MSC survival, constitute the main 
complications of systemic MSC therapy (59, 78). 
We postulated that the outcome of stem cell therapy can potentially be further 
improved by inducing cytoprotective mechanisms. HO has anti-apoptotic, anti-oxidative, 
and anti-inflammatory effects and forms a promising candidate. It was found that HO-1 has 
a prominent role in MSC therapy (79-82). MSC secrete a variety of paracrine factors, of 
which HO-1 critically determines the outcome. Paracrine factors excreted by MSCs from WT 
mice protected against kidney injury after intraperitoneal administration of MSC-derived 
conditioned media, whereas conditioned media of MSCs derived from HO-1 KO mice did 
not provide protection (81). Furthermore, modulating MSC by transfection or chemical 
inducers or inhibitors of HO affect the therapeutic paracrine effects of the MSC (79-82).  
Interestingly, it was shown that HO-1 is upregulated in various tissues after MSC 
therapy, which had a beneficial effect on the function of the different injured organs (83-
87). In addition, induction of HO activity during MSC therapy in the stem cell and 
systemically in the organism further increased the anti-apoptotic, anti-inflammatory and 
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anti-oxidative effects of MSC therapy, and this was significantly attenuated when HO-
activity was inhibited (79, 82, 83, 88, 89). Moreover, angiogenesis and cell migration are 
increased after HO-induction in several animal models (83, 90, 91). All these processes are 
intricately involved in wound healing and create a more friendly wound microenvironment 
and stimulate wound repair. Thus, HO improves the power of MSC therapy by addressing 
the problems that are causative for pathologic wound repair, which ultimately leads to 
better tissue regeneration. 
 
Curcumin induces HO-1 and MSC survival and can be used for wound repair 
 
Since ancient Egyptian times, vegetable substances have been applied to skin wounds, and 
substances such as curcumin are still used to investigate the effects on wound repair (92). 
Curcumin has shown to be beneficial in skin diseases, such as scleroderma, psoriasis, and 
skin cancer, but also enhances normal and impaired wound repair by improving collagen 
deposition, and increasing fibroblast and vascular density in wounds (93, 94). These effects 
are orchestrated by the activation of cytoprotective genes (nrf2, HO-1), and its downstream 
anti-inflammatory and anti-oxidative effects (95, 96). 
 In Chapter 5 of this thesis, we report the results of investigations on the effects of 
curcumin on MSC survival. Curcumin is found to be a potent inducer of HO-1 and provide 
protection against oxidative stress mediated by hydrogen peroxide as shown by the 
increased survival of curcumin pre-treated MSCs when exposed to hydrogen peroxide. This 
protection was prevented when HO-activity was specifically inhibited, pointing to a direct 
protective effect of curcumin via HO-1. Pre-treatment with CO-releasing molecules 
(CORMs) showed that the HO-effector molecule CO could also protect against oxidative-
stress-induced cell death. Altogether, this study demonstrated that preconditioning of 
MSCs improves cell survival and suggests that pre-treatment of MSCs before administration 
may improve MSC therapy outcome.  
Administration of stem cells or its secreted protective paracrine factors forms an 
attractive therapy to improve wound and tissue repair and regeneration. Induction of HO-
1, e.g., by curcumin, or exposure to HO-effector molecules, such as CO, may enhance the 
production of beneficial paracrine factors and may enhance stem cell survival. 
Preconditioning techniques may further improve the beneficial effects of MSC therapy by 
creating a microenvironment that harnesses inflammatory and oxidative stress and 
increases the survival of locally present and administered MSCs. More research is needed 
to investigate whether MSC therapy can be used therapeutically for CL/P patients. 
 
Remote ischemic preconditioning (RIPC) 
Effects of RIPC on wound repair 
 
In contrast to most medicinal drugs, RIPC is a non-invasive, inexpensive and safe approach, 
and hence, clinical trials are performed in diverse disease settings. Although the exact 
mechanism of action still has to be further elucidated, RIPC shows promising pre-clinical 
and clinical results in the field of organ transplantation and cardiovascular diseases by 
inhibition of oxidative and inflammatory insults (97, 98).  
Since oxidative and inflammatory stress plays an important role in CL/P formation 
and wound repair and can be inhibited by RIPC, we next investigated if RIPC could improve 
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wound repair following excisional skin injury. In parallel, we assessed whether HO-1 is 
induced upon RIPC treatment. These studies are described in Chapter 6 of this thesis. 
 Unfortunately, both early and late RIPC did not affect excisional wound repair in 
mice. Interestingly, we observed that RIPC induced HO-1 expression in several organs, 
including skeletal muscle, kidney, and heart, but not in the skin. This suggested that the 
protection mediated by RIPC may act via HO-1, as organs that were previously shown to be 
protected by RIPC (heart, muscle, and kidney), upregulated HO-1 expression, in contrast to 
the skin where no protection was observed. Interestingly, survival of transplanted skin flaps 
was increased when RIPC treatment was applied (99), indicating that RIPC can have 
protective effects in the skin as well. Also, other studies showed that RIPC improves 
microcirculation by an increase in tissue oxygenation and capillary blood flow in the skin 
(100) and skin flaps (101). Other RIPC regimens than the ones we used may be more 
efficient, and other molecular pathways may be involved or may be affected at different 
time-points. RIPC may have therapeutic effects in other wound models. For example, it was 
found that RIPC significantly improves the healing of diabetic foot ulcers (102, 103). In 
addition, there is an ongoing clinical trial where the protective effects of RIPC on the 
microcirculation and pathological wound repair, including burns, non-healing wounds, and 
skin grafts are investigated in more details (clinicaltrials.gov identifier: NCT02417805). 
  
Implications of RIPC to prevent CL/P  
 
RIPC has shown protective effects in several oxidative and inflammatory stress models. 
Since these same conditions increase the risk of CL/P, application of RIPC may act 
protectively against CL/P development. Hereto, RIPC should be applied at the moment or 
before the crucial phases of palatogenesis; e.g., day 10-15 of pregnancy in mice, or week 8-
10 during human embryonic development. In this way, the incidence of CL/P may be 
decreased in women with imminent risk (e.g., having diabetes, obesity, infections, or older 
age) (13-16).  
Moreover, in CL/Fr mice that are genetically predisposed to develop CL/P, 
oxidative stress has shown to be important in affecting the incidence of CL/P (104). Under 
normal conditions, CL/Fr mice spontaneously develop CL/P in 37% of the fetuses. 
Interestingly, when these pregnant mice were exposed to hyperoxic conditions for 24h at 
day 10 of gestation, only 13% of their progeny developed CL/P, whereas exposure to 
hypoxia increased the incidence of CL/P to 89% (104). A similar experimental setup can be 
used to investigate the protective effects of RIPC on the incidence of CL/P. 
RIPC treatment creates short-term hypoxic stress, which subsequently can protect 
against secondary stronger stresses (such as is experienced during CL/P formation). RIPC as 
preconditioning to prevent CL/P formation is still promising and needs further investigation, 
e.g., by applying RIPC shortly before the process of palatogenesis which finishes around day 
15, thus e.g., sometime around day 10-14 in pregnant CL/Fr mice. 
 
Molecular mechanisms of tissue protection 
 
Following injury, the immune system is activated to eliminate pathogenic invaders (105). 
The “danger model” of Matzinger proposed that the immune system only becomes 
activated after a danger signal, such as nucleic acids, heat-shock proteins, or heme, is 
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detected by Toll-like receptors (TLR), which subsequently warn leukocytes (106-108). We 
propose here that there are also signals that can warn the tissue for upcoming danger, and 
act as tissue survival factor (TSF). 
 Therefore, in Chapter 7 we proposed a “tissue survival theory” describing that 
heme scavenging is a discriminating factor between tissue survival and immune activation. 
We used RIPC as a model to present our theory. After RIPC treatment, heme levels are 
slightly but significantly elevated. We postulated that in the presence of hemopexin (hpx), 
heme is directly scavenged and this TSF then binds to the LRP-1 receptor, which via e.g., 
nrf2 can activate cytoprotective genes, such as HO-1 and PRDX1. RIPC indeed induced HO-
1 mRNA and protein expression in the skeletal muscle, kidney, and heart, and HO-1 was co-
expressed with LRP-1 in the cells of the heart. When hpx is exhausted, high levels of free 
heme can bind to TLR-4 and via NF-ΚB can induce pro-inflammatory genes, such as TNF-α 
and ICAM-1. This theory is further supported by various pathological conditions, including 
IRI, hemoglobinopathies, hematoma, hemorrhage, and muscle injury, where large amounts 
of free heme and heme-proteins are found after hemolysis or rhabdomyolysis and act 
harmful (109-112).  
RIPC has shown to protect against several pathological conditions, such as heart 
failure, kidney injury and improves the outcome after organ transplantation (113-116). 
However, results are not always consistent (117-120), and not every tissue and organ is 
protected following RIPC, such as in our study during cutaneous wound repair (121). This 
tissue-specific protection may depend on the function of the tissue. Skin is most frequently 
affected by inflammation by continually being exposed to microbes, which may elevate 
tissue tolerance and make skin less responsive towards internal stressors (22, 122). 
However, this could not explain why RIPC improved wound repair of diabetic foot ulcers. A 
difference with excisional wound repair may be that short following injury heme is 
abundantly released, which results in a pro-inflammatory response that is necessary to 
attract leukocytes and clean up wound debris (123, 124). Hpx that is locally present will then 
quickly be exhausted and not cause fast enough tissue protection, because the excess of 
heme binds to TLR-4, acts pro-inflammatory and can cause damage. Our model is further 
supported by the observation that treatment with heme before renal ischemia-reperfusion 
injury reduced renal damage, while treatment after IRI worsened the renal damage (125). 
This suggests that small amounts of heme only act protectively when it can be in complex 
with hpx. When hpx is depleted, heme will activate TLR-4 and aggravate injuries. 
 In summary, heme scavenging discriminates between activating tissue survival or 
alerting the immune system. This theory may be relevant in a plethora of diseases, and 
therapies using administration of small amounts of heme as preconditioning strategy, or 
administration of hpx, which as TSF activate protective signaling and skews away from TLR-
4-induced inflammation. 
 
Solving part of the puzzle: Novel therapies to transform tissue repair into regeneration 
 
Inflammatory and oxidative stress leads to the release of danger signals, also known as 
damage-associated molecular patterns (DAMPS), pathogen-associated molecular patterns 
(PAMPS), or alarmins, such as heme, heat shock proteins, and S100 proteins (126-128). 
These danger signals can activate the immune system, leading to the mobilization of for 
example granulocytes and macrophages (128). In addition, these danger signals can bind to 
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cell receptors, such as TLRs, and activate pro-inflammatory stress responses that damage 
the tissue (128, 129). Tissue can have different reactions against external stresses, and this 
originates from the difference in tolerance between individuals (Figure 8.1). Everybody has 
a different response (c.q. tolerance) to injurious stressors because of differences in genetic 
makeup, diseases, drug use, age, and behavior (122, 130). The difference in tolerance 
causes that each individual will respond differently to danger signals (122, 130). The use of 
gene knockout makes it possible to investigate the contribution of a specific gene (131). For 
example, it has been shown that the lack of HO activity makes tissue more prone to tissue 
damage, and thus less tolerant towards injurious stresses. Low tolerant cells may have less 
expression or are depleted of protective molecules and molecular protective pathways. 
Exposure of these low tolerant cells to inflammatory and oxidative stress results in tissue 
damage and disease predisposition. In contrast, high tolerant cells may have more 
expression of protective molecules, such as HO-1, making them less susceptible to tissue 
damage. Preconditioning strategies or activation of TSFs may enhance the tolerance of cells 
and make them better equipped to fight off injurious stressors (Figure 8.1A). 
 Preconditioning is a method to induce tolerance and prepare tissue against 
following stresses, in this way harnessing the stress signals and preventing tissue damage 
(130, 132). For example, stimulation of the heme-hpx complex formation can activate the 
LRP-1 receptor leading to the intracellular production of the cytoprotective HO-1. This 
protects the cell against damage and apoptosis. When cells get older, their repair strategies 
get easier exhausted, leading to cell damage and eventually apoptosis. Stem cells can be 
mobilized to the injured tissue and restore and rejuvenate the damaged cells (133). This 
offers therapeutic potential for (mesenchymal) stem cell therapy. However, the stringent 
microenvironment under inflammatory and oxidative stress makes the stem cells 
vulnerable to cell death (59, 78).  
Therefore, preconditioning strategies may further improve the efficacy of stem cell 
therapy (Figure 8.1B). As discussed, this may be achieved by inducing protective pathways, 
such as HO-1, which enhances the protection against external stressors and thereby the cell 
survival (79-82). Moreover, these stem cells can also produce paracrine factors that protect 
their surroundings (61-63). Ideally, the tolerance of the cells must be elevated, preparing 
them for stress and leading to improved cell survival, with the ultimate outcome being 
tissue regeneration. Preconditioning strategies form an attractive option to induce tissue 
survival signals and obtain tissue regeneration. 
 
Clinical relevance for CL/P patients? 
 
Having presented these pre-clinical data, we will now address their possible clinical 
implications. We showed that the lack of protective enzyme systems can promote fetal 
malformations and hampered wound repair (134, 135). In contrast to animal studies using 
specific strains, patients have their own immune system, and the large differences in 
genetics and different exposure to environmental factors between patients make it difficult 
to translate data from animal experiments to the clinic directly (136-138). However, despite 
these translational drawbacks, having the same genetic background (e.g., HO-2 KO mice) 
and standardized environmental factors in animals and in vitro models, makes it possible to 
specifically study the mechanistic contribution of one or a couple of variables in a more 
causal manner (139).  
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Figure 8.1: Tissue tolerance 
A). Inflammatory and oxidative stress leads to the release of danger signals that can activate the immune system 
or directly bind to the cells of the tissue where it promotes injury. Every individual has a different genetic makeup 
and defense against oxidative and inflammatory stressors as a result of illness (e.g., diabetes, infections or age) 
resulting in differential tolerance towards injurious stressors. Cells with decreased tolerance towards oxidative and 
inflammatory stress because of depletion or shortage of anti-oxidant and anti-inflammatory molecules, such as in 
diabetes patients and aged people, are more prone to injury than cells with enough cell protective enzymes. Pre- 
and post-conditioning strategies or induction of tissue survival factors (TSFs) could restore tolerance against 
injurious stressors. For instance, RIPC results in the release of heme, which upon scavenging by hemopexin (hpx) 
forms the heme-hpx complex that as TSF can activate LRP-1 receptors, and lead to the production of the 
cytoprotective enzyme HO-1. Note: hpx should be present or co-administered to achieve cytoprotection. B). 
(Mesenchymal) stem cells produce protective paracrine factors and can renew damaged cells and improve tissue 
repair. Under stressful conditions (e.g., inflammatory or oxidative stress in the wound area), MSCs or tissue may 
die, or lead to low tolerant new cells. However, after preconditioning, cytoprotective systems as HO-1 are also 
induced in these stem cells, which may lead to high tolerant stem cells and increased production of protective 
paracrine factors. These high-tolerant stem cells will then replace damaged tissue and produce paracrine 
protective factors, resulting in tissue regeneration.  
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 Preconditioning of stem cells by induction of HO-1 before inflicting oxidative stress 
resulted in improved stem cell survival (79). Although this data is based on in vitro evidence, 
enhanced survival of local stem cells in wound regions or after administration in stem cell 
therapy may offer better perspectives for the repair and regeneration of damaged tissue 
and could be promising as adjuvant therapy following CL/P surgery.  
Our findings showed that RIPC did not directly contribute to enhanced cutaneous 
wound repair. However, we observed that HO-1 was remotely induced in different organs 
like the kidney and the heart (121). Interestingly, other studies showed that RIPC can act 
protectively in ischemia-reperfusion injury of these remote organs (113-116), and therefore 
we argued that local heme levels upon wounding may be too high to induce protective HO-
1 expression in cutaneous excisional wound repair.  
Our “tissue survival model” describes that heme can play the discriminating factor 
between tissue survival and immune activation. RIPC leads to the release of small amounts 
of heme, that scavenged by hpx form a tissue survival factor (TSF). This TSF can bind to LRP-
1 and induce nrf2 responsive cytoprotective HO-1 signaling, which will warn the tissue 
against injurious stressors. When the scavenger hpx is exhausted, heme will be available for 
binding to TLR-4 and activate immune responses. Attracted leukocytes will excrete more 
pro-inflammatory signals that lead to collateral damage. Therefore, we propose hpx 
administration as novel therapeutic strategy that skews towards tissue protection via LRP-
1 mediated HO-1 signaling for a diversity of pathologies, including heme-mediated diseases 
such as sickle cell disease, malaria, sepsis, fibrosis, but also during inflammation-mediated 
pathologies such as burn wounds, diabetes, pathological pregnancies, and after CL/P 
surgery. Since the TSF heme-hpx complex acts via induction of HO activity, it is also an 
option to pharmacologically induce HO-1 or administer HO-effector molecules, such as CO 
and bilirubin. Typically, treatments start after suffering from a disease, but when damage is 
expected, e.g., following a planned (CL/P) surgery, preconditioning strategies may be a 
better alternative to prevent (collateral) tissue damage. Also, preconditioning can be done 
in high-risk women for having a child with a cleft, and in such cases, the development of 
CL/P and its associated problems might be prevented. However, since our models are 
mainly based on animal studies, more research is needed first. Translational studies and 
clinical trials that further confirm our findings need to be performed. 
There is evidence that the induction of cytoprotective pathways may protect tissue 
against oxidative and inflammatory stress and lead to tissue tolerance. Therefore, RIPC, 
MSC therapy, and the proposed novel pharmacological therapies mentioned above that 
harness inflammatory and oxidative stress during wound repair and palatogenesis should 
be further explored. 
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Chapter 9  
 
Summary 
212 
Chapter 1 introduces the topic of cleft lip and/ or palate (CL/P), its incidence and related 
problems, the process of palatogenesis, and the etiology and treatment strategies of CL/P. 
The close similarity between biological processes involved in palatogenesis and wound 
repair was discussed. We postulated that the balance between injurious and protective 
signaling determines wound repair, the level of scar formation, and the risk of congenital 
abnormalities, such as CL/P. Therefore, we split this thesis into three parts:  
 
I). Decreased protective mechanisms hamper tissue repair and craniofacial development, 
II). Activation of protective mechanisms to enhance tissue regeneration, and  
III). General discussion and Summary 
 
Part I consists of three studies investigating the effects of decreased protective mechanisms 
on wound repair and palatogenesis.  
Chapter 2 evaluated the contribution of the cytoprotective enzyme heme 
oxygenase (HO) during excisional wound repair using HO-2 knockout (KO) and wild-type 
(WT) mice. HO-1 has previously shown to be very important during wound repair and 
embryonic development, and lack of HO-1 results in severe problems. The mild phenotype 
in HO-2 KO animals results in attenuated corneal wound repair, but more data investigating 
the role of HO-2 in other morbidities is scarce. Here, we showed that lack of HO-2 expression 
resulted in hampered wound repair, and reduced collagen deposition and vessel density 
when compared to WT mice. Although there were no differences between the two 
genotypes in inflammation, HO-1 expression, and proliferation and differentiation of 
myofibroblasts, CXCL11 expression was delayed in HO-2 KO mice. Abnormal CXCL11 
regulation has been linked to hampered wound repair and disturbed angiogenesis. This may 
help explain the observed hampered wound repair following HO-2 depletion. 
In Chapter 3, the disappearance of the midline epithelial seam (MES), a crucial 
process during palatal fusion and CL/P formation, was investigated. During palatogenesis 
several processes are similar to wound repair processes, including mesenchymal-epithelial 
cross-talk, chemokine signaling, and cell proliferation, differentiation and apoptosis. 
Therefore, we postulated that chemokine CXCL11, its receptor CXCR3, and HO, which all are 
important factors during wound repair, also play a decisive role during palatogenesis. The 
contribution of HO-2 in this process was studied using HO-2 KO and WT mice. HO-2 KO 
embryos at day 15-16 of intrauterine gestation suffered from fetal growth restriction and 
craniofacial abnormalities, but had no problems with palatal fusion. In both WT and HO-2 
KO mice, CXCR3-positive macrophages were recruited towards the CXCL11 expressing MES, 
and contained multiple apoptotic DNA fragments, supporting the hypothesis that the MES 
was disintegrated by epithelial apoptosis. Since macrophages located near the MES were 
HO-1 positive, and more HO-1 positive cells were present in HO-2 KO mice, HO-1 induction 
forms likely a compensatory mechanism to handle oxidative stressors. HO and 
CXCL11/CXCR3 signaling play thus also an important role in embryogenesis and palatal 
fusion. 
In Chapter 4, since CL/P patients after cleft surgery experience mechanical stress 
during wound repair from myofibroblasts and the growing head, static mechanical stress 
was induced in a mouse model, to simulate the increased injurious environment and the 
effects of decreased protective pathways. Mechanical stress during wound repair was 
applied using a splinted excisional wound model. HO-1 is thought to orchestrate the defense 
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against inflammatory and oxidative insults that drive fibrosis, and therefore we investigated 
the activation of the HO-system in splinted and non-splinted excisional wound models using 
HO-1 luc transgenic mice. These mice co-express luciferase when HO-1 gets induced, which 
can be measured in vivo by administration of the substrate luciferin which results in the 
release of photons. After seven days, splinting had delayed cutaneous wound closure and 
HO-1 protein expression, whereas the number of F4/80-positive macrophages, αSMA-
positive myofibroblasts, and pro-inflammatory signals IL-1β, TNF-α, and COX-2 were 
increased after application of mechanical stress. The pro-inflammatory environment 
following splinting may explain the higher myofibroblast numbers and increased risk of 
fibrosis and scar formation when compared to non-splinted wounds. 
 
Part II consists of three studies investigating the effects of activation of protective pathways 
using preconditioning strategies on mesenchymal stem cell (MSC) apoptosis, wound repair, 
and organs. In the latter study, we designed a novel “tissue survival theory” that could help 
explain how tissue gets first warned by tissue survival factors (TSFs) following injurious 
insults. 
Chapter 5 investigated the effects of the cytoprotective HO-system on MSC 
survival following pharmacological preconditioning. MSC therapy is considered a promising 
strategy for a wide diversity of injuries and diseases. However, the survival of MSCs after 
administration is limited due to the hostile wound microenvironment displaying an 
accumulation of oxidative and inflammatory stressors. A prolonged MSC survival by 
preconditioning strategies could improve their therapeutic efficacy. In this study, the anti-
oxidative and anti-apoptotic effects of HO-1, HO-2 and its effector molecules were 
investigated on adipose-derived MSC (ASC) survival. HO-1 was induced following curcumin 
treatment, and this provided potent protection against oxidative stress, which was 
mediated by hydrogen peroxide (H2O2). This protection was abrogated by simultaneous 
treatment with the selective HO-1 activity inhibitor QC15, supporting an HO-1-dependent 
protective mechanism. Also, exposure to anti-oxidant N-acetylcysteine protected against 
H2O2-induced ASC apoptosis, while the HO-effector molecules and anti-oxidants bilirubin 
and biliverdin did not have an effect. Interestingly, HO-effector molecule CO did also rescue 
H2O2-induced ASC death, suggesting that HO-1 provided protection against apoptosis via CO 
signaling. No differences were found between WT, and HO-2 KO derived ASCs in sensitivity 
towards H2O2, or curcumin and HO-effector molecules-mediated protection. Thus, 
induction of cytoprotective molecules by pharmacological preconditioning led to better 
protection against oxidative stress in an in vitro model of stem cell survival.  
Next, in Chapter 6, we analyzed the effects of remote ischemic preconditioning 
(RIPC) on cutaneous tissue injury. RIPC has shown that transient occlusion of the blood flow 
to a limb will induce a stress response that protects the body against a secondary more 
harmful stress, e.g., transplantation and organ injuries. We aimed to improve excisional 
wound repair using early and late RIPC (respectively 5 min and 24h before wounding) and 
investigated the role of HO-1 using HO-1 luc transgenic mice. HO-1 promotor activity was 
induced dorsally, and locally in the kidneys, following RIPC treatment. On mRNA level, HO-
1 was increased in the ligated muscle, heart, and kidneys, but surprisingly not in the skin. 
Early and late RIPC did not change HO-1 mRNA and protein levels in the wounds seven days 
after cutaneous injury, nor did it accelerate cutaneous wound closure or did it affect 
collagen deposition. Thus, the used RIPC protocol induces HO-1 expression in several 
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organs, but not the skin, and did not improve excisional wound repair, suggesting that the 
skin is insensitive to RIPC-mediated protection. However, other studies showed that RIPC 
improved transplanted skin flap survival and improved healing of diabetic ulcers. Possibly 
other signals play a decisive role. 
Lastly, Chapter 7 proposes a novel molecular mechanism that explains how the 
tissue is protected from injurious agents or collateral damage following the attack by an 
activated immune system. TSFs mediate tissue protection while danger signals alert the 
immune system. Hemopexin (hpx) can scavenge heme, and form the heme-hpx complex 
that can bind to LRP-1 having a protective effect. When hpx levels are exhausted or 
depleted, the excess of free heme can bind to TLR-4 and alarm the immune system resulting 
in a pro-inflammatory effect. We proposed that the presence of hpx is the discriminating 
factor between tissue repair and tissue damage, and provided a new concept of how RIPC 
can induce protective HO-1 signaling. RIPC led to the release of low levels of heme, and the 
induction of HO-1, which was co-expressed with LRP-1. We propose that systemic 
protection mediated by RIPC is orchestrated via binding of the heme-hpx complex, a tissue 
survival factor (TSF), to LRP-1, subsequently activating protective responses, including HO-
1. Therefore, the binding of heme by hpx may regulate tissue protection or immune 
activation. 
 
In Part III, the most important results of this thesis and their clinical relevance were 
summarized and discussed, and future perspectives for therapeutical approaches were 
proposed. 
 
The induction of cytoprotective pathways, such as HO-1, by pharmacological therapy or by 
application of RIPC or administration of hpx, may harness inflammatory and oxidative 
insults. Therefore, these strategies may prevent  CL/P formation and improve the outcome 
of tissue repair in patients with CL/P or burn wounds. However, more mechanistic and 
translational research is necessary before it can be used in the clinic. 
 
In conclusion, decreased activity of protective pathways can hamper wound repair 
and craniofacial development, whereas induction of protective signaling cascades, with a 
focus on pathways that mediate the resolution of oxidative and inflammatory stress, may 
provide a regenerative microenvironment that improves wound repair and regeneration. 
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Chapter 10  
 
Samenvatting 
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Hoofdstuk 1 introduceert het onderwerp schisis (gespleten lip/ gehemelte (CL/P)), de 
incidentie en gerelateerde problemen, de ontwikkeling van het palatum en de etiologie en 
behandelingsstrategieën van CL/P. De sterke overeenkomst tussen de biologische 
processen die betrokken zijn bij palatogenese en bij wondgenezing werden besproken. We 
veronderstelden dat de balans tussen schadelijke en beschermende factoren de 
wondgenezing, de mate van littekenvorming en de kans op aangeboren afwijkingen zoals 
CL/P bepaalt. Het proefschrift bestaat uit drie delen: 
 
I). Belemmering van weefselherstel en craniofaciale ontwikkeling door verminderde 
beschermende mechanismen,  
II). Verbetering van weefselregeneratie door activering van beschermende mechanismen, 
III). Algemene discussie en samenvatting 
 
Deel I bestaat uit drie studies die de effecten van verminderde beschermende 
mechanismen bestuderen op wondgenezing en craniofaciale ontwikkeling. 
 Hoofdstuk 2 evalueerde de rol van het celbeschermende enzym heme 
oxygenase (HO) tijdens wondgenezing met behulp van HO-2 knockout (KO) en wild-type 
(WT) muizen. Eerder is aangetoond dat HO-1 zeer belangrijk is tijdens wondgenezing en 
embryologische ontwikkeling en dat het ontbreken van HO-1 resulteert in ernstige 
problemen. Het mildere fenotype in HO-2 KO muizen leidt tot vertraagde corneale 
wondgenezing, maar meer gegevens over de rol van HO-2 in andere morbiditeiten zijn 
schaars. Wij hebben hier in een excisioneel wondmodel aangetoond dat gebrek aan HO-2-
expressie resulteert in vertraagde wondgenezing, verminderde collageenafzetting en een 
verlaagde vaatdichtheid. Hoewel er in vergelijking met WT muizen geen verschillen waren 
tussen de twee genotypes betreffende ontsteking, de expressie van HO-1 en proliferatie en 
differentiatie van myofibroblasten, was de expressie van CXCL11 wel vertraagd in HO-2 KO 
muizen. Abnormale CXCL11 regulatie is eerder in verband gebracht met belemmerde 
wondgenezing en verstoorde angiogenese. Dit geeft een mogelijke verklaring voor de 
vertraagde wondgenezing na HO-2 uitschakeling. 
In Hoofdstuk 3 werd de fusie van de epitheliale naad (MES) in het midden van het 
palatum onderzocht. Dit is een cruciaal proces tijdens palatale fusie en CL/P-vorming. 
Tijdens palatogenese zijn verschillende ontwikkelingsprocessen vergelijkbaar met 
wondgenezingsprocessen, waaronder mesenchymale-epitheliale communicatie, 
chemokine signalering en proliferatie, differentiatie en apoptose van cellen. Daarom 
veronderstelden we dat het chemokine CXCL11, zijn receptor CXCR3 en het 
celbeschermende HO, die alle belangrijk zijn tijdens wondgenezing, ook een beslissende rol 
spelen bij het samenvoegen van de MES. De rol van HO-2 in dit proces werd bestudeerd 
met behulp van HO-2 KO en WT muizen. HO-2 KO-embryo’s op dag 15-16 van intra-uteriene 
ontwikkeling lijden aan foetale groeibeperking en craniofaciale afwijkingen, maar hadden 
geen problemen met palatale fusie. In zowel WT- als HO-2 KO-muizen werden CXCR3-
positieve macrofagen aangetrokken door CXCL11 dat in de MES tot expressie komt. Deze 
palatale macrofagen bleken meerdere apoptotische DNA-fragmenten te bevatten. Dit 
ondersteunt de theorie dat de MES wordt gedesintegreerd door apoptose van het epitheel. 
Aangezien macrofagen dichtbij de MES HO-1-positief waren en er meer HO-1-positieve 
cellen aanwezig zijn in HO-2 KO-muizen, dient HO-1 inductie mogelijk als 
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compensatiemechanisme om oxidatieve stress te neutraliseren. HO- en CXCL11/CXCR3-
signalering spelen dus een belangrijke rol bij embryogenese en palatale fusie. 
In Hoofdstuk 4 werd statische mechanische stress geïnduceerd met behulp van 
een spalk als model voor de postoperatieve situatie in CL/P patiënten. Op deze manier 
werden de verhoogde schadelijke omgevingsfactoren en de effecten van verminderde 
beschermende processen tijdens wondgenezing gesimuleerd. Deze mechanische stress 
werd toegebracht met behulp van een spalk in een excisioneel wondmodel. HO-1 speelt 
een rol bij de verdediging tegen inflammatoire en oxidatieve insulten die op hun beurt 
fibrose en littekens veroorzaken en daarom onderzochten we de activering van het HO-
systeem in gespalkte en niet-gespalkte excisionele wonden met behulp van HO-1 luc 
transgene muizen. Deze muizen brengen luciferase tot co-expressie wanneer HO-1 wordt 
geactiveerd. Dit kan in vivo worden gemeten door het substraat luciferine toe te dienen dat 
leidt tot het vrijkomen van fotonen. Na zeven dagen heeft het spalken van de wonden de 
wondsluiting en HO-1 eiwit inductie vertraagd, terwijl het aantal F4/80-positieve 
macrofagen, αSMA-positieve myofibroblasten en de pro-inflammatoire signalen IL-1β, TNF-
α en COX-2 verhoogd waren na blootstelling aan mechanische stress. De pro-inflammatoire 
omgeving die ontstaat ten gevolge van het spalken kan het toegenomen aantal 
myofibroblasten en het verhoogde risico op fibrose en littekens verklaren. 
 
Deel II bestaat uit drie studies naar de effecten van activering van beschermende signalering 
met behulp van preconditioneringsstrategieën op celdood van mesenchymale stamcellen 
(MSC), wondgenezing en organen. In de laatstgenoemde studie hebben we een nieuwe 
“weefsel overlevingstheorie” ontworpen die zou kunnen helpen verklaren hoe weefsel 
eerst wordt gewaarschuwd door weefseloverlevingsfactoren (TSFs) na schadelijke prikkels. 
 Hoofdstuk 5 onderzocht de effecten van het celbeschermende HO-systeem op 
MSC overleving na farmacologische preconditionering. MSC therapie wordt beschouwd als 
een veelbelovende behandeling voor een grote verscheidenheid van verwondingen en 
ziekten. De overleving van MSCs na toediening is echter beperkt door de vijandige 
wondomgeving met veel oxidatieve en inflammatoire stress. Een langdurige overleving van 
de MSCs door preconditioneringsstrategieën zou de therapeutische efficiëntie kunnen 
verbeteren. In deze studie werden de anti-oxidatieve en anti-apoptotische effecten van HO-
1, HO-2 en hun effectormoleculen onderzocht op de overleving van MSCs afkomstig uit 
vetweefsel (ASCs). HO-1 werd geïnduceerd door behandeling met curcumine en dit bood 
bescherming tegen waterstofperoxide (H2O2) geïnduceerde oxidatieve stress. Deze 
bescherming werd voorkomen door gelijktijdige behandeling van curcumine met de HO-1 
activiteitsremmer QC15. Deze bevinding ondersteunt een HO-1-afhankelijk beschermend 
mechanisme van curcumine. Ook de anti-oxidant N-acetylcysteïne beschermt tegen H2O2-
geïnduceerde ASC celdood, terwijl de HO-effectormoleculen en tevens anti-oxidanten 
bilirubine en biliverdine dat niet deden. Interessant is dat het koolstofmonoxide (CO) 
afgevend molecuul (CORM) ook H2O2-geïnduceerde ASC-dood voorkwam, wat suggereert 
dat HO-1 bescherming kan bieden via zijn effector molecuul CO. Er werden geen verschillen 
gevonden tussen ASCs afkomstig van WT en HO-2 KO muizen in hun gevoeligheid voor H2O2, 
of de bescherming door curcumine of de HO-effectormoleculen. De inductie van 
celbeschermende moleculen door farmacologische preconditionering leidt tot een betere 
bescherming tegen oxidatieve stress in een in vitro model van stamceloverleving. 
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 Vervolgens onderzochten we in Hoofdstuk 6 de effecten van ischemische 
preconditionering ‘op afstand’ (RIPC) op wondgenezing. Bij RIPC wordt door kortstondige 
afklemming van de bloedstroom naar een ledemaat een niet ernstige stressreactie teweeg 
gebracht. Deze lichte stress beschermt het lichaam tegen een secundaire meer schadelijke 
stress, zoals bijvoorbeeld tijdens transplantaties en orgaanletsel. We probeerden 
excisionele wondgenezing te verbeteren door het toepassen van een ‘vroege’ of ‘late’ RIPC 
behandeling (respectievelijk 5 min en 24 uur voor verwonding) en onderzochten de rol van 
HO-1 hierop met behulp van HO-1 luc transgene muizen. HO-1-promotoractiviteit werd 
dorsaal en lokaal in de nieren geïnduceerd na de RIPC behandeling. Op mRNA niveau was 
HO-1 verhoogd in de afgeklemde spieren, het hart en de nieren, maar verrassend genoeg 
niet in de huid. Zowel ‘vroege’ als ‘late’ RIPC veranderde de HO-1 mRNA en eiwitniveaus 
niet in de dorsale wonden 7 dagen na verwonding, noch beïnvloedde het de snelheid van 
de wondsluiting of de collageenafzetting. Aangezien RIPC de expressie van HO-1 verhoogt 
in verschillende organen, maar niet in de huid en RIPC de excisionele wondgenezing niet 
verbetert, wordt gesuggereerd dat de huid ongevoelig is voor RIPC-gemedieerde 
bescherming. Hoewel andere studies lieten zien dat RIPC de overleving van 
getransplanteerde huidflappen en de genezing van diabetische ulcers verbetert. Mogelijk 
spelen andere signalen een beslissende rol. 
 Tenslotte werd in Hoofdstuk 7 een nieuw moleculair mechanisme voorgesteld 
voor de bescherming van het weefsel tegen schadelijke stoffen of tegen bijkomende schade 
als gevolg van een aanval door een geactiveerd immuunsysteem. TSFs veroorzaken 
weefselbescherming terwijl alarmsignalen het immuunsysteem activeren. Hemopexine 
(hpx) kan heme wegvangen en het haem-hpx complex vormen dat kan binden aan LRP-1 en 
een beschermend effect teweegbrengen. Wanneer hpx is uitgeput of uitgeschakeld, dan 
bindt het in overmaat zijnde vrije haem aan TLR-4 en wordt het immuunsysteem 
gealarmeerd, resulterend in een pro-inflammatoir effect. We stelden voor dat de 
aanwezigheid van hpx de onderscheidende factor is tussen weefselherstel en 
weefselbeschadiging en we komen tot een nieuw concept over hoe RIPC kan leiden tot 
beschermende HO-1 signalering. RIPC leidt tot het vrijkomen van lage hoeveelheden haem 
en de inductie van HO-1, dat samen met LRP-1 gelokaliseerd tot expressie komt. We stellen 
daarom voor dat systemische bescherming gemedieerd door RIPC wordt geregeld door 
binding van de TSF, het haem-hpx-complex, aan LRP-1 en vervolgens beschermende 
mechanisme, zoals HO-1, activeert. Zodoende kan de binding van haem door hpx het 
onderscheid maken tussen weefselbescherming of immuunactivatie. 
 
In Deel III zijn de belangrijkste resultaten van dit proefschrift en wat ze betekenen voor de 
kliniek samengevat en besproken en werden toekomstige therapeutische strategieën 
voorgesteld. 
 
 De inductie van een celbeschermend mechanisme, zoals HO-1, door 
farmacologische behandeling met bijvoorbeeld curcumine of hpx of door toepassing van 
RIPC, kan inflammatoire en oxidatieve stress afwenden. Zodoende vormen deze opties 
interessante strategieën om schisis te voorkomen en de uitkomst van weefselgenezing te 
verbeteren bij patiënten met schisis of brandwonden. Er is echter meer mechanistisch en 
translationeel onderzoek nodig voordat dit klinisch kan worden toegepast. 
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 Concluderend kan worden gesteld dat een verminderde activiteit van 
beschermende processen wondgenezing, craniofaciale ontwikkeling en palatogenese zal 
belemmeren, terwijl inductie van beschermende processen, met name degene die leiden 
tot de opheffing van oxidatieve en inflammatoire stress, een regeneratieve omgeving 
creëren die wondgenezing en regeneratie zal verbeteren. 
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2013 
 
1 
 TEACHING ACTIVITIES Year(s) ECTS 
e) Lecturing 
- Supervision of Bachelor and Master students 
 
2010-2014 
 
4 
  TOTAL 31.25 
Oral and poster presentations are indicated with a * and ^ after the name of the activity, respectively.   
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About the cover: Originally, Da Vinci’s Vitruvian man symbolizes an in proportionate human 
as the center of the universe. Here, a modern touch adds two dimensions. On the left, the 
individual is injured and suffering from impaired wound repair as visualized by a foot ulcer 
and scars on the lip and arm. On the right, diverse medical strategies (pharmacological 
induction of cytoprotective responses, stem cell therapy, and remote ischemic 
preconditioning by ligation of a limb) have attenuated injury and led to regenerated tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
